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Abstract 
Congenital heart defects (CHDs) are the most common human birth defect and the 
leading cause of death from a birth defect in the first year of life. Thus, a further 
understanding of the mechanisms underlying CHDs, which could lead to improved diagnosis 
and treatment, is crucial. The small GTPase, Rac1, acts as a pleiotropic effector of numerous 
cellular processes; however, little is known about its role in embryonic heart development. 
The aim of this thesis was to investigate the role of Rac1 signaling in cardiac development. 
Using the Cre/loxP system, mouse models with an anterior second heart field (SHF) or 
ventricular myocardium specific deletion of Rac1 were generated. I demonstrated that mice 
with a SHF Rac1 deficiency displayed a spectrum of CHDs including bifid cardiac apex and 
septal defects. These Rac1 deficient cardiomyocytes failed to undergo polarization. In 
addition, migration and lamellipodia formation was disrupted in Rac1 deficient 
cardiomyocytes. Decreased SHF Rac1 signaling led to increased apoptosis and 
downregulation of several cardiac developmental transcription factors. Furthermore, my data 
showed that organization of anterior SHF progenitors was disrupted, leading to a spectrum of 
outflow tract (OFT) defects in Rac1 deficient mice. Cardiomyocytes with a Rac1 deficiency 
failed to polarize and undergo myocardialization, causing misalignment of the OFT. At P0, 
Rac1 deficient aortic valves displayed defects in maturation and remodeling and intrauterine 
echocardiography performed at E18.5 showed severe aortic valve regurgitation. Finally, I 
showed that a Rac1 deficiency in the ventricular myocardium resulted in ventricular 
noncompaction and defective trabecular development. The myocardium proliferation rate 
was significantly decreased and expression of the planar cell polarity protein, Scrib, was 
reduced. Actin polymerization was severely disrupted and cardiomyocytes failed to polarize 
in E18.5 Rac1 deficient ventricular myocardium. In conclusion, my thesis is the first to show 
 iii 
 
that Rac1 signaling regulates several pathways, including proliferation, cell survival, gene 
expression and actin polymerization during embryonic heart development. Through these 
mechanisms, Rac1 is a critical regulator of cardiomyocyte polarity, septal and OFT 
development and formation of the ventricular myocardium.   
 
Keywords: Rac1, cardiomyocyte polarity, congenital heart defects, heart development, cell 
organization, migration, outflow tract, second heart field 
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1 Chapter 1 Introduction 
1.1 Heart Development  
The heart is the first organ to form and function in all vertebrates and is critical in 
ensuring proper nutrient and oxygen supply to the developing embryo. Heart 
development is a complex, highly regulated and multi-stepped process of myogenesis and 
morphogenesis where populations of progenitor cells must merge in a temporally and 
spatially coordinated fashion. The heart develops from three distinct populations of cells: 
the first heart field (FHF), second heart field (SHF) and neural crest cells. FHF 
progenitors originate from the anterior lateral plate mesoderm and form two lateral heart 
fields along the midline. The two heart fields will then coalesce and form a crescent 
shape in the anterior embryo by E7.5 in the mouse. At approximately E8.0, the FHF cells 
merge along the ventral midline to form the primitive beating heart tube. The heart tube is 
made up of an interior layer of endocardial cells and an outer layer of myocardial cells 
with extracellular matrix in between the two layers. This tube undergoes rightward 
looping by E9.0 and begins early chamber morphogenesis.1 SHF cells originate from 
pharyngeal mesoderm and lie anteriorly and medially to the FHF cardiac crescent. As the 
heart tube forms, SHF cells migrate into the midline and lie dorsal to the heart tube. Upon 
rightward looping of the heart tube, SHF cells cross the pharyngeal mesoderm and are 
added progressively into the arterial and venous poles of the heart tube, differentiating 
into myocardial, endocardial and smooth muscle cells of the outflow tract (OFT), future 
right ventricle (RV), atria and interventricular septum.2-5 As well, following looping 
morphogenesis, endocardial cushions will begin to form within the OFT and the 
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atrioventricular canal (AVC), which will later help septate the common OFT and divide 
the heart into four chambers (Figure 1.1).6 SHF progenitors have elevated rates of 
proliferation and differentiation delay with respect to the FHF cells that contribute to the 
heart tube.7 The SHF also expresses distinct genes that distinguish it from the FHF 
including the growth factors Fgf10 and Fgf8 and the transcription factors Tbx1, Islet1 
(Isl1) and Mef2c.8-13 Compared to the SHF, the FHF is difficult to locate due to the lack 
of distinguishing markers.2 Along with the SHF progenitors, neural crest cells migrate 
from the neural tube and contribute to the remodeling and septation of the OFT, which 
will become the aorta and pulmonary artery of the heart.14 By E15.5, the embryonic heart 
structure is mostly complete except for the semilunar and atrioventricular valves, which 
will continue to undergo remodeling and maturation after birth.15 
Figure 1.1.  Heart development in the mouse.  
Oblique views (top panels) and frontal views (lower panels) of cardiac progenitor cells in 
the embryonic mouse. FHF progenitors form a cardiac crescent by E7.5 and will merge to 
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form the primary heart tube by E8.0. SHF progenitors will migrate into the heart tube to 
elongate the arterial and venous poles. After rightward looping of the heart tube, cardiac 
neural crest (CNC) cells will also migrate into the OFT to contribute to cardiac 
development. V, ventricle; A, atrium; CT, conotruncus; RA, right atrium; LA, left atrium; 
AS, aortic sac; RV, right ventricle; LV, left ventricle; AVV, atrioventricular valves; Ao, 
aorta; PA, pulmonary artery; DA, ductus arteriosus; RSCA, right subclavian artery; RCA, 
right carotid artery; LCA, left carotid artery; LSCA, left subclavian artery. Figure adapted 
with modifications from Srivastava, D. Cell. 2006;126:1037-1048. 
1.1.1 Second Heart Field  
The existence of extra-cardiac progenitor cells that contribute to later formation of 
the OFT myocardium was first suggested in 1977 by de la Cruz et al.16 The question of 
where the OFT myocardium originated from remained unclear until 2001 when three 
different groups published reports of a separate population of cells that contribute to the 
initial heart tube in both chick and mice.9, 17, 18 In one initial chick study, a group of cells 
called “secondary heart field” was found adjacent and posterior to the OFT region while 
in the other chick study, the newly discovered group of cells was termed “anterior heart 
field” and encompassed a larger region of the cranial pharyngeal mesoderm extending 
into the pharyngeal arches.17, 18 In mice, Kelly et al. discovered a population of anterior 
heart field cells, which expressed lacZ under the control of Fgf10 regulatory elements in 
the splanchnic and pharyngeal mesoderm, contributing to the RV and myocardial cells at 
the arterial pole of the heart tube.9 A later study on the LIM homeodomain transcription 
factor Isl1 found this region of the murine anterior heart field to be actually more 
extensive, extending more posteriorly and contributing to elongation of both the arterial 
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and venous pole of the heart tube. Thus, the SHF is subdivided into an anterior and 
posterior domain where the anterior region is marked by the Fgf10-lacZ transgene while 
Isl1 marks both domains.9, 13 
A complex network of signaling pathways and transcription factors regulate the 
SHF progenitor cell population in the dorsal pericardial wall as it proliferates and 
progressively differentiates in the OFT. One example is retinoic acid signaling, which 
plays a role in defining the posterior boundary of the SHF progenitor cells and later on in 
differentiation of the distal OFT progenitor cells.19 Fibroblast growth factors (Fgf), 
including Fgf3, Fgf8 and Fgf10, play a part in regulating the high rate of SHF progenitor 
cell proliferation in the dorsal pericardial wall.20 Upstream of this, Wnt/β-catenin and 
Notch signaling regulate the expression of FGF ligands.21 Studies have shown that 
conditional loss of Fgf, Wnt/β-catenin and Notch signaling in the SHF leads to a 
shortened OFT and OFT defects.20, 22, 23 In addition, Hedgehog (Hh) signaling has been 
demonstrated to be critical for SHF progenitor cell proliferation by acting through the 
transcription factor, Tbx5.24 Numerous other transcription factors play critical roles in the 
SHF including Isl, Tbx1, Six1, and Eya1, which regulate FGF expression, proliferation 
and cell survival of progenitor cells.25-27 As SHF cells migrate into the heart tube, 
proliferation decreases and there is an onset of myocardial differentiation. Bone 
morphogenetic protein (BMP) signaling at the distal OFT promotes differentiation of 
SHF cells by antagonizing FGF signaling.28 Together with BMP signaling, SHF 
progenitors residing proximal to the heart tube will initiate expression of Gata4, Nkx2.5, 
Tbx20, Mef2c and Hand2 to activate the myocardial gene expression program.18  
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Mef2c is a member of the myocyte-specific enhancing factor 2 (Mef2) family of 
MADS-box transcription factors, which has been shown to be critical for cardiac 
development. There are four Mef2 genes in vertebrates: Mef2a, Mef2b, Mef2c and 
Mef2d,29 which bind a conserved A-T rich DNA control region associated with cardiac, 
skeletal and smooth muscle lineages.30 Mef2c is one of the earliest markers of the cardiac 
lineage at E7.5 and precedes expression of α-cardiac actin, a sarcomeric protein. Strong 
Mef2c expression in the developing heart continues from E7.5 to E11.5 and then begins 
to decline.30 Mef2c-/- mice have a SHF phenotype where the heart fails to loop, the OFT 
has gross abnormalities and the RV does not develop.10 Dodou et al. discovered an 
enhancer and promoter from the Mef2c gene that was expressed exclusively in the 
anterior heart field during cardiac development.11 Subsequent fate mapping studies using 
Cre expression under the control of the Mef2c anterior heart field promoter and enhancer 
(Mef2c-AHF-Cre) show that lacZ expressing cells mark progenitors of the SHF that 
contribute to formation of the RV, ventricular septum and the endothelial and myocardial 
cells of the OFT.31 Thus, the Mef2c-AHF-Cre is the first transgenic mouse line with Cre 
activity restricted to the anterior heart field and its derivatives, making it an excellent tool 
for genetic studies in the SHF. Hence, this Mef2c-AHF-Cre transgenic mouse line was 
used to study the SHF in Study 1 and 2. 
1.1.2 Neural Crest Cells  
Neural crest cells are a multipotent population that migrates from the dorsal 
neural tube during embryonic development to contribute to numerous tissue types 
including the peripheral nervous system, melanocytes and tissues of the head and neck.32-
34 Early transplantation and cell labeling experiments in avian models identified a specific 
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region of the dorsal neural tube that contributed to parts of the heart and associated 
vessels.35 Following these observations, subsequent chick studies showed that ablation of 
the neural crests in the cranial region before the cells became migratory led to a failure of 
the common OFT to divide into aorta and pulmonary trunk, abnormal patterning of the 
aortic arch and great arteries, OFT alignment defects and VSDs.36 Since these seminal 
discoveries in the chick embryo, this population of neural crest cells has been termed 
“cardiac neural crest” due to their importance in heart development. Subsequent studies 
in transgenic mouse models using neural crest promoters have confirmed the importance 
of the cardiac neural crest in cardiovascular development that was first observed in avian 
models.37, 38 Cardiac neural crest cells delaminate from the neural tube at approximately 
E8.5 in the mouse, migrate and pause in the circumpharygeal ridge before migrating into 
and populating pharyngeal arches three, four and six as each arch forms.39 These neural 
crest cells play a critical role in repatterning of the pharyngeal arches to become the great 
arteries of the thorax, including common carotid, aortic arch and ductus arteriosus.40 
Additionally, a subpopulation of cardiac neural crests from the pharyngeal arches will 
migrate into the OFT cushions at approximately E9.5 to form the aorticopulmonary 
septation complex, which will divide the common outflow tract into the aorta and 
pulmonary trunk.41 Development and remodeling of the semilunar valves (aortic and 
pulmonary valves) also rely on tissue-tissue interactions between the cardiac neural crest 
and the SHF cells.42 As neural crest cells migrate into the developing heart, they are 
closely juxtaposed to migrating SHF progenitors in the pharyngeal mesenchyme where 
they are able to influence each other through various signaling mechanisms. Defects in 
SHF progenitors or the cardiac neural crest cell population can have secondary effects on 
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the other cell type, supporting an intricate relationship between these two cell types in 
cardiac development.43-45    
1.1.3 Development of the Septated Heart  
From E8.25 to E10.5 in the mouse, the heart tube will undergo rightward looping, 
which is the first event displaying left-right asymmetry during embryonic development. 
As looping proceeds, the RV and left ventricle (LV) become arranged side by side and 
connected to the common OFT. The distance between the atrial and venous poles shorten 
as they converge and the ventricular bend will shift caudally. In the late stages of looping, 
the proximal OFT will shift to the left and the heart tube will undergo ballooning of the 
atrial and ventricular regions. The OFT undergoes remodeling and the aortic valve 
becomes wedged between the AV valves.46 As looping morphogenesis occurs, SHF 
progenitors are concurrently being added into the heart tube to subsequently give rise to a 
majority of the RV, interventricular septum and OFT. A failure of SHF cells to 
incorporate into the heart tube can interrupt cardiac looping.13 As the heart completes 
looping, it will undergo a septation process through growth of myocardium and valve 
development and remodeling to form a four-chambered heart.  
Separation of the atria from the ventricles occurs through development of AV 
valves (mitral and tricuspid valves), which originate from AV endocardial cushions 
formed at E9.0. The AV endocardial cells undergo a process of EMT and the cushions 
will remodel and gradually maturate to form thin, valve leaflets. During this process of 
remodeling and maturation, the mesenchymal cells will proliferate and extracellular 
matrix (ECM) deposition will extend the cushions to form the valve leaflets. 
Development of the AV valves is dependent on numerous signaling factors secreted by 
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the myocardium underlying the cushions, including BMP, TGFβ and Vegf. These factors 
will promote EMT of the endocardial cushion.47 In addition, the endocardial cells also 
express receptors for Nfatc1 and Vegf, which are critical for valve development.48, 49 The 
semilunar valves (aortic and pulmonary valves) arise from the conal and intercalated 
cushions in the OFT. The right and left leaflets of the semilunar valves are formed from 
the conal cushions.50 The intercalated cushions will develop into the posterior aortic and 
anterior pulmonic leaflets.51 Similar to development of the AV valves, OFT conal 
cushions undergo a process of EMT to give rise to mesenchymal cells that proliferate, 
followed by matrix deposition, elongation and remodeling/thinning of the valve leaflets.52 
Development of the semilunar valves requires similar signaling pathways, transcription 
factors, epigenetics and morphogenetic events as those required for AV valve 
development.53    
Besides development of cardiac valves to septate the heart, the atrial and 
ventricular chambers must also undergo septation to divide it into their left and right 
counterparts. The muscular part of the interventricular septum is formed between the two 
future ventricles from ballooning of the apical components. This muscular septum will 
continue to grow superiorly towards the AV cushions, leaving an opening at the AV 
canal between the two ventricular chambers. This opening will be closed by the 
membranous part of the interventricular septum that develops from the AV cushions.54, 55 
Tbx5 has been shown to be essential for determining LV identity and the interventricular 
boundary. Overexpression of Tbx5 in mice causes expansion of the LV and loss of the 
interventricular septum.56 Compared to ventricular septation, atrial septation is a more 
complex process. A muscular septum, called the primary atrial septum, begins to grow at 
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E9.5 from the atrial roof towards the AV cushions. The edge of the primary septum 
contains a mesenchymal cap. Growth of the primary septum will partially septate the 
atrial chamber, leaving an opening called the ostium primum that allows shunting of 
blood between the two chambers.57 The mesenchymal cap will fuse with the AV cushion 
and the dorsal mesenchymal protrusion (DMP), which is mesenchymal tissue from the 
dorsal mesocardium, to close the ostium primum. As this occurs, apoptosis occurs on the 
anterior side of the primary septum to create a second opening called the ostium 
secundum, which is later closed by the muscular secondary atrial septum.55  Many 
signaling pathways and transcription factors are critical to atrial septum formation 
including BMP signaling and the GATA and TBX family of transcription factors.58-60  
Septation of the heart is dependent on interactions between different cardiac cell 
lineages, including the SHF and cardiac neural crest cells. Besides complex signaling 
mechanisms that exist within each lineage, progenitors of each lineage interact with other 
cells to coordinate the septation process. Lineage tracing studies show that a large part of 
the interventricular septum is derived from SHF progenitors.61 The DMP that contributes 
to atrial septum is also derived from SHF progenitors.62, 63 Many studies have 
demonstrated that disruption of several different signaling pathways in the SHF result in 
defective septation of the heart. For example, disruption of calcineurin/Nfatc1 signaling 
in the SHF led to increased apoptosis, regression of OFT cushions and a subsequent 
absence of semilunar valve formation.64 Hedgehog and BMP signaling is essential for 
development of the DMP for atrial septation.65, 66 In addition, deletion of the transcription 
factor Hand2 or disruption of BMP4 signaling in SHF progenitors lead to defects in 
interventricular septum formation in mouse embryos.27, 67  
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Cardiac neural crest cells have roles in OFT septation and development of the 
semilunar valves as well, with little to no contribution to AV valve development.6 These 
cells are crucial for remodeling and maturation of the semilunar valves and formation of 
the aorticopulmonary complex to septate the OFT.42, 68 Cardiac neural crest cells will also 
interact with surrounding tissues, such as the SHF-derived OFT myocardium through 
semaphorin signaling to migrate into the developing OFT. Specifically, the semaphorin 
Sema3c is expressed in the SHF-derived OFT myocardium and signals to PLXNA2 
receptors expressed on migrating cardiac neural crest cells.69    
1.1.4 Ventricular Myocardium Development  
Maturation of the ventricular chamber myocardium is essential for increased 
cardiac output as an embryo grows and develops. The ventricles grow and mature 
through a process of proliferation and differentiation to form trabeculation and the 
compact myocardial layer. In general, cardiac chamber maturation can be divided into 
three processes: formation of trabeculae, formation of conduction system and thickening 
of the compact myocardium.70 Trabecular formation begins in the mouse at 
approximately E9.5 where cardiomyocytes grow to form protrusions of muscular ridges 
that become lined by invaginating endocardial cells. As these ridges form, the trabecular 
projections grow and spread radially to form a network of trabeculation. This formation 
of trabeculation facilitates oxygen and nutrient exchange in the heart and enhances force 
generation during contraction.71 The trabeculae then undergo a process of remodeling or 
compaction where growth stops and the spaces between trabeculae become capillaries. 
The bases of trabeculae thicken and collapse into the myocardial wall. By E14.5, a 
mature trabecular network is formed, along with formation of a thick, compact 
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ventricular myocardium.72 A gradient of decreasing proliferation and increasing 
differentiation exists from the compact myocardium zone towards the trabecular zone. 
Proliferation of the compact myocardium is concomitant with remodeling of the 
trabeculation.73 Signaling from the endocardium and epicardium to myocardial cells have 
been demonstrated to be critical for trabeculation and ventricular development. For 
example, neuregulin 1, produced by endocardial cells, act on receptors in the 
myocardium to regulate trabecular development.74 The cardiac jelly between the 
endocardium and myocardium plays a crucial role in transmission of signals between 
these two cell types.75 In addition, FGF signaling from the epicardium to myocardial cells 
has been demonstrated to be a critical regulator of ventricular wall development. 
Interestingly, endocardial-derived signals seem to regulate trabecular development while 
epicardial-derived signals seem to mediate compact myocardium development.76 
Numerous signaling pathways have been implicated in maturation of the cardiac 
ventricular chambers including Notch, ephrin, BMP, FGF, retinoic acid and ECM 
signaling pathways. In addition, biomechanical forces such as sheer stress can influence 
signaling pathways that regulate chamber maturation. However, the relationship between 
these physical forces, gene expression and chamber development is not well 
understood.70             
1.1.5 Outflow Tract Development  
In early development, the cardiac OFT forms at the arterial pole of the heart tube, 
connecting the ventricles to the aortic sac. The OFT is composed of an outer myocardial 
layer, derived from the anterior SHF, and an inner lining of endocardial cells. As the 
primitive heart tube undergoes rightward looping, SHF progenitors will migrate 
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progressively from the pharyngeal mesoderm to elongate the heart tube and contribute to 
the myocardial layer of the OFT, which reaches its maximal length by E10.5.2 As the 
heart tube grows, the AV canal, future atrial and ventricular septa and the developing 
OFT will align with the ventricles, facilitating proper septation of the heart. 
Abnormalities in this convergence process often cause major OFT defects.77 The OFT 
also undergoes a wedging process where it rotates in a counterclockwise direction, 
putting the aortic valves behind the pulmonary trunk and to the left to align between the 
two AV valves. Abnormalities in the wedging process leads to misalignment of the OFT 
with the ventricles and failure to complete development of the interventricular septum.78 
As SHF progenitors add to the early OFT, proliferation markers are downregulated and 
early markers of the myocardial lineage are upregulated.79 The early OFT is divided into 
two parts: conal/proximal region, which is adjacent to the RV, and the truncal/distal 
region, which is adjacent to the pharyngeal arches. These two regions of the OFT have 
distinct characteristics and the boundary between the truncal and conal parts plays crucial 
roles in remodeling.53  
Cardiac neural crest cells are involved in numerous events of OFT development 
including remodeling of the pharyngeal aortic arches, truncal cushion development, 
formation of the smooth muscle cell layer and reciprocal signaling to the SHF to regulate 
SHF proliferation and deployment.36, 80 As the truncal portion of the OFT forms, cardiac 
neural crest cells will delaminate from the neural tube at approximately E9.0, migrate 
into the caudal pharyngeal arches and colonize the truncal OFT cushions. These cardiac 
neural crest cells, together with fusion of the truncal cushions of the OFT, will give rise 
to the aorticopulmonary septation complex by E11.0.81 The septation complex will form a 
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shelf-like structure distal to the OFT, between the fourth and sixth aortic arches, growing 
towards the proximal OFT and fusing with the conal OFT cushions to septate the 
common OFT. As the same time, the OFT undergoes counterclockwise rotation and shifts 
to become aligned above the future ventricular septum. The conal cushions also fuse to 
divide the proximal OFT into right and left ventricular outlets. 51, 82 The proximal outlet 
septum becomes muscularized through myocardialization, a process where myocardial 
cells grow and migrate into the flanking mesenchymal tissue. By E14.5, OFT remodeling 
and septation is complete and the aorta is connected to the LV and pulmonary artery is 
connected to the RV.83 
1.1.6 Transcription Factors in Heart Development    
Transcriptional activity and gene expression during heart development is a tightly 
controlled process, involving cascades of interacting transcription factors. A transcription 
factor has sequence-dependent affinity for specific DNA motifs to regulate transcriptional 
activity of numerous downstream target genes. A core group of transcription factors can 
interact with each other or function as biochemical partners in a complex transcriptional 
network to regulate each step of heart development.84, 85 Some key cardiac transcription 
factors and the most well studied to date include TBX5, NKX2.5 and GATA4. Based on 
the multifaceted transcriptional interactions and synergistic regulation of numerous 
pathways by transcription factors, it is not surprising that a mutation in any one of the 
core transcription factors has been shown to cause inherited or sporadic congenital heart 
defects (CHDs) in humans.86-88  
One of the first transcription factor genes identified to be associated with inherited 
CHDs was TBX5. Humans with a heterozygous mutation in TBX5 have Holt-Oram 
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syndrome, which include defects in upper limb and heart development, specifically atrial 
septal defects (ASDs), ventricular septal defects (VSDs) and conduction defects.88, 89 In 
mouse studies, TBX5 has been shown to regulate interventricular septum formation and 
development of the conduction system.90, 91 Mice with a TBX5 null mutation have 
developmental arrest by E9.5, the heart tube fails to loop and the embryos do not survive 
past E10.5. It was shown that TBX5 and NKX2.5 interact to regulate synergistic 
transcriptional activation of atrial natriuretic peptide (ANP) and connexin-40 (Cx40) 
genes.92 Along with that, TBX5 and NKX2.5 interact in a transcriptional cascade to 
regulate development and maintenance of the cardiac conduction system.93  
Mutations in the NKX2.5 gene were the first single-gene defect linked to non-
syndromic CHDs in humans. Mutations in the NKX2.5 gene have been shown to cause 
inherited ASDs, atrioventricular block, VSDs, Ebstein’s anomaly and Tetralogy of Fallot 
(TOF).94, 95 NKX2.5 deficient mice are embryonic lethal by E9.0 due to defects in 
looping morphogenesis of the heart tube.96 Although commitment to the cardiac lineage 
is not compromised in NKX2.5 deficient mice, expression of several cardiac genes is 
reduced including ANP, myosin light chain 2v (MLC2v) and Hand1, indicating that 
NKX2.5 functions near the top of the transcriptional cascade to regulate numerous 
cardiac genes essential for myocardium development beyond the looping stage.96-98 In 
addition to interactions with TBX5,92 NKX2.5 has also been shown to interact directly 
with GATA4 and another transcription factor, serum response factor (SRF), to promote 
cardiac sarcomeric protein expression.99  
The zinc finger transcription factor GATA4 is one of the earliest transcription 
factors expressed in the developing mouse heart beginning at E7.5 and continues to be 
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expressed throughout adulthood where it maintains normal cardiac function and acts to 
protect the heart from stress-induced heart failure.100-103 Studies in mice where GATA4 
expression levels were reduced in varying degrees showed that GATA4 is a dosage-
sensitive regulator of heart development. A graded reduction in GATA4 expression 
resulted in mice with a common AVC, double outlet right ventricle (DORV) and 
hypoplasia of the myocardium.104 Mutations in the GATA4 gene cause inherited ASD and 
VSDs in humans, as well as dilated cardiomyopathy in later life.105 Like the other core 
transcription factors, GATA4 acts in a synergistic manner with other transcription 
factors, such as Smad4 and Mef2 proteins, to regulate valve development and expression 
of cardiac genes.106, 107 In addition, GATA4 functionally interacts with TBX5 to activate 
expression of Cx30.2, a gap junction protein highly expressed in the AV node.108 
In addition to these core transcription factors, TBX5, NKX2.5 and GATA4, other 
notable transcription factors that are discussed in this thesis include the basic helix-loop-
helix (bHLH) transcription factor Hand2 and TBX20. Hand2 is highly expressed in the 
developing RV and Hand2-/- mice are embryonic lethal by E10.5, displaying RV 
hypoplasia and vascular defects.109-111 Along with its previously mentioned interactions, 
NKX2.5 also interacts with Hand2 and Mef2c to regulate ventricular identity.112, 113 The 
Hand factors, Hand1 and Hand2, function in a dose-sensitive manner to regulate cardiac 
development and gene expression.114 Hand2 maps to chromosome 4q33, where 
duplications or mutations have been associated with a range of septal and OFT defects.115 
In a cohort of patients with defects in the RV and OFT, 5% had mutations in the Hand2 
gene, making it a strong candidate gene related to CHDs.116 TBX20 is expressed in both 
the FHF and SHF and acts as a dose-sensitive regulator of OFT, valve and RV 
16 
 
development.117, 118 TBX20 acts to repress TBX2 in the outer curvature to establish 
regional patterning of the myocardium during development and functions to maintain 
adult heart function. TBX20-/- mice fail to undergo heart tube looping and chamber 
formation does not occur.119, 120  
Research in the past two decades has rapidly uncovered an intricate cardiac 
transcriptional network involving numerous transcription factors that is beyond the scope 
of this thesis. Although the importance of these transcription factors in heart development 
have been established, few downstream targets have been identified that can explain the 
precise cellular mechanisms for CHDs. Further research to identify the specific targets 
downstream of the associated transcription factors will be crucial for understanding 
normal heart development and the pathogenesis of CHDs.121 
1.2 Congenital Heart Defects  
  Congenital heart defects (CHDs) are abnormalities in the structure and function 
of the heart that arise during embryonic development. It is the most common human birth 
defect, affecting up to 5% of live births and it is the leading cause of death from a 
congenital malformation in the first year of life in industrialized nations.122, 123 
Tremendous advances in diagnostics, surgical techniques and medical care have 
increased the survival rate of CHD patients in the last 60 years. Due to these 
improvements in care, the population of adult CHD patients has grown rapidly and is 
now estimated to outnumber the childhood population 66% to 34%, respectively, in 
Canada.124 However, adult patients can face ongoing health and disease burdens 
throughout their lives including multiple re-operations, arrhythmias, bacterial 
endocarditis and heart failure, which are major causes of morbidity and mortality.125 Our 
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current understanding of the etiology of CHDs is still limited as only 20% of cases can be 
attributed to a known cause.126 CHDs can be linked to genetic or environmental factors, 
or a combination of both. Some environmental factors include maternal alcohol 
consumption, use of therapeutic drugs, and maternal illnesses and conditions such as 
diabetes and rubella infection.127 Genetic factors include chromosomal disorders like 
trisomy 21, deletion syndromes such as DiGeorge Syndrome or single gene disorders like 
Holt-Oram caused by TBX5 mutations.128 Despite much progress in our understanding of 
heart development, the cellular and molecular mechanisms underlying CHDs are still not 
fully understood. A further understanding of the intricate developmental mechanisms 
regulating cardiogenesis is critical for potential future advancements in diagnostics, 
prevention and treatment of CHDs. 
1.2.1 Atrial and Ventricular Septal Defects  
Holes that exist between the atria or ventricles and allow mixing of oxygenated 
and deoxygenated blood between the two chambers are defined as septal defects. When 
accounting for all the different types of CHDs, defects in ventricular and atrial septation 
are one of the most common types, with reported prevalence of 30.7% for VSDs and 
11.6% for ASDs.129 A VSD can occur in either the muscular or membranous part of the 
ventricular septum, with membranous VSDs occurring more frequently.122 VSDs can also 
occur as an isolated cardiac defect or as part of a complex CHD, such as TOF and 
transposition of the great arteries. ASDs can be divided into two major types: ostium 
primum or ostium secundum defect. If the primary atrial septum or the secondary atrial 
septum fails to form properly, an ostium secundum defect occurs. If the ostium secundum 
defect is large, it may lead to right atrial overload due to left-right shunting and cause 
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complications such as atrial fibrillation and pulmonary hypertension.130 Ostium primum 
defect is less common but more severe compared to ostium secundum defects. This 
defect is an incomplete septation between the inferior margin of the primary atrial septum 
and arises from abnormal growth of the primary septum or development of the 
endocardial cushions.131 Like other CHDs, the etiology of atrial and ventricular septal 
defects is complex and multifactorial. As described above, mutations in cardiac 
transcription factors TBX5, NKX2.5 and GATA4 are associated with VSDs and ASDs in 
humans. Functional interaction of these cardiac transcription factors is critical for septal 
development.88, 94, 105, 132 Besides a genetic factor, environment influences such as 
pregestational diabetes and teratogens are associated with septation defects in the fetus.127  
Moreover, numerous mouse studies have shown perturbations in SHF progenitor 
signaling pathways can lead to ASDs and VSDs, since the SHF is a major contributor of 
these cardiac structures.61-63  
1.2.2 Ventricular Noncompaction Defects  
Aberrant ventricular chamber maturation can lead to left ventricular non-
compaction (LVNC), which is characterized by excessive trabeculae, deep recesses 
within the ventricular cavity and a thin compact myocardium. This defect is called LVNC 
because it affects mostly the LV but in rare cases, this defect can also occur as an isolated 
incident in the RV. LVNC can occur as an isolated event or combined with other CHDs, 
leading to heart failure, thromboembolic events, arrhythmias and/ or sudden cardiac 
death.133-135 LVNC is the third most common cardiomyopathy after dilated 
cardiomyopathy and hypertrophic cardiomyopathy.136 Numerous studies have shown that 
ventricular noncompaction arises from impaired maturation or arrest of the developing 
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ventricular myocardium. This defect has been linked to mutations in mitochondrial 
proteins, along with cytoskeleton, Z-line and sarcomeric proteins. For example, in one 
family with LVNC, a mutation in the cardiac troponin T gene was found. However, 
recapitulation of this mutation in a mouse model did not cause LVNC. Overall, this type 
of defect is still relatively not well understood and there seems to be a lack of a genotype-
phenotype link, suggesting genetic heterogeneity in patients.137, 138 Numerous mouse 
models have been developed in the past 10 years to study the genetic and molecular 
mechanisms of LVNC including the Noonan syndrome SHP2 gain-of-function mutation 
mouse and mouse with myocardial deletion of M1B1, a gene involved in the Notch 
pathway.139, 140 However, the defects in the ventricular myocardium are not homogenous 
between the mouse models, likely reflecting the complexity underlying chamber 
development and maturation.        
1.2.3 Outflow Tract Defects  
Proper development of the cardiac OFT requires complex temporal and spatial 
coordination between different cardiac progenitor populations, as previously described 
above. Due to the developmental intricacies of this part of the heart, the OFT is 
particularly susceptible to developmental defects. Abnormalities in OFT development 
account for 20 – 30% of the CHDs seen at birth in humans.141 Even after postnatal 
surgical correction, patients can still face health risks throughout their lives.142 The OFT 
defects discussed in this thesis include OFT alignment defects, which include DORV and 
overriding aorta, transposition of the great arteries (TGA), persistent truncus arteriosus 
(PTA), aortic and pulmonary artery stenosis and vascular rings.  
• Double Outlet Right Ventricle (DORV) 
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During normal cardiac development, the heart tube undergoes rightward looping, 
convergence of the inflow and outflow poles of the heart tube and wedging of the aorta 
between the two atrioventricular valves.143 Correct alignment of the aorta and pulmonary 
artery with the LV and RV, respectively, is dependent on proper lengthening of the 
venous (inflow) and arterial (outflow) poles of the primary heart tube. Consequently, a 
shortened heart tube alters the alignment of the arterial pole, causing DORV, where both 
the pulmonary artery and aorta connect to the RV, or overriding aorta, where the aorta is 
positioned above a VSD (Figure 1.2B).43 DORV account for 1-3% of CHDs and requires 
surgical correction. The causes of DORV are complex and multifactorial including 
chromosomal and non-chromosomal genetic abnormalities and teratogenic exposures in 
utero.144 From animal studies, DORVs have been shown to arise from impaired neural 
crest cell and SHF progenitor contribution to the primary heart tube, leading to a 
shortened heart tube and subsequent defects in cardiac looping.80 In addition, defects in 
the myocardialization process have been shown to also lead to DORV. Myocardialization 
is a process where myocardial cells migrate and grow into the adjacent mesenchymal 
tissue. At E12, myocardial cells of the OFT will invade the neighbouring cushion 
mesenchyme, leading to a gradual replacement of the mesenchymal tissue with 
myocardium to form the muscular outlet septum.145 Failure of myocardialization leads to 
misalignment of the OFT and the aorta remains in contact with the RV.146  
• Transposition of the Great Arteries (TGA) 
TGA occurs when the aorta is connected incorrectly to the RV and the pulmonary 
artery is connected incorrectly to the LV (Figure 1.2C). TGA arises from abnormal 
septation of the aorticopulmonary septum between the aorta and pulmonary artery. 
21 
 
During normal development, the aorticopulmonary septum is formed in a spiral shape, 
causing the OFT to rotate and the aorta and pulmonary artery to align with their 
respective ventricles. TGA arises when the aorticopulmonary septum does not spiral and 
forms a straight, linear septum instead.78, 147 TGA is estimated to occur in 3.5/10,000 live 
births, making it one of the more common major CHDs requiring corrective surgery 
shortly after birth.148 Post-surgery, later health risks into adulthood can include atrial 
arrhythmias, tricuspid regurgitation, RV dysfunction and pulmonary hypertension.125 The 
detailed pathogenesis of TGA is still relatively unknown. A study in chick demonstrated 
that neural crest ablation may lead to TGA but the mechanisms are unclear.149 TGA is 
strongly associated with heterotaxy in humans and some patients with TGA have 
mutations in ZIC3, CFC1 and Nodal, which are genes associated with laterality.150, 151 
Along with genetic factors, environmental factors such as maternal diabetes and 
infections have also been linked to development of TGA.148     
• Persistent Truncus Arteriosus (PTA) 
PTA, also known as common arterial trunk, occurs when the OFT fails to divide into 
aorta and pulmonary artery during development, resulting in one common artery that 
arises from the ventricles (Figure 1.2D). The process of OFT septation is dependent on 
cardiac neural crest cells, which migrate into the distal OFT and condense to form the 
aorticopulmonary septation complex, dividing the common artery into two equal sized 
vessels.41, 68 Studies have shown that ablation of cardiac neural crests in chick embryos 
result in PTA.152 In mouse studies, alterations to the cardiac neural crest cells also lead to 
PTA.153 Sema3c, a secreted axonal guidance molecule, is critical for migration and 
targeting of cardiac neural crest cells to the OFT. Loss of Sema3c leads to PTA and aortic 
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arch defects.69, 154 Other genetic mutations in mice that have been associated with PTA 
include the transcription factors Pax3, AP2α and Pitx2, and signaling proteins, BmprII 
and Alk2.36 PTA occurs in approximately 1% of infants born with CHDs and up to 50% 
of PTA cases are associated with chromosome 22q11.2 deletion syndrome.155, 122 PTA is 
often considered the most severe type of OFT defect, as it is usually associated with a 
poor prognosis and complete repair is not possible in some patient cases. However, in the 
last 30 years, surgical procedures for PTA have improved with a 95% survival rate. Many 
patients often require later interventions related to RV flow obstruction and repair of the 
truncal valves.156, 157  
• Aortic & Pulmonary Artery Stenosis  
Stenosis of the pulmonary artery occurs when there is abnormal constriction or 
narrowing of the pulmonary artery vessel. This leads to development of higher pressure 
in the RV in an effort to overcome the narrowing of the pulmonary artery.158 Pulmonary 
artery stenosis makes up one of the four characteristics of TOF, which also include VSD, 
RV hypertrophy and overriding aorta.159 In addition, pulmonary artery stenosis is often 
associated with Williams syndrome, which arises from deletion of a portion of 
chromosome 7 and presents as connective tissue abnormalities, endocrine abnormalities 
and mental retardation. Treatments for pulmonary artery stenosis include balloon dilation, 
stent placement or surgical repair.160 Similar to pulmonary artery stenosis, stenosis of the 
aorta is a narrowing of the blood vessel. This condition is also called supravalvular aortic 
stenosis because the narrowing occurs above the aortic valve. This defect can be caused 
by mutations in the ELN gene, which is responsible for production of tropoelastin, the 
precursor of elastin. However, over 50% of supravalvular aortic stenosis has no known 
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genetic cause.161 Surgical intervention is the primary treatment for supravalvular aortic 
stenosis.162  
• Vascular Ring 
A vascular ring is a vascular encirclement of the esophagus and trachea due to a 
failure of the aortic arch arteries to remodel during cardiac development. Vascular rings 
are found in less than 1% of CHDs. Some cases of vascular rings are asymptomatic while 
others can present with major symptoms such as compression or obstruction of the 
esophagus or airway.163 Up to 50% of patients with vascular rings also have other CHDs 
such as VSD, TOF or patent ductus arteriosus (PDA). Non-cardiovascular associations 
include genetic syndromes such as DiGeorge syndrome, Down syndrome and cleft lip-
palate.164, 165 Several types of vascular rings exist with the two most common being 
double aortic arch and right aortic arch with left ligamentum arteriosum, comprising 85-
95% of vascular ring cases.164, 166 During early embryonic development, the dorsal and 
ventral aortic arch are connected by six bilateral embryonic arches. Each arch will 
develop into vasculature or regress. The first, second, fifth arches and part of the fourth 
arch will regress. The third arch will become the common carotid arteries and the sixth 
arch will form the proximal pulmonary artery and ductus arteriosus. Vascular rings can 
arise when development or regression of one or more of the arches does not occur 
normally.167 During development, a subpopulation of cardiac neural crest cells will 
migrate into pharyngeal arches three, four and six to remodel the arteries. Failure of 
cardiac neural crest cells to populate and remodel this region can lead to vascular rings.168 
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 Figure 1.2.  Schematic representation of outflow tract defects.   
In the normally developed heart, the OFT is fully septated. The aorta (Ao) connects to the 
LV and the pulmonary artery (PA) connects to the RV (A). In cases of DORV, both the 
aorta and pulmonary artery connect to the RV (B). In TGA, the aorta and pulmonary have 
switched connections to their respective ventricles, where the Ao now connects to the RV 
and the pulmonary connects to the LV (C). When the OFT fails to septate, a PTA occurs 
(D). For all defects shown in B-D, there is an obligatory VSD.   
1.3 Rac1 GTPase  
1.3.1 Rac1 Overview  
Rac GTPases are small (20-30 kDa) monomeric, signaling GTP-binding proteins, 
which are a subfamily of the Rho GTPase family. The Rho GTPase family is comprised 
of 8 subfamilies encompassing a total of 20 intracellular signaling molecules. The Rac 
family contains 4 members: Rac1, Rac2, Rac3 and RhoG. 169, 170 Rac proteins play an 
important role in various cellular events, including actin cytoskeletal reorganization and 
lamellipodia formation for migration, transformation, proliferation, cell survival, gene 
expression, endocytosis and trafficking and superoxide production.171-175 Rac1, Rac2 and 
Rac3 have similar genetic sequences with different expression patterns. Rac1 is 
ubiquitously expressed, whereas Rac2 expression is restricted to cells of hematopoietic 
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origin176, 177 and Rac3 is most abundant in the brain.178, 179 RhoG has the lowest sequence 
similarity to Rac1 and is ubiquitously expressed.180 The most well studied and 
characterized protein of the Rac family is Rac1. 
1.3.2  Activation of Rac1  
Rac1 act as a molecular switch, cycling between active (Rac1-GTP) and inactive 
(Rac1-GDP) forms on the cell membrane. Under basal conditions, inactive Rac1 localizes 
in the cytosol and is bound to a GDP dissociation inhibitor (GDI). Upon stimulation by 
various factors such as cytokines, Rac1-GDP dissociates from GDI and attaches to the 
membrane. Two major classes of proteins facilitate binding and hydrolysis of GTP to 
GDP on Rho GTPases, which are guanine nucleotide exchange factors (GEFs) and the 
GTPase activating proteins (GAPs), respectively.  
GEFs become activated and will open the Rac1 nucleotide-binding site to allow 
the exchange of GDP for GTP and subsequent activation of downstream effectors.181 
Activation of GEFs through upstream activation signals can occur through several 
different mechanisms, which include protein-protein or protein-lipid interactions, binding 
of second messengers and posttranslational modifications.182 For example, a common 
activator of Rac-GEFs is phosphoinositide 3-kinase (PI3K) which induces GEF 
membrane translocation and/or conformational changes.183 Some Rac-GEFs known to be 
activated through PI3K include P-Rex, SWAP-70, Tiam1, Pix, Sos and Vav.183, 184 Some 
common second messengers can also activate GEFs, including cyclic adenosine 
monophosphate (cAMP), Ca2+ and diacylglycerol (DAG).182 Over 70 GEFs have been 
reported in humans and in most cases, each GEF can activate multiple Rho GTPases, 
creating a network of complex crosstalk between GEFs and Rho GTPase proteins.185 For 
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example, the GEF Tiam1 can activate Rac1, Rac2 and Rac3 while another GEF, Vav1, 
can also activate Rac1 along with RhoA, RhoG and Cdc42.186 Similar to GEFs, over 80 
GAPs regulate Rho GTPases and can act on multiple Rho GTPases. Although GTPase 
proteins have their own intrinsic GTP hydrolysis activity, the reaction speed is slow and 
interaction with a GAP can accelerate the GTP hydrolysis reaction by several orders of 
magnitude (Figure 1.3).187 To account for the large numbers of GEFs and GAPs 
compared to Rho GTPase proteins, it has been shown that some GEFs and GAPs have 
spatial-temporal specific expression and may regulate a specific Rho GTPase signaling 
pathway.188 181 
 
Figure 1.3.  Schematic representation of the Rac1 activation cycle.  
Rac1 will cycle from an inactive GDI-bound state in the cytosol to an inactive GDP-
bound state on the cell membrane. GEFs enable the exchange for GDP for GTP to 
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activate Rac1, which will then activate downstream effectors. GAPs facilitate the 
exchange of GTP for GDP, thus inactivating Rac1.  
1.3.3 Pleiotropic Effects of Rac1  
Activated Rac1 interacts with a multitude of effectors to activate downstream 
signaling cascades and influence numerous, diverse physiological responses. Some 
effectors of activated Rac1 include p67phox, IQ motif containing GTPase activating 
proteins (IQGAPs), p21 activating kinases (PAK), Wiskott-Aldrich syndrome protein 
with a V-domain (WAVE), and partitioning-defect-6 (PAR-6).171, 189 Interaction of 
activated Rac1 with p67phox leads to activation of NADPH oxidase and production of 
superoxide.190 IQGAPs stabilize active Rac1 and acts as a scaffolding protein to regulate 
cell adhesion, actin cytoskeleton and cell cycle progression signaling pathways.191 Cell 
adhesion and cytoskeleton dynamics can also be partially regulated through PAKs, along 
with transcription and cell survival.192 Binding of activated Rac1 to WAVE protein leads 
to activation of the actin-related-protein-2/3 (Arp2/3) complex which promotes actin 
polymerization from the sides of existing filaments, creating a branched-actin-filament 
network and lamellipodia formation.170 Activated Rac1 can also interact with PAR-6, 
which forms a complex with PAR-3 and the Ser/Thr kinase atypical protein kinase C 
isoform PKC (aPKC). PAR-6, PAR-3 and aPKC form the PAR complex, which is 
involved in various aspects of cell polarity.193 Rac1 can also promote gene expression 
through several different pathways, including NF-κB and PAK.194, 195 Through PAK, 
Rac1 can mediate c-Jun N-terminal kinase (JNK) regulated canonical Wnt-signaling, 
leading to downstream TCF/β-catenin transcriptional signaling.196 As well, studies have 
shown that Rac1 activation of NF-κB, JNK and p38 mitogen-activated protein kinase 
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(MAPK) can induce expression of the transcription factor activator protein-1 (AP1), 
leading to expression of genes that regulate cell cycle progression.174 Hence, Rac1 is a 
critical component of a complex signaling network in normal physiology and abnormal 
Rac1 signaling has been implicated in various pathophysiologies including cardiac 
hypertrophy, heart failure and atherosclerosis (Figure 1.4).197        
 
Figure 1.4.  Downstream effectors of Rac1.  
Activated Rac1 signals to numerous downstream effectors to regulate diverse cellular 
functions.  
1.3.4    Rac1 and Embryonic Development  
Rac1-/- mice are embryonic lethal by E9.5 with defects in germ layer formation 
due to reduced cell adhesion and motility and apoptosis of the mesoderm tissue.198 Due to 
the early lethality of Rac1-/- mice, many tissue specific Rac1 conditional knockout mouse 
models using the Cre/loxP system have been generated to study tissue specific roles of 
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Rac1. To date, Rac1 has been shown to be involved in numerous cellular processes in the 
development of many tissues and organs. Mice with an endothelial-specific Rac1 
excision are embryonic lethal by E9.5 with development defects of the major vessels and 
a complete absence of small branched vessels. Endothelial cell-specific deletion of Rac1 
blocks cell migration, adhesion, lamellipodia formation, permeability and 
tubulogenesis.199 In addition, mice with a forebrain-specific loss of Rac1 exhibit 
decreased proliferation and migration of cortical neurons during development and 
increased apoptosis of progenitors.200 During embryogenesis, specification of the 
anterior-posterior body axis depends on migration of an extra-embryonic organizer 
known as the anterior visceral endoderm (AVE).201 Rac1 is critical for specification of 
the anterior-posterior axis by acting cell-autonomously within the migrating AVE cells to 
extend projections and change cell shape. Rac1-/- mice fail to specify an anterior-posterior 
axis since AVE cells do not migrate.202 In the mouse epiblast, deletion of Rac1 results in 
embryonic lethality by E8.5. These mice have decreased migration of the mesoderm 
tissue and large scale cell death leading to defects in embryonic morphogenesis including 
failure of the lateral heart anlage to fuse, defects in closure of the neural tube and 
defective paraxial mesoderm formation.203 Regarding cardiac development, when Rac1 is 
specifically deleted in neural crest cells, OFT cushions are abnormally positioned, fused 
and smaller. In these neural crest cell Rac1 mutants, the pharyngeal arches also failed to 
remodel and the OFT remains unseptated, resulting in a common arterial trunk.  Post-
migratory Rac1-deficent neural crest cells also have an increased level of apoptosis and 
decreased proliferation, along with defective cell organization.204 To date, the role of 
Rac1 in other cardiac progenitor cells or cardiac tissues during development is unclear. 
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One study by Wei et al., used a transgenic mouse line overexpressing RhoGDIα under 
control of the cardiac-specific α-myosin heavy chain (αMHC) promoter.  RhoGDIα is an 
endogenous inhibitor of many Rho protein members including RhoA, RhoB, Rac1, Rac2 
and Cdc42. RhoGDIα transgenic mice were found to have defects in cardiac looping and 
ventricular maturation along with reduced cardiomyocyte proliferation. This study 
established Rho proteins as critical regulators of cardiac development; however, the roles 
and involvement of each specific Rho protein remained unclear.205 Therefore, the overall 
three aims of this project were to determine the specific roles of Rac1 during embryonic 
heart development.   
1.4 Cell Polarity 
Cell polarity is the asymmetrical organization of cell membrane proteins, 
intracellular organelles and the actin cytoskeleton to influence cell shape and structure 
and to regulate specialized cellular functions.206 Almost every eukaryotic cell possesses 
polarity, which is coordinated spatially and temporally and regulated by numerous 
signaling cascades and cytoskeleton dynamics. Many biological processes including 
proliferation, apoptosis, cell shape and morphology, migration and differentiation are 
coordinated and linked to polarization of a cell.  In addition to polarity within an 
individual cell, polarity between neighbouring cells must also be coordinated in order to 
form functional tissues and organs.207 Through cell polarization, diverse cell types with 
specific functions are formed within an organism. A prime example is neurons, which 
have a dendritic end for synaptic inputs and an axonal end for signaling outputs. Many 
neurons will connect with each other to form a complex network to propagate signals 
throughout the body. 208 Cell polarity is established through conserved polarity proteins 
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complexes, which include partitioning defect (PAR), Crumbs and Scribble. These 
polarity protein complexes will respond to extrinsic and intrinsic cues such as growth 
factor gradients and cytoskeleton dynamics, respectively, to establish cell polarity. 
Interestingly, recent studies have shown a critical requirement for crosstalk between 
polarity protein complexes and effectors of small Rho GTPases in regulation of polarity 
in several cell types including neurons, epithelial cells and T cells.193 For example, tight 
junction formation in keratinocytes is dependent on the activation of PAR-3, a 
component of the PAR complex, by the Rac1-GEF, Tiam1.209 Numerous studies have 
shown a direct link between aberrant cell polarization and pathophysiologies such as 
developmental defects in neural tube closure and cancer.210-212  
1.4.1 Types of Cell Polarity  
Different types of cell polarity exist including front-rear polarity seen in polarized 
migrating cells, apico-basal polarity in epithelial cells and planar cell polarity (PCP). A 
cell can take on different polarity characteristics depending on developmental cues and 
spatial and temporal factors. For example, in formation of epithelial cells during 
development, migratory mesenchymal cells undergo a mesenchymal-to-epithelial 
transition (MET), transitioning from a migratory cell with front-rear polarity to one of an 
epithelial cell with apical-basal polarity. This polarity transition involves dynamic 
changes to the actin cytoskeleton, protein localization and trafficking pathways.213  
• Front-Rear Polarity 
Front-rear polarity exists when the front leading edge and the back end of a migrating 
cell show morphological and functional asymmetry.206, 214 The Rho GTPases, Cdc42, 
32 
 
RhoA and Rac1, are distinctly localized to the front (Rac1 and Cdc42) or back (RhoA) 
while centrosomes, microtubules and Golgi are oriented towards the front of a migrating 
cell. Polarity protein complexes also tend to be localized to the leading edge.215, 216 
Cellular functions such as protein trafficking are also polarized in a migratory cell. 
Through the endocytic pathway, integrins are redistributed from the back to the front of a 
migrating cell. The exocyst complex, which tethers transport vesicles to sites of fusion, is 
localized to the front of a migratory cell and is responsible for exocytosis and endocytosis 
of integrins in the front.217, 218 This distinct organization between the front leading edge 
and back of cells is intrinsic to migratory ability (Figure 1.5A).214  
• Apical-Basal Polarity 
Apical-basal polarity is cellular asymmetry along the apical-basal cell axis and is a 
major feature of epithelial cells. Mammals have over 150 different types of epithelial 
cells that play critical roles in embryo morphogenesis, along with formation and function 
of numerous organs.219 The apical membrane domains of epithelial cells face the lumen 
or external environment while the basolateral membrane domain maintains contact with 
neighbouring cells or the underlying ECM. The correct localization of polarity proteins 
and cell-cell junctions is crucial for establishment of polarity and for designating the 
apical and basolateral domains. The PAR and Crumbs polarity protein complex define 
the apical domain while the Scribble polarity protein complex is found in the basolateral 
domain.220, 221 Cell-cell junctions, which include adherens junctions, tight junctions, gap 
junctions and desmosomes, are located at distinct regions along the apical-basal axis. 
Tight junctions prevent the diffusion of proteins between the apical and basolateral 
surfaces, thus maintaining apical-basal polarity. Adherens junctions, found basal to tight 
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junctions, form a band that encircles the cell and provide adhesion between neighbouring 
epithelial cells. The formation of both adherens junctions and tight junctions are highly 
interconnected where formation of early adherens junctions are a prerequisite for tight 
junction formation.222, 223 Along with structural polarity, functional polarity involving ion 
channels also exist to create a sodium gradient to move other ions and solutes across the 
epithelium. A polarized epithelial layer permits functional compartmentalization, 
allowing exchange of nutrients and waste between the internal and external environments 
(Figure 1.5B). A wide range of signaling pathways have been implicated in regulation of 
apical-basal polarity including TGFβ, integrin, Hippo and Wnt.224, 225 Establishment of 
apical-basal polarity is also linked to numerous cellular processes including proliferation, 
cell morphology and maintenance of overall tissue architecture.226 Loss of apical-basal 
polarity in epithelial cells is the source of approximately 90% of all human cancers.227   
• Planar Cell Polarity 
PCP is the alignment of cells across a tissue plane. PCP is orthogonal to the axis of 
apical-basal polarity and occurs between adjacent cells, allowing for coordinated 
alignment of numerous cells in a tissue. The PCP signaling pathway is well understood in 
Drosophila and many of the signaling components are well conserved in vertebrates and 
mammals. Various processes such as gastrulation, orientation of stereocilia within the 
inner ear, neural tube closure and oriented cell division are dependent on PCP genes.228-
231 PCP can be divided into two distinct molecular systems: a global group of proteins 
(Fat, Dachsous and Four-jointed), which regulate polarity in the direction of the body 
axis and a core group of proteins (Frizzled, Dishevelled, Prickle, Van Gogh, Diego and 
Flamingo), which regulate polarization signals within individual cells. A common feature 
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of both the global and core system is the asymmetrical distribution of their components 
(Figure 1.5C).232 The PCP pathway will signal to downstream effectors that include 
RhoA and Rac1, leading to changes in the actin cytoskeleton and generation of 
morphological asymmetry (Figure 1.6). In vertebrates, non-canonical Wnts, which 
include Wnt5a and Wnt11, will bind to the Frizzled receptor. This leads to recruitment of 
Dishevelled to the plasma membrane and activation of diverse pathways. Specifically, 
Dishevelled binds Daam1 (DVL-associated activator of morphogenesis 1) and activates 
RhoA to regulate the actin cytoskeleton in cell polarity and migration. In a parallel PCP 
pathway, Dishevelled binds to Rac1 to signal through JNK, leading to gene transcription 
and changes in the actin cytoskeleton and cell polarity.233, 234 Disruptions to PCP 
signaling can cause severe developmental defects including skeletal defects, left/right 
patterning defects and ciliopathies.235-237  
35 
 
 
Figure 1.5. Different types of cell polarity.   
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(A) Rho GTPases, polarity protein complexes, along with other cellular components have 
a polarized distribution, creating front-rear polarity in a migratory cell. (B) Epithelial 
cells have apical-basal polarity. The apical and basal domains have distinct localization 
of polarity protein complexes, cell-cell junctions and ion channels to regulate epithelial 
function. (C) PCP is the alignment of adjacent cells within the plane of a cell sheet. Core 
PCP proteins have an asymmetrical distribution within a cell, which is critical for 
establishment of PCP in a tissue. C, centrosome; TJ, tight junction; AJ, adherens junction 
Figure adapted with modifications from Nelson, WJ. Cold Spring Harb Perspect Biol. 
2009;1:a000513 and Devenport, D. J Cell Biol. 2014;207(2):171-179.      
 
Figure 1.6. The outcome of PCP: Actin cytoskeleton organization, cell shape, 
migration and alignment.  
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Core PCP proteins in the posterior end of a cell (Frizzled, Diego and Dishevelled) signal 
to downstream effectors, which include Rac1 and RhoA, leading to actin reorganization 
and overall polarization of cells.   
1.4.2 Rac1 & Cell Polarity 
Rac1 signaling has been shown to be a critical regulator of several cell 
polarization events including polarized migration, apical-basal polarity and PCP. The 
crucial role of Rac1 in establishment of cell polarity is not surprising, given its 
established function in actin polymerization and regulation of cytoskeleton dynamics.170   
In front-rear polarity, proper polarization and directed cell migration requires Rho 
GTPase activity and crosstalk with polarity proteins. Cell migration is the net outcome of 
Cdc42 and Rac1-directed formation of cell protrusions at the front leading edge and 
RhoA-directed retraction of adhesion complexes at the rear of a migrating cell.238 In 
migratory cells, activated Rac1 will localize at the front leading edge to form adhesions 
and activate WAVE and Arp2/3 protein complexes, leading to subsequent actin 
polymerization and lamellipodia formation. RhoA is mutually antagonistic to the activity 
of Rac1 and is most active at the rear and sides of a cell, responsible for actomyosin 
contraction necessary for cell detachment during migration.215, 216 In addition, the polarity 
protein complexes, PAR, Crumbs and Scribble, are located at the leading edge of a 
migrating cell.215, 216 Scribble can localize Rac1 to the front edge, promoting subsequent 
polarization of the Golgi apparatus and cell migration.239 Decreased Scribble expression 
can lead to reduced Rac1 activation, indicating a direct or indirection regulation of Rac1 
by Scribble.211 Defects in front-rear polarity induced through inhibition of the small 
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GTPases, Rac1 or RhoA, or disruptions in cytoskeleton organization have been shown to 
result in global loss of migratory ability in neutrophils.214     
Spatiotemporal regulation of Rac1 signaling has been demonstrated to be 
important for correct apical-basal polarization. Rac1 activity is critical for directing 
where the apical domain will form. Rac1 promotes assembly of the laminin basement 
membrane by regulating dystroglycan or β1-integrins, thus generating the correct tissue 
architecture to orient apical-basal polarity. Blocking Rac1 activity and laminin assembly 
leads to inversion of apical-basal polarity.240, 241 Activity of Rac1 is also differentially 
regulated along the apical-basal axis, with activity being higher at adherens junctions and 
lower at tight junctions, which is crucial for cell-cell junction formation.242, 243 Clustering 
of E-cadherin at sites of cell-cell contact formation leads to activation of Rac1. Local 
Rac1 activity will drive the formation of actin-based protrusions, leading to formation of 
lamellipodia and promotion of E-cadherin-mediated adherens junction formation with 
neighbouring cells.244, 245 In addition, activation of the PAR polarity complex by Rac1-
Tiam is required for tight junction formation.246 Aberrant Rac1 activity can disrupt 
adherens junction formation and perturb tight junction function, causing overall loss of 
apical-basal polarity. Thus, proper formation of cell junctions and establishment of 
apical-basal polarity requires tight regulation of Rac1 activity, coinciding with correct E-
cadherin localization and regulators of the actin cytoskeleton.247, 248  
Overall tissue organization and polarity is also regulated in part by Rac1 
signaling. However, the downstream effectors of PCP can vary between organisms and 
tissues. In Drosophila eye development, Frizzled and Dishevelled will signal to Rac1, 
leading to nuclear activation through JNK.249 In vertebrates, non-canoical Wnts (Wnt5a 
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and Wnt11) will bind to the transmembrane receptor, Frizzled, leading to recruitment of 
the scaffolding protein, Dishevelled and downstream activation of Rac1.250 Rac1 has 
been shown to be a crucial effector of the PCP pathway during convergent-extension 
movements in gastrulation.198, 251 In addition, the core transmembrane PCP protein, 
Vangl2, recruits Rac1 to regulate adherens junctions, which is critical to neural tube 
closure.252 Rac1 signaling through PAK and downstream regulation of actin dynamics 
play a critical role in morphogenesis of the auditory sensory epithelium and stereociliary 
bundle of the inner ear. Conditional loss of Rac1 activity in the developing inner ear lead 
to overall misorientation and misalignment of hair bundles, similar to what is observed in 
PCP mutants.253  
1.4.3 Cell Polarity & Heart Development  
Development of the heart is a dynamic process involving changes in cell shape 
and morphology, cell orientation and migration and tissue remodeling. Cell polarity is 
implicated early on in cardiac development during migration of cardiac progenitors to the 
embryonic midline and establishment of the early heart tube.254, 255 In early development, 
cardiomyocytes are a spherical, cuboidal-like shape and junctional proteins are 
distributed uniformly throughout the cell membrane.256 By E13.5, cardiomyocytes start to 
elongate and cell junctional proteins will begin to rearrange within the membrane. 
Following two weeks after birth, cardiomyocytes will continue the polarization process to 
acquire the typical rod-shape of adult cardiomyocytes, undergoing progressive alignment 
with neighbouring cardiomyocytes. Junctional proteins, which include adherens junctions 
and desmosomes that anchor actin filaments and intermediate filaments, respectively, will 
become restricted to the intercalated discs by P10. Gap junction proteins have a distinct 
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pattern from junctional proteins and are only restricted to the intercalated discs by one 
month after birth.256, 257 Beyond the cellular level, a recent study showed that within the 
developing embryonic myocardium, cardiac cells are locally coordinated and 
preferentially align and divide in a plane parallel to the outer surface of the heart.258 In 
addition, different areas of the ventricle have various orientations of cardiomyocyte 
growth, following a circumferential, radial or perpendicular orientation relative to the 
ventricular wall.259, 260 Cardiomyocytes in the subendocardial and subepicardial layers 
form helical sheets while cardiomyocytes in the middle layer form a circular sheet.261 
Although the cardiomyocyte polarization process has been well documented, the signals 
regulating and coordinating this process of polarization during embryonic and postnatal 
development are still relatively unclear.  
Recent studies have demonstrated a critical role for PCP in embryonic heart 
development. Specifically, mutations in Vangl2 or Scribble, components of the PCP 
pathway, led to abnormal organization and noncompaction of the ventricular 
myocardium. The developing cardiomyocytes failed to elongate and polarize, instead, 
retaining a spherical shape in PCP mutants.146, 262 As well, common to many PCP mutants 
was a defect in septation and alignment of the great arteries with their respective 
ventricles, strongly supporting a critical role for PCP signaling in OFT development.262-265 
However, these mutation studies were unable to determine the major cell types in which 
PCP signaling was required for cardiac development. Subsequent studies involving 
tissue-specific deletions of the PCP genes, Dvl1/2, Vangl2 and Wnt5a revealed a critical 
requirement for PCP signaling in SHF cells. Disruption of PCP signaling in the SHF 
resulted in defects in SHF progenitor cell deployment, shortened OFT length, defects in 
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cardiac looping and abnormal SHF progenitor cell morphology and behaviour.266-268 
Interestingly, the importance of PCP signaling during cardiac development seems to be 
species and cell type dependent. Although a critical requirement for PCP signaling in 
neural crest cells was described in fish and frogs, the role of PCP signaling in mouse 
neural crest cells is still relatively unclear.269, 270 Vangl2 (looptail; Lp/Lp) mutant mice 
lack PCP signaling and fail to complete neural tube closure. However, neural crest cell 
specification and migration occurs normally in the Lp/Lp mice.269 In addition, although 
Lp/Lp mice have CHDs, migration of cadiac neural crest cells into the developing OFT 
was shown to be normal.263 In contrast, Dvl2 mouse mutants were reported to have OFT 
defects and displayed abnormalities in cardiac neural crest cell migration into the 
developing heart.271 However, a subsequent study using the cardiac neural crest specific 
Wnt1-Cre mouse to delete Dvl1 and Dvl2 found no CHDs or defects in cardiac neural 
crest cells.266 Potential explanations for these conflicting findings regarding PCP 
signaling in mouse neural crest cells include functional redundancy between PCP genes 
and/or secondary defects to other cell types, such as the SHF cells. Further studies with 
cardiac neural crest specific deletions of PCP genes should be performed to determine the 
exact role of the PCP pathway in mouse neural crest cells. 
In addition to PCP, SHF progenitors also exhibit characteristics of apical-basal 
polarity. Before discovery of the SHF, a pioneering study in 1973 was one of the first to 
describe a population of cells adjacent to the distal border of the heart that formed a 
cuboidal epithelium of mesenchymal cells.272 In later studies in chicks, SHF progenitors 
were described to possess a pseudo-stratified columnar layer of epithelium.273 This 
organized, epithelial characteristics of SHF progenitors with apical-basolateral domains, 
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tight junctions and adherens junctions, apical monocilia and dynamic basal filopodia has 
also been confirmed in subsequent mouse studies.268, 274 The transcription factor, TBX1, 
was shown to be a critical regulator of SHF apical-basal polarity and cell morphology. 
TBX1 regulates proliferation and differentiation of the SHF and is the major gene affected 
in DiGeorge syndrome (DGS). DGS manifests from heterozygous deletion of a region of 
chromosome 22q11.2 causing OFT defects along with other developmental defects.275, 276 
Loss of TBX1 resulted in cell shape changes in the SHF, decreased basolateral membrane 
domain and impaired filopodia activity, demonstrating a critical link between the 
epithelial properties of SHF progenitors and OFT development.274  However, the role of 
Rac1 in regulation of cell polarity in SHF progenitors and OFT development is not clear.  
1.5 Rationale and Hypothesis  
CHDs are the most common type of congenital defect in humans, representing 
28% of all major congenital anomalies worldwide.277 Medical advancements have 
dramatically increased the survival rate of patients born with these types of defects. 
However, CHD adult patients often need long-term expert medical care and treatment, 
making this disease a major global health burden.278 The origins of CHDs are often 
complex and multifactorial, with both environmental and genetic contributions. Despite 
much progress in our understanding of the molecular and cellular mechanisms of heart 
development through the use of various animal models, our understanding of the etiology 
of CHDs is still incomplete.127, 128 
In recent years, research has demonstrated a critical role for cell polarity in 
embryonic development of the heart. Mature cardiomyocytes are oriented and organized 
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in a polarized manner within the heart but the signaling pathways regulating this polarity 
are not well known.256, 259 Using mouse models, several studies showed that SHF 
progenitors require PCP signaling for proper development of cardiac structures such as 
the OFT and ventricular myocardium. In addition, SHF progenitors form an apicobasally-
polarized epithelium in the dorsal pericardial wall before migration and differentiation in 
the heart tube. Disruption of this SHF polarity at an early stage impacts downstream 
development of SHF-derived cardiac structures.257, 274 Rac1 is a pleiotropic effector of 
numerous cellular processes including actin polymerization and regulation of 
cytoskeleton dynamics, which are processes involved in regulation of cell polarity.170 The 
role of Rac1 has been demonstrated in various aspects of cell polarity including front-rear 
polarity during neutrophil cell migration, orientation of epithelial apical-basal polarity 
and in PCP-regulated convergent-extension movements during gastrulation.214, 240, 251 
However, the role of Rac1 and regulation of cardiomyocyte polarity during heart 
development is unknown. Thus, the main goal of this thesis project is to understand the 
role of Rac1 in cell polarity during heart development. The overall hypothesis of this 
thesis is that Rac1 is required for cardiomyocyte polarity and embryonic heart 
development.    
1.5.1 Aim 1: Rac1 and Cardiomyocyte Polarity  
The first aim of this thesis was to study the role of Rac1 in cardiomyocyte polarity 
and embryonic heart development using a mouse line with an anterior SHF-specific Rac1 
deficiency, Rac1SHF. Early cardiomyocytes have a cuboidal shape and will gradually take 
on a polarized, elongated morphology by two weeks postnatally in the mouse. Junctional 
proteins go from being uniformly distributed in embryonic cardiomyocytes to restricted 
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at the ends of the rod-shaped adult cardiomyocytes.256, 257 What regulates this 
cardiomyocyte polarization process is still not fully understood. Rac1 is involved in 
reorganization of the actin cytoskeleton, which drives cell shape changes and 
migration.251 Studies have shown that PCP mutants have cardiomyocytes that fail to 
elongate and polarize during development.146, 262 However, whether Rac1 is a downstream 
effector of the polarity pathways that exist in developing cardiomyocytes is unclear. 
Thus, the hypothesis of the first aim of this thesis is that Rac1 is a critical regulator 
of cardiomyocyte polarity and development of RV myocardium and cardiac septum.   
The objectives of the first study were: 
1. Generate a mouse line with an anterior SHF-specific Rac1 deficiency, Rac1SHF.  
2. Analyze Rac1SHF hearts for CHDs and defects in cardiomyocyte polarity. 
3. Determine the role of Rac1 in SHF progenitors during embryonic heart 
development.   
1.5.2 Aim 2: Rac1 and Outflow Tract Development  
Development of the OFT seems to be especially dependent on cell polarity 
signaling mechanisms. Disturbances in PCP signaling in the SHF result in a spectrum of 
OFT defects, supporting a critical role for polarity in development of the OFT.266, 267 In 
addition to PCP signaling, SHF progenitors in the dorsal pericardial wall are organized 
into a polarized epithelium. Disruption of SHF progenitor apical-basal polarity impacts 
proper development of the OFT.274 This suggests that Rac1 signaling in the SHF may 
have a crucial role in OFT development, given its known role in actin organization 
downstream of cell polarity signaling pathways.251 Therefore, the hypothesis of the 
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second aim of this thesis is that Rac1 regulates SHF progenitor polarity and OFT 
development.           
The objectives of the second study were: 
1. Analyze Rac1SHF embryos for defects in SHF progenitor cell polarity. 
2. Analyze Rac1SHF hearts for OFT defects. 
3. To understand the mechanism by which Rac1 signaling in the SHF regulates 
OFT development. 
1.5.3 Aim 3: Rac1 and Ventricular Myocardium Development  
The developing ventricles have a high rate of proliferation and undergo a process 
of remodeling and compaction to form the trabeculae and compact myocardium. The 
mature myocardium is high organized with aligned, polarized cardiomyocytes.72 Multiple 
signaling pathways have been shown to play a role in ventricular myocardium 
development including Notch, BMP, FGF, retinoic acid and PCP signaling.70, 279 
However, the complete signaling mechanisms underlying ventricular myocardium 
development are still not completely understood. The known role of Rac1 in regulation of 
proliferation and cell organization suggests a role for Rac1 signaling in development of 
the ventricular myocardium.171 The Nkx2.5-Cre transgenic mouse was used for the third 
study to elucidate the role of Rac1 in ventricular myocardium development. The Cre 
recombinase in the Nkx2.5-Cre transgenic mouse is activated by E8.5.114 Therefore, the 
hypothesis of the third aim of this thesis is that Rac1 regulates proliferation and 
orientation of cardiomyocytes and development of the ventricular myocardium.  
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The objectives of the third study were: 
1. To generate a ventricular myocardium specific Rac1 conditional knockout mouse 
(Rac1Nkx2.5). 
2. To analyze Rac1Nkx2.5 hearts for CHDs and defects in proliferation and orientation 
of cardiomyocytes.   
3. To understand the mechanisms by which Rac1 signaling regulates proliferation 
and organization of cardiomyocytes in the ventricular myocardium. 
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2 Chapter 2  
2.1 Chapter Summary 
Defects in cardiac septation are the most common form of congenital heart disease but 
the mechanisms underlying these defects are still poorly understood. The small GTPase 
Rac1 is implicated in planar cell polarity of epithelial cells in Drosophila. However, its 
role in mammalian cardiomyocyte polarity is not clear. Here, we tested the hypothesis 
that Rac1 signaling in the second heart field (SHF) regulates cardiomyocyte polarity, 
chamber septation and right ventricle (RV) development during embryonic heart 
development. Mice with SHF-specific deficiency of Rac1 (Rac1SHF) exhibited ventricular 
and atrial septal defects, a thinner RV myocardium and a bifid cardiac apex. Fate-
mapping analysis showed that SHF contribution to the interventricular septum and RV 
was deficient in Rac1SHF hearts. Notably, cardiomyocytes had a spherical shape with 
disrupted F-actin filaments in Rac1SHF compared to elongated and well aligned 
cardiomyocytes in littermate controls. Expression of Scrib, a core protein in planar cell 
polarity, was lost in Rac1SHF hearts with decreased expression of WAVE and Arp2/3, 
leading to decreased migratory ability. Additionally, Rac1 deficient neonatal 
cardiomyocytes displayed defects in cell projections, lamellipodia formation and cell 
elongation. Furthermore, apoptosis was increased and the expression of Gata4, Tbx5, 
Nkx2.5 and Hand2 transcription factors was decreased in the Rac1SHF RV myocardium. 
Deficiency of Rac1 in the SHF impairs elongation and cytoskeleton organization of 
cardiomyocytes, and results in congenital septal defects, thin RV myocardium and a bifid 
cardiac apex. Our study suggests that Rac1 signaling is critical to cardiomyocyte polarity 
and embryonic heart development.   
72 
 
2.2 Introduction 
The adult cardiomyocytes are highly polarized with a rod shape and the majority of 
their cell junction proteins localized to the intercalated discs, joining the cells end to end to 
facilitate electrical conduction and contraction of the heart.1 However, during embryonic 
development, cardiomyocytes are initially formed in spherical shapes. They begin to 
elongate at E13.5 and gradually assume a rod shape during fetal and postnatal development. 
The spatial differences or asymmetries in the shape, orientation and structure of cells define 
cell polarity, which is controlled by planar cell polarity (PCP) signalling, also known as the 
non-canonical Wnt pathway.2 Initially identified in Drosophila, the PCP pathway is well 
conserved in mammalian species.1, 3 The ligands of this pathway include Wnt5a and 
Wnt11. The transmembrane receptors involved are Frizzled and Vangl2/Scrib. Through 
recruitment of Dishevelled, the PCP signals are transduced to the small GTPases RhoA 
and Rac, which in turn regulate actin polymerization and cell polarity.1, 2 The important 
role of PCP signaling in regulating cardiomyocyte polarity and embryonic heart 
development has recently emerged. Genetic knockout or mutation of PCP components 
such as Wnt11, Vangl2, Scrib, and Dishevelled2 in mice all show congenital heart 
defects.4-6 Additionally, Wnt11-/- and Vangl2 mutant mice show thin myocardium and 
defects in cardiomyocyte elongation, organization and migration.4, 5 However, the role of 
Rac in cardiomyocyte polarity and embryonic heart development is unknown. 
Rac GTPases are small (20-30 kDa) monomeric, signaling GTP-binding proteins, 
which are a subfamily of the Rho family of GTPases with four members: Rac1, Rac2, 
Rac3 and RhoG.7 Rac1 is a key molecule in the PCP pathway to promote cell polarity of 
the eyes and wings in Drosophila.8, 9 Rac1 is also an important regulator of cell migration 
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and survival. Whole body Rac1-/- mice die before E9.5, with defects in germ layer 
formation due to reduced cell adhesion and motility and increased apoptosis within the 
mesoderm.10 Furthermore, Rac1-/- embryos fail to specify an anterior-posterior axis since 
cells in the anterior visceral endoderm do not migrate,11 suggesting an important role of 
Rac1 in cell polarity during embryogenesis. 
The heart develops from three distinct populations of cells: the first heart field 
(FHF), second heart field (SHF) and cardiac neural crest. Initially, the primary heart tube 
is formed mainly from the FHF progenitors. SHF cells are then added to the heart tube to 
form the right ventricle and the outflow tract with contributions from the cardiac neural 
crest cells.12, 13 Additionally, SHF progenitors are critical to the formation of the cardiac 
septum. Abnormalities in SHF development result in congenital heart defects (CHDs) in 
mice including septal defects, which are some of the most common types of CHDs in 
humans.14, 15 To specifically study the role of Rac1 in cardiomyocyte polarity, right 
ventricle and cardiac septal development, we have generated a novel mouse model with a 
SHF (or anterior heart field, AHF) specific deficiency of Rac1 (Rac1SHF) using the 
Mef2c-Cre mouse, which directs Cre activity in the SHF.16 Our results show that Rac1 
signaling in the SHF is critical to cardiomyocyte polarity, cardiac septation and RV 
development. 
2.3 Methods 
2.3.1 Mice 
 Rac1f/f C57BL/6 mice (Stock #5550),17 and C57BL/6 mT/mG mice (Stock 
#7676)18 were obtained from Jackson Laboratory (Bar Harbor, Maine). The mT/mG 
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mouse is a global double-fluorescent Cre reporter mouse, which expresses membrane-
targeted Tomato (mT) before Cre-excision and membrane-targeted GFP (mG) after 
excision of mT.18 The Mef2c-Cre embryos16 were obtained from Mutant Mouse Regional 
Resource Centers (MMRRC, Chapel Hill, North Carolina) and rederived. A breeding 
program was carried out to generate Mef2c-Cre;Rac1f/f (Rac1SHF), Mef2c-Cre;mT/mG and 
Rac1SHF;mT/mG transgenic mice. Genotyping was performed by PCR using genomic 
DNA from tail biopsies. Primer sequences can be found in Table 2.1. All mouse 
experiments and procedures were carried out in accordance with the guidelines of the 
Canadian Council of Animal Care and approved by the Animal Use Subcommittee at the 
University of Western Ontario, Canada.   
Table 2.1.  The genotyping PCR primer sequences. 
Gene Forward Reverse 
Mef2c-Cre tgccacgaccaagtgacagc ccaggttacggatatagttcatg 
Rac1f/f tccaatctgtgctgcccatc gatgcttctaggggtgagcc 
mTmG ctctgctgcctcctggcttct cgaggcggatcacaagcaata 
Mutant reverse: 
tcaatgggcgggggtcgtt 
 
2.3.2 Histological Analysis  
Neonatal and embryonic samples were fixed overnight in 4% paraformaldehyde at 
4°C, dehydrated and paraffin embedded. Embryos were serially sectioned at 5 µm from 
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the top of the aortic arch to the apex with a Leica RM2255 microtome. Sections were 
mounted onto positively charged albumin/glycerin coated microslides in a set of five, 
with 25 µm intervals between each section. Slides were stained with hematoxylin and 
eosin (H/E) for histological analysis. Images were captured using a light microscope 
(Observer D1, Zeiss, Germany). 
2.3.3 Immunohistochemistry  
Immunohistochemical staining was performed on heart sections (5 µm). Antigen 
retrieval was carried out in sodium citrate buffer (pH 6.0) at 92 °C using a BP-111 
laboratory microwave (Microwave Research & Applications, Carol Stream, Illinois). 
Immunostaining was performed with primary antibodies for Rac1 (Santa Cruz), 
phosphohistone-H3 (phospho S10) (Abcam), cleaved caspase-3 (Cell Signaling), active 
(non-phosphorylated) β-catenin (Cell Signaling) and GFP (Abcam). All slides were 
imaged with Zeiss Observer D1 microscope using AxioVision Rel 4.7 software. For 
phalloidin and wheat germ agglutinin (WGA) staining, P0 heart samples were fixed in 
4% paraformaldehyde, cryoprotected in 30% sucrose, embedded in FSC22 frozen section 
media (Leica) and sectioned with a Leica cryostat at 10 µm thick onto glass slides. Slides 
were incubated with Alexa Fluor 488 phalloidin (Life Technologies), Alexa Fluor 647 
WGA (Invitrogen) and Hoechst 33342 (Invitrogen). Confocal images were obtained with 
a Zeiss LSM 510 Duo microscope using ZEN 2012 software (Zeiss, Germany). 
2.3.4 Western Blot Analysis  
Rac1 protein expression from P0 RV was measured by western blot analysis. 
Briefly, 40 µg of protein from isolated RV tissue was separated by 12% SDS-Page gel 
and transferred to nitrocellulose membranes. Blots were probed with antibodies against 
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Rac1 (1:500, Santa Cruz) and GAPDH (1:3000, Santa Cruz). Blots were then washed and 
probed with horseradish peroxidase conjugated secondary antibodies (1:2500, Bio-Rad) 
and detected using an ECL detection method. Signal quantification was performed by 
densitometry. 
2.3.5 RV Explant Culture  
Embryos were harvested at E12.5 and embryonic hearts were dissected to separate 
RV tissue from the whole heart. RV tissues were cultured on 1% collagen-coated tissue 
culture plastic multiwell plates, as previously described 19 with the following adaptations. 
Explants were incubated for six days at 37°C with 5% CO2 in Dulbecco’s modified eagle 
medium (DMEM) containing 10% FBS and 1% penicillin/streptomycin. Media was 
refreshed every two days.       
2.3.6 Quantitative Real-Time RT-PCR 
Total RNA was isolated from E13.5 RV using the RNeasy Mini Kit (QIAGEN). 
Reverse transcription reaction was performed using M-MLV Reverse Transcriptase 
(Invitrogen) and EvaGreen qPCR Mastermix (Applied Biological Materials Inc.) was 
used for real time thermal cycling. Samples were amplified for 35 cycles using the 
Eppendorf Mastercycler Realplex Real-Time PCR machine. 28S rRNA was used as an 
internal control. Primer sequences can be found in Table 2.2. The mRNA levels in 
relation to 28S rRNA were determined using a comparative CT method.20 
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Table 2.2.  The real-time RT-PCR primer sequences.  
Gene Forward Reverse 
Arp2 ggcttttctctccctcacct gcttctgctcctgctcaata 
Arp3 cggcgtcctctctacaagaa cagcattgaccctccaaacc 
Abi1 ttgactccacagatccctctcac ttcatagtccacaggaggaggtg 
WAVE2 gcaaggaagagtgggagaagatg cagagaatgaaggggaaggtgag 
Nkx2.5 tcaatgcctatggctacaacg gacgccaaagttcacgaagttgct 
Gata4 cactatgggcacagcagctc gcctgcgatgtctgagtgac 
Tbx5 acacaggatgtctcggatgc gttaggtgggggcagaaggt 
Rac1 aacctgcctgctcatcagtt ttgtccagctgtgtcccata 
Tbx20 cacctatggggaagaggatgttc gtcgctatggatgctgtactggt 
Hand2 gctacatcgcctacctcatggat tcttgtcgttgctgctcactgt 
28S ttgaaaatccgggggagag acattgttccaacatgccag 
 
2.3.7 Scratch Assay  
Wild-type neonatal cardiomyocytes were prepared and cultured as previously 
described.21 Cardiomyocytes were infected with adenoviruses expressing a dominant-
negative form of Rac1 (Ad-Rac1N17, Vector Biolabs, Philadelphia, PA, USA) or β-
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galactosidase (Ad-β-gal, Vector Biolabs) as a control at a multiplicity of infection of 10 
plaque forming units/cell. The scratch was performed 6 hours after adenoviral infection. 
Cells were fixed and immunostained with primary antibodies for Rac1 (Santa Cruz) and 
α-actinin (Sigma) 24 hours after scratch.   
2.3.8 Statistical Analysis 
Data are means ± SEM. Unpaired Student’s t test was used when data passed a 
normality test. Nonparametric Mann-Whitney test was employed when samples size was 
3-4 per group. Differences were considered significant at P≤0.05. 
2.4 Results 
2.4.1 Generation of a transgenic mouse with Rac1 knockdown in the 
SHF 
To elucidate the role of Rac1 in the SHF, the Mef2c-Cre mouse was crossed to the 
Rac1f/f mouse to generate Mef2c-Cre;Rac1f/f  (Rac1SHF) offspring. Rac1SHF mice have 
Rac1 gene specifically knocked down in SHF progenitors and their derivatives. 
Embryonic samples were collected and loss of the Rac1 transcript was confirmed in 
Rac1SHF hearts by quantitative RT-PCR. Rac1 mRNA expression was reduced by 51% in 
the RV myocardium of E13.5 Rac1SHF compared to littermate Rac1f/f controls (Fig. 2.1A). 
Immunostaining for Rac1 protein was also performed to further confirm the loss of 
myocardial Rac1 expression in SHF derivatives. In P0 Rac1SHF hearts, robust staining for 
Rac1 was observed in the LV. In the same P0 Rac1SHF heart section, the Rac1 signal 
intensity was markedly decreased in the RV when compared to the LV (Fig. 2.1B). Ratio 
of Rac1 to GAPDH protein was reduced by 40% in P0 Rac1SHF RV compared to 
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littermate Rac1f/f controls as determined by Western blot analysis (Fig. 2.1C). These data 
show that the Mef2c-Cre mediated recombination downregulates Rac1 expression in SHF 
derivatives of the embryonic heart.     
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Figure 2.1.  Confirmation of Rac1 deletion in Rac1SHF hearts.  
(A) Rac1 mRNA levels were significantly decreased in Rac1SHF RV compared to Rac1f/f 
controls at E13.5, as measured by quantitative RT-PCR. **P<0.01 by unpaired Student’s 
t test. (B) Immunostaining shows that Rac1 protein levels were reduced in P0 Rac1SHF 
RV compared to the LV myocardium. (C) Western blot analysis of P0 RV showed a 
significant decrease in Rac1 protein in Rac1SHF compared to Rac1f/f controls. *P<0.05 by 
Mann-Whitney test. Scale bars: 100 µm (B, top panel), 20 µm (B, lower panels).  
2.4.2 Deficiency of Rac1 in the SHF results in congenital heart 
defects 
The most prominent defect upon initial analysis of P0 Rac1SHF hearts was a gross 
morphological abnormality in the overall shape of the heart. Instead of a distinct apex, all 
P0 Rac1SHF hearts (28/28) had a deep interventricular groove and bifurcation of the two 
ventricles, resulting in a bifid cardiac apex, a rare CHD in humans (Table 2.3, Fig. 2.2A, 
B). Atrial septal defects (ASD) were observed in 82% (23/28) of Rac1SHF hearts but not 
in littermate control Rac1f/f P0 hearts (0/19) (Table 2.3, Fig. 2.2C, D). Ventricular septal 
defects (VSD) were seen in 100% (28/28) of P0 Rac1SHF hearts (Table 2.3, Fig. 2.2C, 
D). Additionally, the RV myocardium had poor trabeculation and the compact 
myocardium was significantly thinner in Rac1SHF hearts compared to littermate controls 
(Fig. 2.2E-G and Table 2.3).  These findings implicate a critical role for SHF Rac1 
signaling in cardiac septation and RV development. 
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Figure 2.2.  Mef2c-Cre induced Rac1 deletion in SHF results in congenital heart 
defects. 
 (A, B) Bifurcation between RV and LV (arrow) in P0 Rac1SHF hearts. (C, D) Atrial 
septal defect (arrow head) and ventricular septal defect (arrow) were found in P0 Rac1SHF 
hearts. (E-G) P0 Rac1SHF RV compact myocardium (double arrows) was significantly 
thinner. ***P<0.001 by unpaired Student’s t test. RA, right atrium; LA, left atrium; RV, 
right ventricle; LV, left ventricle. Scale bars: 100 µm (C, D), 50 µm (E, F).  
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Table 2.3.  Incidence of congenital heart defects in P0 Rac1SHF hearts.   
 Rac1f/f 
(n=19) 
Mef2c-Cre;Rac1f/+ 
(n=10) 
Rac1SHF 
(n=28)* 
 n %    n    %         n % 
Normal 19 100    10    100        0        0 
ASD 0 0    0    0        23       82 
VSD 0 0    0    0        28 100 
Bifid apex 0 0    0    0        28 100 
Defective RV 0 0    0    0        28 100 
ASD, atrial septal defect; VSD, ventricular septal defect; RV, right ventricle. *21 alive 
and 7 collected dead at P0. Since penetrance of congenital heart defects is 100% in 
Rac1SHF hearts, statistical analysis is not necessary. 
2.4.3 Rac1SHF hearts exhibit defective cardiomyocyte polarity 
Cardiomyocyte organization and alignment were severely disrupted in P0 Rac1SHF hearts. 
Cell membrane staining with wheat germ agglutinin (WGA) revealed rounded, spherical 
shaped cardiomyocytes in Rac1SHF RV (Fig. 2.3B) compared to Rac1f/f RV, which had 
elongated cardiomyocytes (Fig. 2.3A). Actin cytoskeleton organization was also severely 
disrupted in Rac1SHF RV, as shown by phalloidin staining to mark F-actin filaments (Fig. 
2.3D). Rac1SHF RV had an absence of long F-actin filaments while Rac1f/f RV 
myocardium exhibited long, parallel running F-actin fibers (Fig. 2.3C). In addition, 
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active (non-phosphorylated) β-catenin staining between cell junctions was also reduced in 
E13.5 Rac1SHF RV compared to Rac1f/f RV (Fig. 2.3E and F). Overall, these data 
strongly implicates disruption of cardiomyocyte polarity in Rac1SHF hearts.   
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Figure 2.3.  Rac1SHF hearts exhibit defective polarity. 
(A, B) Wheat germ agglutinin (WGA) staining to mark cell membranes of P0 Rac1SHF 
RV shows rounded cardiomyocytes compared to the elongated cells of littermate 
controls. (C, D) Phalloidin staining to mark F-actin shows disorganization in cellular 
structure and a deficiency in long actin filaments in the Rac1SHF RV. (E, F) Active (non-
phosphorylated) β-catenin staining is reduced at cell-cell junctions in E13.5 Rac1SHF RV. 
White arrows indicate cell adhesion. Scale bars: 20 µm (A-D), 10 µm (E, F).    
2.4.4 Expression of Scrib protein is lost in Rac1SHF hearts  
Scrib, the mouse homolog of the Drosophila protein Scribble, is a component of the PCP 
pathway. Immunostaining shows Scrib protein was expressed mainly in the lower part of 
RV and the cardiac apex in Rac1f/f hearts (Fig. 2.4A-B, E-F), and the number of Scrib+ 
cells was about 10 times higher in E15.5 than E12.5 Rac1f/f hearts (Fig. 2.4I-J). Notably, 
Scrib expression was almost absent in both E12.5 and E15.5 Rac1SHF hearts (Fig. 2.4C-
D, G-H) and the number of Scrib+ cells was significantly decreased in Rac1SHF hearts 
compared to littermate controls (Fig. 2.4I-J). The loss of Scrib expression implicates 
disruption of the PCP pathway and further supports a failure to establish cardiomyocyte 
polarity in Rac1SHF hearts.  
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Figure 2.4.  Decreased Scrib protein expression in Rac1SHF hearts.  
(A-D) Scrib immunostaining was performed on E12.5 paraffin sections. Arrows indicate 
Scrib protein expression. B and D are magnifications of box in A and C, respectively. (E-
H) Scrib immunostaining was performed on E15.5 paraffin sections. Arrows indicate 
Scrib protein expression. F and H are magnifications of box in E and G, respectively. (I, 
J) Number of Scrib positive cells was significantly decreased in E12.5 and E15.5 
Rac1SHF hearts. n=3 hearts per group, *P=0.05 by Mann-Whitney test. Scale bars: 100 
µm (A, C, E, G), 20 µm (B, D, F, H). 
2.4.5 Rac1 is required for lamellipodia formation and cardiomyocyte 
migration  
Cell migration is a fundamental process of gastrulation, morphogenesis and 
formation of organs and tissues during development.22 To determine whether Rac1 plays 
a migratory role in SHF derived-cells, RV from E12.5 Rac1SHF;mTmG and control 
Mef2c-Cre;Rac1f/+;mTmG control hearts were isolated and explants cultured on collagen 
gels for six days. The mTmG global double-fluorescent Cre reporter mouse expresses 
membrane-targeted Tomato (mT) before Cre-mediated excision and membrane-targeted 
GFP (mG) after excision of mT.18 Thus all SHF-derived cells in Rac1SHF;mTmG and 
Mef2c-Cre;Rac1f/+;mTmG are GFP+. It was observed that Mef2c-Cre; Rac1f/+;mTmG 
control explants had both non-SHF derived (mT - labeled) and SHF-derived (mG - 
labeled) cells migrating out from the RV explant by day six (Fig. 2.5A-C). In contrast, 
Rac1SHF;mTmG explants only had non-SHF derived cells (mT - labeled) migrating out 
from the RV explant and very little to no SHF-derived (mG - labeled) cell migration (Fig. 
2.5D-F). The migration defects observed in the Rac1SHF;mTmG RV explants indicate that 
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Rac1 regulates migration of SHF-derived progenitor cells, likely through actin 
organization controlled by the WAVE and Arp2/3 pathway downstream of Rac1.23 A 
significant decrease was found in Abi1, WAVE2, Arp2 and Arp3 expression, components 
of the WAVE and Arp2/3 complex, in E13.5 Rac1SHF RV compared to littermate controls 
(Table 2.4). To further assess cell migration, scratch assays were performed on neonatal 
cardiomyocytes infected with adenoviral constructs of β-galactosidase (Ad-βgal) or 
dominant negative Rac1 (Ad-Rac1N17). It was observed that 24 hours after scratch, Ad-
βgal-treated cardiomyocytes were aligned perpendicular to the scratch edge and had 
projections along the scratch edge, indicative of actin organization and lamellipodia 
extension (Fig. 2.5G). In contrast, no projections and lamellipodia formation were 
observed in Ad-Rac1N17 cardiomyocytes and the cells were disorganized and arranged 
in a random orientation along the scratch edge (Fig. 2.5H). Overall, these findings 
implicate Rac1 in the regulation of cell migration and lamellipodia extension in 
cardiomyocytes.        
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Figure 2.5.  Rac1 deficiency results in defective cell migration and lamellipodia 
formation. 
(A-C) E12.5 RV explant cultures of Mef2c-Cre;mTmG;Rac1f/+ hearts have both SHF-
derived (mG) and non-SHF-derived (mT) migrating cells. (E-F) E12.5 RV explant 
cultures of Rac1SHF;mTmG hearts have only non-SHF-derived (mT) migrating cells 
without any SHF-derived migrating cells (mG). (G-H) Scratch assays of adenoviral 
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infected neonatal cardiomyocytes show cellular projections and lamellipodia extensions 
(arrows) beyond the scratch edge in Ad-βgal treated cells and none in Ad-Rac1N17 
treated cells 24 hours post-scratch. Dotted white line indicates scratch edge. Shown are 
representative images from 3 independent experiments.  
Table 2.4.  Real-time PCR analysis of gene mRNA levels in E13.5 Rac1SHF RV. 
   Gene Rac1f/f 
 
Rac1SHF 
 
P Values 
 
 Nkx2.5 
            
   Gata4 
 
   Tbx5 
 
   Hand2 
 
   Tbx20 
 
   Abi1 
 
   WAVE2 
 
   Arp2 
 
   Arp3 
 
   β-actin 
0.0583 ± 0.00423 (n=6) 
0.0410 ± 0.00206 (n=6) 
  0.0124 ± 0.00043 (n=8) 
0.0315 ± 0.00281 (n=6) 
0.0428 ± 0.0038 (n=6) 
0.0268 ± 0.00215 (n=8) 
0.1174 ± 0.00902 (n=8) 
0.0246 ± 0.00239 (n=8) 
0.1306 ± 0.00639 (n=8) 
0.2977 ± 0.0395 (n=6) 
0.0462 ± 0.00467 (n=6) 
0.0299 ± 0.00405 (n=6) 
0.0090 ± 0.00135 (n=8) 
0.0211 ± 0.00116 (n=6) 
0.0331 ± 0.00423 (n=8) 
0.0177 ± 0.00341 (n=8) 
0.0756 ± 0.0140 (n=8) 
0.0167 ± 0.00109 (n=8) 
0.0901 ± 0.0109 (n=8) 
0.2220 ± 0.0298 (n=6) 
     0.0320 
     0.0338 
     0.0320 
     0.0065 
     0.1256 
     0.0404 
     0.0247 
     0.0098 
      0.0063 
      0.1534 
Data are ratios to 28S and presented as mean ± SEM. Significance in gene expression 
difference between Rac1SHF and Rac1f/f littermates analyzed by unpaired Student’s t test. 
P<0.05 was considered statistically significant. No significant differences were found in 
Tbx20 and β-actin mRNA expression. 
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2.4.6 Rac1SHF cardiomyocytes are shortened and rounded  
Neonatal cardiomyocyte cultures from Rac1SHF RV tissues showed that these cells had 
disrupted actin organization as indicated by phalloidin staining and the absence of distinct 
cell projections compared to Rac1f/f cardiomyocytes. Interestingly, patterning of α-actinin 
seemed to be disrupted as well in Rac1SHF cardiomyocytes (Fig. 2.6A, B). Measurement 
of cardiomyocyte long axis length revealed significantly shorter Rac1SHF cardiomyocytes 
compared to littermate control cardiomyocytes (Fig. 2.6E). Additionally, neonatal 
Rac1SHF cardiomyocytes were rounded compared to control Rac1f/f cardiomyocytes, 
which had an elongated morphology (Fig. 2.6C, D). No rounded cardiomyocytes were 
found in Rac1f/f cultures while over 40% of Rac1SHF cardiomyocytes exhibited a rounded 
morphology (Fig. 2.6F). These data strongly support the role of Rac1 in regulating 
elongation and polarization of cardiomyocytes. 
 
92 
 
 
93 
 
Figure 2.6.  Cells are rounded and cell length is reduced in cultured neonatal 
Rac1SHF cardiomyocytes. 
 (A, B) Phalloidin and α-actinin staining of neonatal cardiomyocytes show defective 
cellular organization and projection formation in Rac1SHF cells. (C, D) Rac1SHF 
cardiomyocytes are a spherical shape compared to Rac1f/f controls. (E, F) Long axis 
measurements of Rac1SHF cardiomyocytes showed that these cells are significantly 
shorter and are more spherical compared to Rac1f/f controls. n=3 independent cultures per 
group, * P=0.05 by Mann-Whitney test (E). Since penetrance of round cardiomyocyte is 
0% in Rac1f/f cultures, statistical analysis is not necessary (F). Scale bars: 10 µm (A, B), 
20 µm (C, D).  
2.4.7 Contribution of SHF progenitors to Rac1SHF hearts is decreased 
Histological analysis showed that a deep fissure between the RV and LV was observed in 
E11.5 Rac1SHF hearts while this was not evident and the early muscular interventricular 
septum was beginning to form in littermate control hearts (Fig. 2.7A, B). At E12.5, 
bifurcation of the RV and LV in Rac1SHF hearts continued to be present (Fig. 2.7C, D) 
and by E15.5 a distinct apex was formed in control hearts while Rac1SHF hearts continued 
to have a deep cleft separating the ventricles (Fig. 2.7E, F). Fate-mapping with the 
mT/mG global double-fluorescent Cre reporter mouse18 was performed to follow the 
developmental progression of the SHF progenitors. A deficiency in the SHF lineage 
contributing to the developing E11.5 Rac1SHF;mTmG hearts was evident, especially in the 
early forming muscular interventricular septum between the RV and LV (Fig. 2.7G, H). 
At E12.5 and E15.5, the interventricular septum in Rac1SHF;mT/mG hearts had a major 
deficiency of SHF-derived cells, leading to formation of a bifid apex (Fig. 2.7I-L). These 
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findings implicate a critical role of SHF Rac1 signaling in muscular interventricular 
septum formation.  
 
Figure 2.7.  Deficient SHF progenitor contribution to Rac1SHF hearts.  
(A-F) H/E staining of E11.5, E12.5 and E15.5 heart sections shows defective 
interventricular septum formation (arrow) in Rac1SHF hearts, leading to a bifid cardiac 
apex. (G-L) Fate mapping with mT/mG reporter shows a decreased SHF progenitor 
contribution to the interventricular septum (arrow) in Rac1SHF hearts. Paraffin sections 
were immunostained with anti-GFP. Scale bars: 100 µm (A-J), 200 µm (K, L).  
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2.4.8 Rac1 promotes cell survival in SHF-derived myocardium  
Aberrant apoptosis or decreased proliferation in the SHF may contribute to CHDs. To 
determine whether an abnormality in proliferation was a factor in Rac1SHF hearts, 
phosphohistone-H3 (pHH3) protein staining was performed on E11.5 heart sections (Fig. 
2.8A-F). No differences in proliferation were observed between Rac1SHF and Rac1f/f 
control hearts (Fig. 2.8G). Next, we stained for cleaved caspase-3 (the active form of 
caspase-3) on E11.5 heart sections to detect cell apoptosis (Fig. 2.9A-D). Cleaved 
caspase-3 staining was quantified as a percentage to the total number of cells. E11.5 
Rac1SHF hearts had significantly higher levels of apoptosis in the RV compared to 
littermate controls (Fig. 2.9E, P<0.05). Similarly, increased apoptosis was also observed 
in the interventricular septum of E11.5 Rac1SHF hearts (Fig. 2.9B, D, E, P<0.05). No 
significant difference in apoptosis was observed in the LV between E11.5 Rac1SHF and 
control hearts (Fig. 2.9E, P=0.27). Together, this data defines a requirement for Rac1 in 
cell survival but not proliferation in the development of SHF-derived cardiac structures.   
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Figure 2.8.  Phospho histone H3 (pHH3) protein staining to assess cell proliferation 
in E11.5 Rac1SHF hearts. 
(A-F) Representative pHH3 staining in transverse heart sections. Arrows indicate 
positive signals. Scale bars: 20 µm. (G) No significant differences in cell proliferation 
were found between E11.5 Rac1SHF and Rac1f/f  hearts. n=3 hearts per group.  
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Figure 2.9.  Increased apoptosis in Rac1SHF RV and interventricular septum. 
(A-D) E11.5 heart sections were immunostained with cleaved caspase-3 antibody to mark 
apoptotic cells. Arrows indicate positive signals. B and D are magnifications of the box in 
A and C, respectively. (E) Quantification of apoptosis in RV, LV and the cardiac septum. 
* P<0.05 vs. corresponding Rac1f/f by Mann-Whitney test. Scale bars: 100 µm (A, C), 10 
µm (B, D). (F) The proposed pathway of Rac1 signaling in SHF derivatives during 
embryonic heart development. Rac1 regulates actin organization to promote 
cardiomyocyte polarity and cell migration. Additionally, Rac1 promotes cell survival and 
the expression of cardiac developmental genes. Overall, these effects of Rac1 contribute 
to normal RV and septal development of the heart. 
2.4.9 Downregulation of transcription factors  
 Heart development is regulated by a complex network of transcription factors, 
which interact synergistically and in a dose-dependent manner to activate target genes.24 
To address the genetic pathways regulated by Rac1 signaling in the SHF, we analyzed 
known transcription factors important for heart development. Expression levels of Gata4, 
Nkx2.5 and Tbx5 mRNA were significantly decreased in the RV of E13.5 Rac1SHF 
compared to Rac1f/f hearts (Table 2.4). Hand2 and Tbx20 are two transcription factors 
shown to be expressed predominantly in the RV and regulate RV development.25, 26 
Hand2 expression was significantly decreased in the RV of E13.5 Rac1SHF compared to 
Rac1f/f hearts (Table 2.4). However, no significant differences were found in Tbx20 
expression between Rac1f/f and Rac1SHF RV (Table 2.4). Taken together, these findings 
indicate that transcriptional regulation of RV development was severely disrupted in the 
Rac1SHF hearts.  
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2.5 Discussion 
The present study was carried out to examine the role of Rac1 in SHF progenitors. 
Using the SHF specific Mef2c-Cre mouse line to delete Rac1 in SHF progenitors and 
derivatives, we demonstrated that a Rac1 deficiency in the SHF leads to 100% penetrance 
of CHDs including septal defects, thin RV myocardium and defective trabeculation and 
most notably, a bifid cardiac apex. Our data showed for the first time that Rac1 signaling 
is critical to cardiomyocyte polarity and embryonic heart development with contributions 
of cell migration, survival and cardiac gene expression (Fig. 2.9F).  
Rac1 has been shown to be a downstream effector of the PCP pathway by 
modulating the cytoskeleton and regulating actin dynamics in Drosophila and Xenopus.9, 
27 However, the role of Rac1 in mammalian cardiomyocyte polarity and heart 
development is not known. Studies have shown that disruption of the PCP pathway in 
mice by deletion of Scrib resulted in cellular disorganization, defective trabeculation, thin 
myocardium and chamber septation defects,6 which are strikingly similar to the defects 
observed in this study and strongly supports a disruption of PCP signaling in Rac1SHF 
hearts. Interestingly, we observed that Scrib protein expression pattern is most abundant 
in the RV and interventricular septum junction during embryonic heart development. 
Notably, Scrib protein expression in this distinct cardiac tissue area is lost in Rac1SHF 
hearts. We postulate that cardiomyocytes at the RV and interventricular junction must be 
highly polarized and oriented to align with the forming cardiac apex. The rounded, non-
polarized and disorganized Rac1SHF cardiomyocytes are likely unable to bridge the RV 
and interventricular junction to unify the two ventricles to form a cardiac apex resulting 
in bifurcation of the muscular septum. In addition, a decrease in cell number due to 
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increases in apoptosis in this area may also contribute to the development of bifid apex. It 
has been reported that genetic deletion of transcription factor Ets1 also results in VSD 
and bifid cardiac apex.28 However, another group using the same Ets1 knockout mouse 
did not observe a bifid cardiac apex.29 This makes the role of Ets1 still unclear in the 
formation of a bifid cardiac apex. Recorded cases of bifid cardiac apex in humans are 
very rare and have usually been reported concomitantly with other congenital heart 
anomalies including ASD, VSD and defective RV development,30, 31 which are very 
similar to the type of defects that were observed in Rac1SHF hearts. Thus, it is possible 
that the bifid cardiac apex and associated cardiac defects found in humans could be 
partially associated with abnormalities in Rac1 signaling and defects in cardiomyocyte 
polarity during embryonic heart development.  
It is well established that actin is the most abundant cytoskeleton protein and 
plays a critical role in controlling cell orientation, cell shape and migration. Rac1 is an 
important regulator of actin polymerization, ruffle formation, lamellipodia extension and 
migration in numerous cell types.7 Rac1 is known to activate the Wiskott-Aldrich 
syndrome protein (WASP)-family verprolin-homologous protein (WAVE) complex, 
which is recruited to the plasma membrane and regulates the actin cytoskeleton through 
the actin-related protein-2/3 (ARP2/3) complex. ARP2/3 associates with actin filaments 
to promote formation of new filaments from the sides of existing filaments, creating a 
dendritic network of branched actin filaments to extend lamellipodia and propel cells 
forward during migration.32, 33 The combined defects in cell polarity, morphology, 
lamellipodia formation and actin organization observed in SHF-derived cells led to an 
overall inhibition of cardiomyocyte migratory ability in Rac1SHF embryos. Furthermore, 
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Rac1 has been shown to promote cell survival by activation of the PI3K/ Akt pathway.34-
36 Decreased migration ability and an increased rate of apoptosis in SHF-derived cells 
likely concomitantly contribute to an overall deficiency in SHF contribution to the 
developing Rac1SHF heart.  
Numerous studies have found that Rac1 can regulate gene expression through 
different pathways. Interestingly, it has been shown that Rac1 can activate the canonical 
Wnt pathway by promoting nuclear accumulation of β-catenin, the effector of the Wnt 
pathway.37, 38 Ai el al. showed that deletion of β-catenin in the SHF led to abnormalities 
in development of the RV and interventricular septum,39 very similar to the defects 
observed in Rac1SHF mice in the present study. However, whether the defects were also 
due to loss of β-catenin cell-cell adhesion was not addressed in their study. Our data 
showed a loss of β-catenin cell adhesions in the Rac1SHF RV myocardium, supporting a 
defect in polarity and places non-canonical Wnt signaling as the main driver of the 
cellular and morphological defects observed. Our data is supported by Abhul-Ghani et al, 
where they showed that non-canonical Wnt, which is highly active during cardiogenesis, 
antagonizes the canonical Wnt pathway.40 However, the contribution of canonical Wnt 
signaling cannot be ruled out in our study since it has been shown to play a role in 
specification and expansion of early SHF progenitors.41 Rac1 can also promote gene 
expression through NF-κB and JNK pathways.42, 43 Our data showed that Rac1SHF hearts 
have decreased expression of Gata4, Tbx5, Nkx2.5 and Hand2 transcription factors in the 
developing RV. Thus, it is plausible that a Rac1 deficiency in the SHF will lead to 
decreased NF-κB and/or JNK signaling and down-regulation of key cardiac transcription 
factors during embryonic heart development. Tbx20 acts in a dose-sensitive manner as an 
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essential regulator of outflow tract, cardiac valve and RV development.26  However, no 
significant down-regulation of Tbx20 expression was found in the Rac1SHF hearts. A 
hierarchy of distinct cardiac transcription factor regulation exists in the developing 
heart.44, 45 Our data suggests that Rac1 regulates a distinct network of cardiac 
transcription factors that do not include Tbx20 in SHF-derivatives. Future studies will be 
necessary to determine what exact downstream pathways Rac1 regulates in the SHF to 
promote cardiac gene expression.  
Tbx5 is essential in the SHF for atrial septation,46 despite it is predominately 
expressed in the LV during early heart development.47, 48 In addition, Später et al recently 
challenged the view of Tbx5 as a classical FHF marker,49 where they showed an overlap 
of expression pattern between the posterior end of the Tbx5-positive FHF domain and the 
Isl1-positive SHF domain, thus implicating a role for Tbx5 in the SHF. Our data is 
compatible with the studies on Tbx5 from Nadeau et al,50 and Xie et al,46 where they 
showed that Gata4 and Tbx5 co-operatively regulate atrial septum development and 
haploinsufficiency of Tbx5 in the SHF results in ASDs.   
Although further investigations are required to analyze potential RAC1 gene 
mutations in humans with bifid cardiac apex, the present study has shown that SHF Rac1 
is critical to septal and RV development and deficiencies in SHF Rac1 can give rise to 
bifid cardiac apex along with the associated CHDs. Our data is the first to show Rac1 as 
an essential regulator of cardiomyocyte polarity during heart development and to provide 
a possible mechanism for how bifid cardiac apex arises. Establishment of cellular polarity 
is essential for the processes regulating cell morphology, lamellipodia formation and cell 
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migration in the developing embryo and this seems to be especially critical in formation 
of a distinct cardiac apex during embryonic heart development. 
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Chapter 3 
3.1 Chapter Summary 
The small GTPase Rac1 regulates diverse cellular functions, including both apicobasal 
and planar cell polarity (PCP) pathways. However, its role in cardiac outflow tract (OFT) 
development remains unknown. In the present study, we aimed to examine the role of 
Rac1 in the anterior second heart field (SHF) splanchnic mesoderm and subsequent OFT 
development during heart morphogenesis. Using the Cre/loxP system, mice with an 
anterior SHF-specific deletion of Rac1 (Rac1SHF) were generated. Embryos were 
collected at various developmental time points for immunostaining and histological 
analysis. Intrauterine echocardiography was also performed to assess aortic valve blood 
flow in E18.5 embryos. The Rac1SHFsplanchnic mesoderm exhibited disruptions in SHF 
progenitor cellular organization and proliferation. Consequently, this led to a spectrum of 
OFT defects along with aortic valve defects in Rac1SHFembryos. Mechanistically, it was 
found that the ability of the Rac1SHF OFT myocardial cells to migrate into the proximal 
OFT cushion was severely reduced. In addition, expression of the neural crest 
chemoattractant semaphorin, Sema3c, was decreased. Lineage tracing showed that 
anterior SHF contribution to the OFT myocardium and aortic valves was deficient in 
Rac1SHF hearts. Furthermore, functional analysis with intrauterine echocardiography at 
E18.5 showed aortic valve regurgitation in Rac1SHFhearts, which was not seen in control 
hearts.  Disruptions to Rac1 signaling in the anterior SHF results in aberrant progenitor 
cellular organization and defects in OFT development. Our data show Rac1 signaling as a 
critical regulator of cardiac OFT formation during embryonic heart development. 
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3.2 Introduction 
Cardiac outflow tract (OFT) defects account for approximately one third of all 
congenital heart defects (CHDs) reported in human births and often requires intervention 
within the first year of life. Even after surgical correction, risk of morbidity and mortality 
from OFT defects remains high.1, 2 However, the molecular mechanisms underlying OFT 
defects are not well defined. Understanding the developmental mechanisms of OFT 
formation is crucial for new insights into improving diagnostics and designing 
therapeutic approaches for CHD patients.  
Cell polarity is the asymmetrical organization of cell membrane proteins, 
intracellular organelles and actin cytoskeleton that can influence cell fate and specialized 
functions such as migration and proliferation.3 Establishment of polarity is a critical step 
in a multitude of developmental events, including formation of the OFT.4, 5  The intricate 
process of OFT development involves coordination and interactions between two distinct 
cell types, second heart field (SHF) progenitors and cardiac neural crest cells.6 The SHF 
progenitors give rise to the myocardial and endothelial cells of the OFT, semilunar 
valves, along with vascular smooth muscle cells at the base of the aorta and pulmonary 
trunk. Neural crest cells contribute to septation of the OFT and remodeling of the aortic 
arches and semilunar valves.7, 8 At approximately E8.5, cardiac neural crest cells will 
delaminate from the neural tube, migrate into the pharyngeal region and become closely 
apposed with SHF progenitors in the dorsal pericardial wall.9 SHF cells form an 
apicobasally-polarized epithelium in the splanchnic mesoderm and maintenance of this 
apicobasal polarity is crucial for heart tube elongation and OFT morphogenesis.10 Planar 
cell polarity (PCP), which is orthogonal to apicobasal polarity, has also been shown to be 
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a critical regulator of the SHF as tissue-specific deletion of core PCP genes, Vangl2 and 
Dishevelled1/2, recapitulates the spectrum of OFT defects reported in the full-body 
mutants.11, 12 Recent studies have suggested that apicobasal polarity and PCP signaling 
are interconnected where crosstalk occurs to maintain cellular polarity and overall tissue 
architecture.13, 14  
Rac1 is a small signaling GTPase from the Rac subfamily of Rho GTPases and 
has been implicated in both apicobasal polarity and PCP signaling pathways.15, 16 Rac1 
acts as a pleiotropic effector of numerous cellular processes including regulation of the 
actin cytoskeleton and overall cell shape and morphology, which are critical components 
of cell polarity.17 The role of Rac1 in cell polarity has been shown by orientation of hair 
cells in the cochlea, convergent extension cellular movements and anterior-posterior body 
axis specification during development.18-20 We have recently demonstrated Rac1 to be a 
critical regulator of cardiomyocyte polarity and cardiac septation during heart 
development.21 However, the role of Rac1 in OFT development is unknown. The SHF 
progenitors in the dorsal splanchnic mesoderm can be further subdivided into two 
subdomains: the anterior and the posterior SHF.22, 23 A Mef2c-Cre transgenic mouse has 
been developed that drives expression of Cre recombinase solely in the anterior 
subdomain of the SHF, which contributes to the right ventricle and the OFT. Specifically, 
the Cre recombinase sequence in the Mef2c-Cre transgenic mouse is under regulatory 
control of an anterior heart field specific enhancer and promoter, which was first 
discovered by Dodou et al.8, 24 In order to study the role of Rac1 in OFT formation, we 
generated an anterior SHF-specific deletion of Rac1 using the Mef2c-Cre transgenic 
mouse as described previously.21 We show that Rac1 signaling in the anterior SHF is 
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critical for progenitor cellular organization in the splanchnic mesoderm and disruptions in 
Rac1 signaling result in a spectrum of OFT defects, along with aortic valve defects. 
Furthermore, we showed that a Rac1 deficiency, restricted to the anterior SHF, leads to 
neural crest cell migration defects.    
3.3 Methods 
3.3.1 Mice 
Rac1f/f (Stock #5550) and mT/mG C57BL/6 mice (Stock #7676) were purchased from 
Jackson Laboratory, Bar Harbor, Maine.24, 25 The anterior SHF specific Mef2c-Cre 
transgenic mice were rederived from embryos obtained from the Mutant Mouse Regional 
Resource Centers (MMRRC, Chapel Hill, North Carolina).8 A breeding program to 
generate C57BL/6 Mef2c-Cre;Rac1f/f (Rac1SHF) mice was carried out and genotyping was 
performed as described previously.21 All mouse experiments and procedures were 
approved by the Animal Use Subcommittee at the University of Western Ontario in 
accordance with the guidelines of the Canadian Council of Animal Care.  
3.3.2 Fate Mapping Analysis  
Fate mapping analysis was performed using Mef2c-Cre and the mT/mG global double-
fluorescent Cre reporter mice to trace the anterior SHF and derivatives.8, 25 A breeding 
strategy was carried out to generate Mef2c-Cre;mT/mG and Mef2c-Cre;Rac1f/f;mT/mG 
(Rac1SHF;mT/mG) mice. The mT/mG mice possess loxP sites on either side of the 
membrane-targeted Tomato (mT) cassette with a membrane-targeted green fluorescent 
protein (GFP) cassette downstream. Before Mef2c-Cre mediated excision, mT (red 
fluorescence) is expressed in all cells. After Mef2c-Cre mediated excision, the mT 
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cassette is cleaved out and membrane-targeted GFP (mG) is expressed in all SHF 
progenitors and SHF-derived tissues.   
3.3.3 Histological Analysis  
Neonatal and embryonic samples were fixed overnight in 4% paraformaldehyde at 4°C, 
dehydrated and embedded in paraffin. Embryos were serially sectioned at 5 µm thick 
sections with a Leica RM2255 microtome and sections were mounted onto positively 
charged albumin/glycerin coated slides as previously described.21 Slides underwent a 
dewaxing process, stained with hematoxylin and eosin (H/E) or picrosirius red for 
morphological analysis. Images were captured with an Observer D1 light microscope 
(Zeiss, Germany). 
3.3.4 Immunohistochemistry  
For immunohistochemical staining on paraffin sections, samples underwent a deparaffin 
process and antigen retrieval was performed in sodium citrate buffer as described 
previously.21 The primary antibodies used for immunostaining include phosphohistone-
H3 (phospho S10, Abcam), GFP (Abcam), α-actinin (Sigma), Sema3c (Santa Cruz) and 
AP2α (Santa Cruz). Slides were then incubated with biotinylated secondary antibody 
followed by incubation with avidin and biotinylated HPR from the Santa Cruz 
ImmunoCruz ABC staining system kit. Antigen was visualized with diaminobenzidine 
(DAB) substrate solution and slides were counterstained with hematoxylin. All images 
were captured with Zeiss Observer D1 microscope using AxioVision Rel 4.7 software. 
For frozen sections, embryos were fixed for one hour in 4% paraformaldehyde, 
cryoprotected in 30% sucrose and embedded in FSC22 frozen section media (Leica). 
Embryos were sectioned in a sagittal orientation at 10 µm thick and immunostained with 
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the primary antibodies for Scrib (Santa Cruz), aPKCζ (Santa Cruz), and active (non-
phosphorylated) β-catenin (Cell Signaling). Additional staining was also performed with 
AlexaFluor 488 phalloidin (Life Technologies), AlexaFluor 647 wheat germ agglutinin 
(Invitrogen) and Hoechst 33342 (Invitrogen). A Zeiss LSM 510 Duo microscope with 
ZEN 2012 software (Zeiss, Germany) located at the Biotron Experimental Climate 
Change Research Center at Western University, London, Ontario was used to obtain 
confocal images.  
3.3.5 Intrauterine Echocardiography  
Echocardiography was performed on pregnant mice using Vevo 2100 (VisualSonics, 
Canada).26 Briefly, pregnant mice were anaesthetized with isoflurane and fur was shaved 
from the abdomen to better image embryos. A map was drawn of the location of embryos 
relative to each other to facilitate harvesting of embryos after intrauterine 
echocardiography. A dynamically focused 40 MHz probe was used to obtain 2-
dimensional images of embryonic hearts in short-axis view. Diastolic and systolic left 
ventricular internal diameters (LVID) were measured from M-mode recordings. 
Calculations were performed as followed: ejection fraction (EF, %) = [(LVIDd)3 - 
(LVIDs)3]/(LVIDd)3×100. Fractional shortening (FS, %) = (LVIDd-LVIDs)/LVIDd×100. 
To assess aortic valve regurgitation, the transducer was aligned with the long axis of the 
heart and Color flow and Pulsed-Wave Doppler were used to visualize direction of blood 
flow in the aorta. In Color Doppler mode, red indicated flow towards the transducer and 
blue indicated blood flow away from the transducer. Pulsed-Wave Doppler mode was 
used to measure direction of blood flow, bloodflow velocity and duration of the aortic 
valve regurgitation.27 
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3.3.6 Statistical Analysis 
Data are presented as means ± SEM. When data passed a normality test, an unpaired 
Student’s t test was employed to test for significance. Nonparametric Mann-Whitney test 
was used when samples size was 3 per group. Differences were considered significant at 
P<0.05. 
3.4 Results 
3.4.1 Early defects in the splanchnic mesoderm of Rac1SHF 
Lineage tracing analysis using Mef2c-Cre and mT/mG global double fluorescent 
reporter mice revealed that lack of Rac1 in the anterior SHF resulted in defects in 
splanchnic mesoderm at E9.5. Large acellular spaces were observed between GFP+ SHF 
progenitor cells and less cells resided in the overall splanchnic mesoderm region of E9.5 
Rac1SHF;mTmG embryos (Fig. 3.1C, D) compared to littermate Mef2c-
Cre;mTmG;Rac1f/+ controls (Fig. 3.1A, B). The number of GFP+ SHF progenitor cells in 
the splanchnic mesoderm was significantly less in Rac1SHF embryos compared to controls 
(Fig. 3.1E). Before differentiation, the SHF progenitor population in the splanchnic 
mesoderm is highly proliferative.28 To analyze SHF proliferation, phosphohistone-H3 
(pHH3) immunostaining was performed on sagittal sections of E9.5 embryos (Fig. 3.1F, 
G). The proliferation rate of SHF progenitors in E9.5 Rac1SHF was significantly reduced 
compared to littermate Rac1f/f controls (Fig. 3.1H). This reduced proliferation rate likely 
resulted in a reduced number of SHF progenitors within the Rac1SHF splanchnic 
mesoderm. Overall, these results define a requirement for Rac1 signaling in SHF 
progenitor cell proliferation.  
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Figure 3.1.  Early defects in E9.5 Rac1SHF splanchnic mesoderm. 
Lineage tracing with Mef2c-Cre;mT/mG showed a decreased number of GFP+ SHF cells 
along with large acellular spaces in the splanchnic mesoderm of Rac1SHF;mT/mG (C, D) 
compared to littermate control embryos (A, B). The number of GFP+ SHF progenitor 
cells in the splanchnic mesoderm was significantly reduced in E9.5 Rac1SHF;mT/mG 
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compared to controls (E). Immunostaining for phospho-histone H3 (pHH3) in the 
splanchnic mesoderm (F, G) showed a reduced proliferation rate in Rac1SHF SHF 
progenitors compared to Rac1f/f controls (H). *P<0.05, **P<0.01 by Student’s t-test, n=4-
5 embryos per group. Scale bars: 100 µm (A, C), 10 µm (B, D), 20 µm (F, G). OFT, 
outflow tract; IFT, inflow tract; SpM, splanchnic mesoderm.     
3.4.2 Disruption of cell shape and organization in Rac1SHF splanchnic 
mesoderm 
SHF progenitor cells possess apicobasal polarity which form a polarized epithelial 
layer in the dorsal pericardial wall.10 Our data show that cellular organization was 
severely disrupted in the E9.5 Rac1SHF anterior SHF progenitors (Fig. 3.2). The 
basolateral and apical domains of the Rac1f/f splanchnic mesoderm were marked by 
Scribble and aPKCζ, respectively. In addition, the SHF progenitors have a cuboidal 
shape, with neighbouring cells aligned with one another to form the epithelial layer (Fig. 
3.2A-C). In comparison, organization of the Rac1SHF SHF epithelial layer was lost and 
SHF progenitor cells exhibited a rounded morphology. Cellular organization in the E9.5 
Rac1SHF splanchnic mesoderm was disturbed where the basal domains of neighbouring 
SHF progenitors were no longer aligned with one another and the cells displayed a 
rounded morphology (Fig. 3.2D-F). Orientation of the long axis of the anterior SHF 
progenitor cells were measured relative to the axis of the dorsal pericardial wall (Fig. 
3.2G) and it was found that E9.5 Rac1SHF SHF progenitor cells had a random, 
unorganized orientation compared to Rac1f/f controls. Rac1f/f SHF progenitors had an 
orientation range of 62 – 89.5°, averaging 78.5° relative to the dorsal pericardial wall 
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axis. In comparison, Rac1SHF SHF progenitors oriented with a significantly smaller angle 
averaging 41.8° relative to the dorsal pericardial wall axis (Fig. 3.2H). Cell-cell 
junctions, as marked by active (non-phosphorylated) β-catenin expression, was disrupted 
in the E9.5 Rac1SHF splanchnic mesoderm compared to Rac1f/f controls, further 
supporting a disruption in SHF progenitor cell organization (Fig. 3.2I, J). Taken together, 
these findings support a critical role of Rac1 signaling in regulation of overall SHF 
progenitor cell shape and maintenance of cell organization.  
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Figure 3.2.  Disrupted apicobasal cell polarity and orientation in Rac1SHF splanchnic 
mesoderm. 
In E9.5 Rac1f/f SHF progenitors, the basolateral domain is marked by Scribble (B, 
arrows) and the apical domain is marked by aPKCζ (A, arrowheads). The SHF 
progenitors have a distinct cuboidal shape, forming an organized epithelial layer (C). 
Polarity is disrupted in Rac1SHF SHF progenitors where the Scribble+ basal domains (E, 
arrows) and aPKCζ+ apical domains (D, arrowheads) of individual cells are no longer 
aligned with neighbouring cells due to the rounded morphology of the SHF progenitors 
(F). C is an overlay of A and B. F is an overlay of D and E. The angle of E9.5 SHF 
progenitor cell long axis (dashed line) was measured relative to the axis of the dorsal 
pericardial wall (dashed arrow line) to obtain the degree of orientation (G). Images in G 
are from C and F with an overlay of schematic axis and angle measurements. E9.5 Rac1f/f 
SHF progenitor cells were approximately perpendicular to the dorsal pericardial wall 
axis. E9.5 Rac1SHF SHF progenitors had a random range of orientation with an average of 
41.8° (H).  ***P<0.001 by Student’s t-test, n=4 each group. Active (non-phosphorylated) 
β-catenin marked cell-cell junctions in E9.5 Rac1f/f SHF progenitors (I, arrows). In 
comparison, cell-cell junctions were disrupted in E9.5 Rac1SHF SHF progenitors (J). 
Scale bars: 10 µm (A-F, I-J).   
3.4.3 Loss of Rac1 in the SHF results in shortened OFT and 
myocardial defects of the OFT 
Sufficient lengthening of the heart tube from SHF progenitors ensures 
convergence of the inflow and outflow poles during cardiac looping. A shortened outflow 
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tract alters looping and leads to arterial pole misalignment defects such as double outlet 
right ventricle (DORV) and overriding aorta.29, 30 The sagittal length of the OFT was 
measured at E10.5 (Fig. 3.3A, B) and it was found that the Rac1SHF OFT was 
significantly shorter compared to controls (Fig. 3.3C). Closer analysis of the SHF-
derived OFT myocardium revealed a disorganized myocardial layer in E10.5 Rac1SHF 
OFT compared to controls (Fig. 3.3D-G). Myocardial cells in the Rac1f/f OFT were 
aligned with one another and had a general oval or cuboidal cell shape (Fig. 3.3D, F). In 
contrast, myocardial cells in the Rac1SHF OFT were not as well aligned and the shapes of 
the cells were not as distinctly oval or cuboidal (Fig. 3.3E, G). In addition, cell-cell 
adhesion junction marked by β-catenin was generally disrupted in the myocardium of 
E10.5 Rac1SHF OFT compared to Rac1f/f controls (Fig. 3.3H, I). Myocardial cells of 
Rac1f/f OFT had distinct cell-cell borders with neighbouring myocardial cells and β-
catenin was localized to the basolateral region. Basolateral localization of β-catenin was 
disrupted in the myocardium of E10.5 Rac1SHF OFT. These results suggest an important 
role of Rac1 in generating the cellular organization of the myocardial layer and 
lengthening of the OFT.  
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Figure 3.3.  Defects in early Rac1SHF outflow tract development. 
(A-C) Length of the OFT at E10.5 was measured in sagittal sections (A, B) and was 
found to be significantly shorter in Rac1SHF compared to Rac1f/f controls (C). *P<0.05 by 
Student’s t-test, n=4-5 each group. (D, E) Wheat germ agglutinin (WGA) staining to 
mark cell membranes of SHF cells in the OFT at E10.5 show a disorganized myocardial 
layer in Rac1SHF compared to Rac1f/f littermate controls. F and G are schematic diagrams 
of D and E, respectively. (H, I) Active (non phosphorylated) β-catenin staining is reduced 
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at cell-cell junctions in E10.5 Rac1SHF OFT myocardial cells. White arrows indicate cell-
cell adhesion sites. Dotted white lines indicate boundaries of the OFT myocardial layer in 
D, E and H, I. Scale bars: 100 µm (A, B), 10 µm (D, E, H, I). Myo indicates 
myocardium.   
3.4.4 OFT defects in Rac1SHF hearts 
Examination of Rac1SHF hearts revealed a spectrum of OFT defects from E14.5 to 
P0 that was 100% penetrant (Table 3.1). The majority of the defects found were OFT 
alignment defects. Over one third of Rac1SHF hearts (23/64) displayed DORV (Fig. 3.4A-
D) and over another one third (24/64) exhibited an overriding aorta (Fig. 3.4E, F). 
Transposition of the great arteries (TGA) was found in one P0 Rac1SHF sample (Fig. 
3.4G, H). In addition to defects in OFT alignment, defects in septation of the OFT 
resulting in persistent truncus arteriosis (PTA) or common arterial trunk was observed in 
9.4% (6/64) of Rac1SHF hearts (Fig. 3.4I, J). Narrowing of the great arteries was also 
observed in Rac1SHF hearts including stenosis of the pulmonary artery (Fig. 3.4K, L) and 
aortic atresia (Fig. 3.4M, N). In one case of aortic atresia in Rac1SHF hearts, aortic valves 
were also severely malformed (Fig. 3.4O, P). In addition, we observed abnormalities in 
aortic arch artery remodeling resulting in a retroesophageal right subclavian artery or a 
vascular ring, a congenital defect in which vascular structures surround and constrict the 
esophagus and trachea. This was evident in 18.8% (12/64) of Rac1SHF hearts and of the 12 
samples that had a vascular ring, 3/12 had a right-sided aortic arch (Fig. 3.5A-F and 
Supplemental Videos and Footnotes). Taken together, all of these data strongly support 
a critical requirement for Rac1 signaling in anterior SHF progenitors for normal OFT 
morphogenesis.   
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Figure 3.4.  Spectrum of OFT defects found in E14.5 - P0 Rac1SHF hearts. 
Double outlet right ventricle (DORV) was found in E15.5 Rac1SHF hearts (A-D). The 
pulmonary artery (PA) connects to the RV in both Rac1SHF and Rac1f/f hearts (A, B). The 
Rac1SHF aorta (arrow) incorrectly connects to the RV compared to Rac1f/f controls, where 
the aorta connects to the LV (C, D). Overriding aorta, where the aorta is positioned 
directly over a ventricular septal defect (arrow), was observed in Rac1SHF hearts (E, F). 
Transposition of the great arteries (TGA) was found in one Rac1SHF sample where the 
aorta and pulmonary artery openings were switched, which resulted in the aorta (Ao) 
connecting to the RV in Rac1SHF and the pulmonary artery to the LV (G, H), 
respectively. Persistent truncus arteriosus (PTA), where the common OFT is not divided 
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into aorta and pulmonary, was observed in Rac1SHF hearts (I, J). Stenosis of the 
pulmonary artery was observed in Rac1SHF hearts (K, L). Aortic atresia was observed in 
Rac1SHF hearts (M, N) and in one sample with aortic atresia, distinct aortic valves were 
absent (O, P). RA, right atrium; LA, left atrium. Scale bars: 100 µm.    
Figure 3.5.  Vascular rings in E15.5 Rac1SHF hearts. 
A right-sided aortic arch (AA) was observed in Rac1SHF (D) hearts compared to Rac1f/f 
controls (A). An aberrant retroesophageal right subclavian artery (SCA), which arose 
from aortic arch, was observed next to the trachea (Tr) and esophagus (Eo) in Rac1SHF 
hearts (E) compared to Rac1f/f controls (B). The SCA in Rac1SHF hearts joined with the 
pulmonary artery (PA), forming a vascular ring (F) in Rac1SHF hearts compared to 
controls (C). DA indicates dorsal aorta. Scale bars: 100 µm.   
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Table 3.1. Outflow tract defects in Rac1SHF hearts (E14.5 – P0). 
 ! TGA PTA DORV Overriding 
aorta 
Aortic 
atresia 
Vascular 
ring 
 
N=64 
 
 
1 
 
 
6 
 
23 
 
 
32 
 
 
5 
 
 
12 
 
% 
 
1.6 
 
 
9.4 
 
35.9 
 
50 
 
7.8 
 
18.8 
TGA, transposition of great arteries; PTA, persistent truncus arteriosus; DORV, double 
outlet right ventricle. All 64 Rac1SHF hearts had one or more OFT defects. No OFT 
defects were found in Rac1f/f hearts (N=36). 
3.4.5 Myocardialization defects in Rac1SHF hearts 
Myocardialization is a process where myocardial cells migrate and grow into the 
flanking mesenchyme. At E12, myocardial cells of the OFT begin to invade the 
neighbouring cushion mesenchyme. This leads to a gradual replacement of the 
mesenchymal tissue with myocardium to form the muscular outlet septum by E17.31 
Abnormalities in muscularization of the OFT cushions was observed in E12.5 Rac1SHF 
hearts. The Rac1SHF OFT myocardium lacked a polarized morphology and did not extend 
as far into the cushion mesenchyme compared to controls (Fig. 3.6A, B). Muscularization 
of the proximal OFT septum is complete in P0 Rac1f/f control hearts as shown by α-
actinin positive muscle tissue separating the aorta from the RV (Fig. 3.6C). In P0 
Rac1SHF hearts, the proximal OFT septum remained non-muscularized and remnant 
collagen rich mesenchymal tissue remained (Fig. 3.6D), staining positive for picrosirius 
red (Fig. 3.6E, F). Rac1SHF samples with defects in muscularization of the proximal OFT 
septum also presented with OFT misalignment defects including overriding aorta and 
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DORVs.  These results further support a crucial role for Rac1 signaling in regulating 
polarity, along with elongation and migration of cardiomyocytes during the process of 
OFT myocardialization.  
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Figure 3.6.  Abnormalities in Rac1SHF OFT myocardialization. 
E12.5 Rac1SHF OFT cardiomyocytes, marked by α-actinin immunostaining (B), exhibited 
a blunted morphology instead of a polarized morphology and did not extend as far into 
the OFT cushions compared to controls (A). Red arrows indicate invading 
cardiomyocytes. The proximal OFT septum remained non-muscularized in P0 Rac1SHF 
hearts (D), indicated by an absence of α-actinin staining (arrows in D) compared to 
control (C) where the septum is muscularized (arrow in C). The non-muscularized 
proximal OFT septum in Rac1SHF hearts (F) stained positive for picrosirius red (arrows in 
F), indicating that this tissue remained mesenchymal compared to controls (E) which had 
become muscularized (arrow in E). N=3 for each staining per group. Ao, aorta; RV, right 
ventricle. Scale bars: 10 µm (A, B), 50 µm (C-F).   
3.4.6 Decreased cardiac neural crest cell migration in Rac1SHF 
The aortic arch artery and OFT septation defects observed in Rac1SHF hearts 
suggests abnormal formation or remodeling of the arteries involving cardiac neural crest 
cells. Semaphorin 3c (Sema3c) is a secreted glycoprotein part of the semaphorin protein 
family, which plays a role in axon guidance.32 Sema3c is expressed in the OFT 
myocardium and acts as a chemoattractant, navigating neural crest cells to the OFT. 
Neural crest cells express the multimeric complexes of plexins and neuropilin, which are 
the receptors that recognize semaphorin ligands.33 Interactions between SHF progenitors 
and cardiac neural crest cells have been shown to be critical for development of the aortic 
arches and semilunar valves.6, 7 Sema3c expression was analyzed in Rac1SHF hearts and 
intensity of Sema3c protein staining in E11.5 Rac1SHF OFT myocardium was found to be 
decreased compared to Rac1f/f controls (Fig. 3.7C, D, F). Along with this, the mRNA 
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level of Sema3c, as measured by real-time PCR, was significantly reduced in Rac1SHF 
hearts compared to littermate controls at E13.5 (Fig. 3.7G). Consequently, this would be 
predicted to result in a reduction in the chemoattractant signal attracting the migrating 
neural crest cells into the developing heart. The number of migrating cardiac neural crest 
cells, marked by the transcription factor AP2α, was significantly decreased in the region 
between the foregut and pericardial cavity in E10.5 Rac1SHF embryos (Fig. 3.7A, B, E). 
Overall, these results suggest that disruption of Rac1 signaling in the SHF-derived OFT 
myocardium leads to reduced expression of axonal guidance signals that attract migrating 
neural crest cells into the developing OFT. 
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Figure 3.7.  Defects in neural crest cell contribution to OFT development in Rac1SHF 
hearts. 
(A, B) AP2α immunostaining was performed to mark neural crest cells in the pharyngeal 
region of E10.5 samples. (C, D) Sema3c immunostaining (brown color) in Rac1SHF and 
Rac1f/f OFT myocardium at E11.5. (E) The number of neural crest cells was significantly 
reduced in E10.5 Rac1SHF pharyngeal arches compared to controls. (F) Intensity of 
Sema3c staining in the E11.5 OFT myocardium was ranked on a scale from 1 to 5. 
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Overall intensity of Sema3c staining was reduced in Rac1SHF compared to Rac1f/f 
controls. (G) The level of Sema3c mRNA in Rac1SHF hearts at E13.5 was significantly 
reduced compared to controls. *P<0.05 by unpaired Student’s t-test, n=4-5 hearts (E, F) 
and 7-8 hearts (G) per group. FG, foregut; PC, pericardial cavity. Scale bars: 20 µm (A, 
B), 10 µm (C, D).  
3.4.7 Aortic valve defects in Rac1SHF hearts 
Formation of valves involves a complex process of cushion formation, elongation, 
valve remodelling and maturation.34 Both SHF progenitors and cardiac neural crest cells 
contribute to aortic valve development. Neural crest cells are known to be involved in late 
gestation remodelling and maturation of the aortic valves.7, 8 Thus, we predicted that the 
decreased number of migrated cardiac neural crest cells into Rac1SHF hearts would also 
affect development of Rac1SHFaortic valves. P0 Rac1SHF heart sections were analyzed and 
found to have large, thickened aortic valve leaflets compared to controls which in 
contrast had undergone remodeling and matured into thin, elongated leaflets (Fig. 3.8A, 
B). Cell density of the aortic valve leaflets was also significantly decreased in P0 Rac1SHF 
hearts compared to P0 Rac1f/f hearts (14.3 ± 1.0 vs. 17.8 ± 0.8 cells/1000 µm2, *P<0.05, 
n=5-7), suggesting defects in ECM remodeling, which is necessary for the dense packing 
of cells in the elongating valves.  
To assess glycosaminoglycans (GAG), a component of ECM in the aortic valve, 
toluidine blue staining was performed.35 The acellular space of the valve leaflets stained 
light purple indicating the presence of GAG (Fig. 3.8C, D). Notably, a significantly 
larger amount of GAG was present in Rac1SHF aortic valves compared to littermate 
Rac1f/f controls at P0 (**P<0.01, Fig. 3.8G).  
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During early stages of development there is little to no collagen present in the 
semilunar valves. As the valves mature, collagen content increases, especially at the 
commissure of the valves.36 Analysis of P0 Rac1f/f aortic valves after Masson’s trichrome 
staining revealed early signs of maturation with collagen present at the valve commissure 
(Fig. 3.8E). In comparison, P0 Rac1SHF aortic valves were less mature and had little to no 
collagen present at the valve commissure (Fig. 3.8F).  
Lineage tracing with mT/mG at E12.5 revealed decreased SHF progenitor 
contribution to the OFT cushions in Rac1SHF hearts compared to control hearts which had 
numerous SHF-derived GFP+ cells in the cushion mesenchyme (Fig. 3.9A, B, black 
arrows). At E14.5, SHF contribution to the aortic valve leaflets continues to be severely 
reduced in Rac1SHF hearts (Fig. 3.9C, D, black arrows). In addition, at both E12.5 and 
E14.5, contribution of SHF progenitors to the Rac1SHF OFT myocardium seems to be 
decreased compared to controls (Fig. 3.9A-D, red arrows). This lineage tracing data 
strongly suggests an overall impairment in overall SHF progenitor cell contribution to the 
developing heart in Rac1SHF embryos and a critical role for SHF Rac1 in maturation and 
remodeling of the aortic valves.  
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Figure 3.8.   Aortic valve defects in Rac1SHF hearts. 
Over 30% (9/28) of P0 Rac1SHF hearts exhibited thick aortic valve leaflets (B) compared 
to the thin, remodeled valves of controls (A). Toluidine blue staining showed 
glycosaminoglycans (GAG, light purple color) occupies the acellular space of Rac1SHF 
and littermate valve leaflets (C and D). Masson’s trichrome staining in Rac1f/f aortic 
valves showed collagen in the commissure of valve leaflets (E, arrows), which was 
absent in Rac1SHF aortic valves (F, arrows). GAG positive area (light purple color) in 
each valve leaflet (C and D) was quantified in G. **P<0.01 by unpaired Student’s t-test, 
n=5-6 hearts per group. RCC, LCC and NCC are right, left and non-coronary cusps, 
respectively. Scale bars: 100 µm (A-D), 10 µm (E, F).     
 
 
 
 
 
 
 
Figure 3.9.   Decreased SHF contribution to Rac1SHF OFT. 
Fate mapping with mT/mG reporter shows a decreased SHF progenitor contribution to the 
OFT myocardium (red arrows in B and D) in E12.5 and E14.5 Rac1SHF hearts compared 
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to controls (red arrows in A and C). SHF contribution to the valve leaflets was also 
severely reduced in Rac1SHF hearts compared to controls (black arrows, A-D). Paraffin 
sections were immunostained with anti-GFP. Scale bars: 20 µm.    
3.4.8 Abnormal aortic valve function in Rac1SHF hearts 
The observed aortic valve defects would be predicted to result in functional impairment 
of the valves.  To assess the function of the malformed Rac1SHF aortic valves, intrauterine 
echocardiography at E18.5 was performed. Embryos from timed pregnant females were 
analyzed prior to genotyping and thus echo analysis was performed in a blinded manner. 
All E18.5 Rac1f/f control embryos did not demonstrate any evidence of aortic valve 
regurgitation (Fig. 3.10A). On the other hand, E18.5 Rac1SHF embryos were found to 
have severe aortic regurgitation during diastole (Fig. 3.10B). In addition, left ventricular 
internal diameter during systole (LVIDs) was significantly increased in Rac1SHF hearts 
while no significant differences were observed in left ventricular internal diameter during 
diastole (LVIDd). Both ejection fraction and fractional shortening in E18.5 Rac1SHF 
embryos were also significantly reduced compared to controls (Table 3.2). Decreased left 
ventricular function in Rac1SHF hearts is likely related to the defects in myocardial 
development reported in our previous study.21 Overall, this echocardiography data further 
defines a requirement for SHF Rac1 in development and functional maturation of the 
aortic valves. 
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Figure 3.10.   Aortic valve regurgitation in Rac1SHF hearts. 
Intrauterine pulsed-wave echocardiography at E18.5 showed that Rac1SHF hearts had 
severe aortic regurgitation during diastole (B, red arrows), which is not observed in 
Rac1f/f littermates (A).  White arrows in A and B indicate forward blood flow during 
systole. Shown are representatives of 5 fetuses per group from 4 mothers. 
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Table 3.2. Intrauterine echocardiography in E18.5 Rac1SHF hearts.  
 Rac1f/f  
 
(n=5) 
Rac1SHF 
 
(n=5) 
 
Duration of backflow (ms) 0 198 ± 20 
Velocity of backflow (mm/s) 0 256 ± 96 
LVIDd (mm) 0.87 ± 0.03 0.89 ± 0.05 
LVIDs (mm) 0.57 ± 0.02 0.66 ± 0.03 * 
Ejection Fraction (%)  33.88 ± 1.15 25.64 ± 1.42 ** 
Fractional Shortening (%) 70.99 ± 1.49 58.71 ± 2.37 ** 
LVIDd, left ventricular internal diameter in diastole; LVIDs, left ventricular internal 
diameter in systole. *P<0.05, **P<0.01 by unpaired Student’s t-test.  
3.5 Discussion 
Recent studies have established cell and tissue polarity as important regulators of cardiac 
OFT development, especially factors involved in the PCP pathway.11, 12 However, the 
role of Rac1 in cardiac OFT development is not clear. In the present study, we 
demonstrated that a deficiency of Rac1 signaling in the anterior SHF disrupted progenitor 
cell shape and overall epithelial organization in the splanchnic mesoderm. In addition, the 
proliferation rate of SHF progenitors was decreased with a loss of Rac1 signaling. 
Subsequently, as heart development progressed, these early defects in the SHF splanchnic 
mesoderm resulted in a spectrum of OFT and aortic valve defects. We also showed that 
Rac1 deficiency disrupted the levels of Sema3c, a chemoattractant for cardiac neural 
crest cells, generated by the SHF-derived OFT myocardium, that would provide a 
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mechanism for our observed reduction in migrating neural crest cells observed in the 
developing OFT (Fig. 3.11).   
 
  
 
 
 
 
 
 
Figure 3.11.   Schematic diagram of mid-sagittal section of E9.5 splanchnic 
mesoderm. 
At E9.5, the Rac1f/f anterior SHF progenitors in the splanchnic mesoderm are organized 
into a polarized epithelium (a). Chemotactic signals, such as Sema3c, secreted by the 
OFT myocardium act as axonal guidance cues for migration of cardiac neural crest (NC) 
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cells from the neural tube (A). In Rac1SHFembryos, the anterior SHF progenitors are 
rounded and disorganized, displaying a loss of polarized epithelium characteristics (b). 
Expression of chemotactic signals is reduced, resulting in decreased migration of neural 
cells into the OFT (B).  
Intricate signaling cascades exist between the cardiac neural crest and the SHF. 
Defects in the cardiac neural crests can affect the SHF progenitors and vice versa. 
Ablation of cardiac neural crest cells lead to a failure of the SHF progenitors to lengthen 
the heart tube and to contribute to the OFT myocardium.30, 36 In addition to ablation, 
tissue-specific genetic deletions in the cardiac neural crest cells, which affect signaling 
pathways including Bmp, Smad and in the transcription factor Tbx3, all have secondary 
effects on the SHF and result in defects to OFT remodeling, alignment and elongation.37-
39 Conversely, tissue-specific genetic deletions in the SHF tissue, including in Notch and 
Tbx1, can also have a non-cell autonomous effect on migration of cardiac neural crest 
cells into the developing heart.7, 40 Our study showed that conditional deletion of Rac1 in 
the SHF reduced the migration of cardiac neural crest cells into the pharyngeal region, 
supporting a role for Rac1 in supporting the intercellular signaling that exists between the 
SHF and neural crest. The mechanism by which Rac1 signaling regulates expression of 
the neural crest chemoattractant Sema3c in the SHF-derived OFT myocardium remains to 
be determined. Studies have shown that Rac1 activates c-jun N-terminal kinase (JNK) to 
increase gene expression, including expression of the zinc-finger transcription factor 
Gata6.41, 42 Sema3c can be transcriptionally regulated by Gata6 and in humans, Gata6 
mutations can cause PTA through disruptions in the semaphorin-plexin signaling 
pathway.43, 44 Whether this Rac1-JNK-Gata6-Semaphorin signaling pathway is conserved 
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in the SHF-derived OFT myocardium, and subsequently signals to the migrating cardiac 
neural crest during cardiac morphogenesis remains to be determined in future studies.  
The OFT defects observed in the Rac1SHF embryos in the present study are likely 
due to a combination of abnormalities in several development events which are linked to 
initial establishment of cell polarity, including proliferation and migration. Firstly, 
proliferation of the Rac1SHF SHF progenitors in the splanchnic mesoderm is dramatically 
reduced, thus decreasing the overall number of anterior SHF cells contributing to OFT 
development. The two biological processes of cell polarity and proliferation are 
coordinated during development, where the polarized state of a progenitor affects its 
proliferation rate. This linkage has been clearly observed in development of the nervous 
system.45, 46 In this study, we showed that a deficiency of Rac1 signaling in the anterior 
SHF progenitors resulted in a loss of cellular organizationand is correlated with a 
decrease in proliferation rate, further supporting a link between these two developmental 
processes. Francou et al has also demonstrated a correlation with direct alteration of the 
epithelial properties of the anterior SHF progenitors, resulting in reduced progenitor 
proliferation rate and ectopic differentiation of the SHF progenitor cells.10 However, the 
direct mechanistic link between proliferation and cell polarity in the SHF progenitors 
remains unclear. In neural progenitors, apically localized aPKC attenuates the activity of 
p27Xic1, which is an inhibitor of cyclin-dependent kinase-2 (Cdk2). This leads to 
increased Cdk2 activity and shortening of the G1 and S phases, thus increasing the rate of 
proliferation.47 Whether a similar mechanism exists in anterior SHF progenitors remains 
to be determined. Furthermore, concomitant to a decrease in SHF progenitor cell 
proliferation, a decreased migratory ability of the Rac1SHF anterior SHF progenitors to 
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add to the arterial pole of the heart tube likely contributed to the observed OFT defects. 
Establishment of cell polarity is intrinsically linked to migratory ability. Both polarization 
and migration are events dependent on dynamic changes to the actin cytoskeleton, which 
is regulated by Rac1.48 Evidence of impaired migratory ability of the Rac1SHF SHF during 
heart development was recently demonstrated in our previous study.21 Migration defects 
were also observed in the present study based on mT/mG lineage tracing, which showed 
reduced contribution of SHF cells to the aortic valves and OFT, and impaired migration 
of cardiomyocytes into the Rac1SHF proximal outlet septum during the myocardialization 
process. Overall, these observations support establishment of SHF progenitor epithelial 
organization as critical to the developmental process.  
Valve remodeling and development is regulated by coordinated actions between 
matrix metalloproteinase (MMPs) and a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS) families of zinc metalloproteinases.49 Studies have 
shown a role for Rac1 in the regulation of ECM degradation along with MMP expression 
and activity.50, 51 The thickened Rac1SHF aortic valve leaflets along with decreased valve 
cell density and increased deposition of glycosaminoglacans observed in this study 
strongly suggest defects in valvular ECM degradation and remodeling. However, whether 
Rac1 signaling in the SHF-derived cells residing in the aortic valve leaflets also regulate 
the ECM through MMPs remains to be determined in future studies. Along with this, 
blood flow-induced hemodynamics can influence valve morphogenetic cues.52 Our 
previous study reported atrial and ventricular septal defects along with abnormalities in 
development of the ventricles in Rac1SHF hearts.21 Whether these structural defects 
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altered the hemodynamic flow and subsequently affected remodeling of the Rac1SHF 
aortic valves remains to be determined.   
In summary, our study is the first to show that Rac1 signaling in the anterior SHF 
is critical to normal cell organization in the splanchnic mesoderm. Loss of Rac1 leads to 
disruptions in anterior SHF progenitor cellular organization early in development and 
impacts subsequent steps of heart development, including OFT and aortic valve 
morphogenesis, along with signaling to the neural crest cells. Our study suggests that 
perturbed Rac1 signaling in the anterior SHF could account for some of the OFT defects 
observed in humans.   
3.6 Footnotes 
Supplemental Video Legends 
Video S1. 3D reconstruction of OFT in E15.5 Rac1f/f heart. In Rac1f/f hearts, the aortic 
arch (pink) is located on the left side, giving rise to the ascending and descending aorta 
(red). The dorsal aorta runs parallel to the esophagus (yellow) and trachea (green). 
Pulmonary artery is blue.  
Video S2. 3D reconstruction of vascular ring in E15.5 Rac1SHF heart. In Rac1SHF hearts, 
the aortic arch (pink) is located incorrectly on the right side, giving rise to the ascending 
and descending aorta (red). The dorsal aorta wraps around the esophagus (yellow) and 
trachea (green), forming a vascular ring. Pulmonary artery is blue.   
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Myocardium-specific deletion of Rac1 causes ventricular myocardium and outflow 
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Chapter 4 
4.1 Chapter Summary 
Left ventricular noncompaction (LVNC) is a cardiomyopathy that can lead to 
arrhythmias, embolic events and heart failure. Despite our current knowledge of cardiac 
development, the mechanisms underlying noncompaction of the ventricular myocardium 
are still poorly understood. The small GTPase Rac1 acts as a crucial regulator of 
numerous developmental events; however, its role in ventricular myocardium 
development is unclear. In the present study, we tested the hypothesis that Rac1 signaling 
is critical for development of the ventricular compact myocardium. Using the ventricular 
myocardium specific Nkx2.5-Cre transgenic mouse crossed to Rac1f/f, mice with a 
ventricular myocardium specific deletion of Rac1 were generated (Rac1Nkx2.5). Embryonic 
Rac1Nkx2.5 hearts at E13.5 - E18.5 were collected for histological analysis. Overall, 
Rac1Nkx2.5 hearts displayed bifurcation of the ventricles, along with defective 
trabeculation formation and a thin compact myocardium. Rac1Nkx2.5 hearts also exhibited 
ventricular septal defects (VSDs) and double outlet right ventricle (DORV) or overriding 
aorta. Cardiomyocytes in Rac1Nkx2.5 hearts were not polarized and expression of Scrib, a 
PCP protein, was reduced. In addition, the proliferation rate of E9.5 Rac1Nkx2.5 ventricular 
myocardium was reduced compared to controls. A Rac1 deficiency in the ventricular 
myocardium impairs cardiomyocyte polarization and ventricular myocardium 
organization, along with proliferative growth of the heart. A spectrum of CHDs arise in 
Rac1Nkx2.5 hearts, implicating Rac1 signaling in the ventricular myocardium as a crucial 
regulator of OFT alignment, along with trabecular and compact myocardium growth and 
development.  
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4.2 Introduction 
Congenital heart defects (CHDs) are the most common human birth defect, 
affecting up to 5% of live births.1, 2 The severity of these types of defects range from 
simple defects with no symptoms at birth, such as a small atrial septal defect (ASD), to 
complicated defects that are life-threatening and require intervention, such as Tetralogy 
of Fallot (TOF).3-5 One particular defect known as left ventricular noncompaction 
(LVNC) or “spongy myocardium” has no treatment at present, with the major therapy 
being heart failure medications and anticoagulation medications.6 LVNC is classified as a 
rare genetic cardiomyopathy, occurring in 0.01% to 0.27% of the population, 
characterized by arrest of normal myocardium development, leading to a thin compact 
myocardial layer and an extensive non-compacted trabecular network.7, 8 Noncompaction 
of the ventricular myocardium can increase the risk of cardiac embolism, atrial 
fibrillation, ventricular arrhythmia and heart failure.6, 8 Although this defect occurs 
mostly in the LV, RV noncompaction has also been reported in less than one-half of 
LVNC patients.9, 10  
The ventricles grow and mature through a process of proliferation and 
differentiation to form trabeculation and compact myocardium.11 In the mouse, trabecular 
formation begins at approximately E9.5 where cardiomyocytes grow to form protrusions 
of muscular ridges.12 The trabeculae then undergo a process of remodeling/compaction 
where the bases of the trabeculation thicken and collapse into the myocardial wall. 
Proliferation of the compact myocardium is concomitant with remodeling. By E14.5, 
mature trabeculation is formed, along with a thick, compact myocardium.13, 14 Numerous 
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signaling pathways have been implicated in development of the ventricular chambers 
including Notch, BMP, FGF, retinoic acid and PCP signaling.11, 15 In addition, various 
mouse models of ventricular noncompaction defect have been generated but the 
ventricular defects between the mouse models are not consistent, reflecting the complex 
process of ventricular myocardium development. To date, the complete signaling 
mechanisms underlying ventricular myocardium development are still not completely 
understood. 16, 17   
The small GTPase, Rac1, acts as a crucial regulator of numerous developmental 
events including proliferation, cell cycle progression, cell survival, differentiation and 
regulation of cell shape, morphology and polarity.18 Specifically, the importance of Rac1 
signaling in embryonic heart development has emerged in recent studies19, 20 Our work 
has demonstrated a critical role for Rac1 signaling in the anterior SHF and anterior-SHF 
derived structures including the RV, interventricular septum and the OFT. Rac1 regulates 
cardiomyocyte polarization in the RV and formation of the cardiac apex.19 However, the 
role of Rac1 in development of the LV myocardium is unclear. In order to study the role 
of Rac1 in the ventricular myocardium, we generated a ventricular myocardium specific 
deletion of Rac1 using the Nkx2.5-Cre transgenic mouse, which has Cre recombinase 
activity in both the RV and LV.21 We show that Rac1 signaling is crucial for ventricular 
myocardium development and downregulation of Rac1 leads to a spectrum of CHDs 
including thin compact myocardium and defective trabeculation development, similar to 
the features of LVNC. Rac1 deficient hearts also had a bifid cardiac apex and OFT 
alignment defects. Furthermore, we showed that a Rac1 deficiency in the ventricular 
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myocardium disrupts proliferation along with the organization and polarization of 
cardiomyocytes.   
4.3 Methods 
4.3.1 Mice 
The Rac1f/f C57BL/6 mouse line (Stock #5550) and mT/mG C57BL/6 mouse line (Stock 
#7676) were purchased from Jackson Laboratory, Bar Harbor, Maine 22, 23. The Nkx2.5-
Cre C57BL/6 transgenic mouse was a generous gift from Dr. Chi-Chung Hui at SickKids 
Hospital, University of Toronto, originally generated by McFadden et al.21 The mT/mG 
mouse is a global double-fluorescent Cre reporter mouse. This reporter mouse expresses 
membrane-targeted Tomato (mT) before Cre-excision and membrane-targeted GFP (mG) 
after excision of mT.23 A breeding program to generate Nkx2.5-Cre;Rac1f/f (Rac1Nkx2.5) 
and Nkx2.5-Cre;mT/mG mice was carried out and genotyping was performed as 
described previously.19 Genotyping primer sequences are listed in Table 4.1. Mouse 
experiments and procedures were approved by the Animal Use Subcommittee at the 
University of Western Ontario in accordance with the guidelines of the Canadian Council 
of Animal Care. 
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Table 4.1. Genotyping PCR primer sequences. 
Gene Forward Reverse 
Nkx2.5-Cre tgccacgaccaagtgacagc ccaggttacggatatagttcatg 
Rac1f/f tccaatctgtgctgcccatc gatgcttctaggggtgagcc 
mTmG ctctgctgcctcctggcttct cgaggcggatcacaagcaata 
Mutant reverse:  
tcaatgggcgggggtcgtt 
 
4.3.2 Histological Analysis  
Embryonic samples (thoracic cavity) were fixed overnight in 4% paraformaldehyde at 
4°C, dehydrated and paraffin embedded. Samples were serially sectioned at 5 µm from 
the top of the aortic arch to the apex of the heart with a Leica RM2255 microtome. 
Sections were mounted onto positively charged albumin/glycerin coated microslides. 
Slides were stained with hematoxylin and eosin (H/E) for histological analysis and 
images were captured using a light microscope (Observer D1, Zeiss, Germany). 
4.3.3 Immunohistochemistry 
Immunohistochemical staining was performed on paraffin heart sections. Antigen 
retrieval was carried out in sodium citrate buffer (pH 6.0) at 92 °C using a BP-111 
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laboratory microwave (Microwave Research & Applications, Carol Stream, Illinois). 
Immunostaining was performed with primary antibodies for GFP (Abcam) and Scrib 
(Santa Cruz) followed by incubation with biotinylated secondary antibody and avidin and 
biotinylated HPR (Santa Cruz). Diaminobenzidine (DAB) substrate solution was used to 
visualize the substrate and slides were counterstained with hematoxylin.  Images were 
captured with Zeiss Observer D1 microscope using AxioVision Rel 4.7 software. For 
proliferation and apoptosis analysis, E9.5 heart samples were fixed in 4% 
paraformaldehyde for one hour, cryoprotected in 30% sucrose and embedded in FSC22 
frozen section media (Leica). Samples were sectioned in a sagittal orientation with a 
Leica cryostat at 10 µm thick onto glass slides. Slides were incubated with 
phosphohistone-H3 (phospho S10) (Abcam), cleaved caspase-3 (Cell Signaling) primary 
antibody, Alexa Fluor 647 wheat germ agglutinin (Invitrogen), Alexa Fluor 488 
phalloidin (Life Technologies) and counterstained with Hoechst 33342 (Invitrogen). 
Confocal images were obtained at the Biotron Research Centre, Western University with 
a Zeiss LSM 510 Duo microscope using ZEN 2012 software (Zeiss, Germany).  
4.3.4 Quantitative Real Time RT-PCR  
Total RNA was isolated from E12.5 ventricular myocardium using the RNeasy Mini Kit 
(QIAGEN). Reverse transcription reaction was performed, as described previously.19 
Briefly, M-MLV Reverse Transcriptase (Invitrogen) and EvaGreen qPCR Mastermix 
(Applied Biological Materials Inc.) was used for real time thermal cycling. 28S rRNA 
was used as an internal control. The Eppendorf Mastercycler Realplex Real-Time PCR 
machine was used and samples were amplified for 35 cycles. The mRNA level of Rac1 in 
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relation to 28S rRNA was determined using a comparative CT method.24 Real time RT-
PCR primer sequences are listed in Table 4.2.  
Table 4.2. Real time RT-PCR primer sequences.  
Gene Forward Reverse 
Rac1 aacctgcctgctcatcagtt ttgtccagctgtgtcccata 
28S ttgaaaatccgggggagag acattgttccaacatgccag 
 
4.3.5 Western Blot Analysis 
Rac1 protein expression from E12.5 ventricular myocardium was measured by western 
blot analysis. Briefly, 25 µg of protein from isolated ventricular tissue was separated by 
12% SDS-Page gel and transferred to nitrocellulose membranes. Blots were probed with 
antibodies against Rac1 (1:500, Santa Cruz) and α-actinin (1:5000, Sigma). Blots were 
then washed and probed with horseradish peroxidase conjugated secondary antibodies 
(1:2500, Bio-Rad) and detected using an ECL detection method. Densitometry was then 
performed to quantify the signal. 
4.3.6 Statistical Analysis 
Data are presented as means ± SEM. An unpaired Student’s t test was employed to test 
for significance when data passed a normality test. Differences were considered 
significant at P<0.05.   
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4.4 Results 
4.4.1 Generation of a transgenic mouse with a Rac1 deficiency in the 
ventricular myocardium  
Nkx2.5-Cre transgenic mice and Rac1f/f mice were crossed to generate Nkx2.5-
Cre;Rac1f/f (Rac1Nkx2.5) offspring. The Cre recombinase in the Nkx2.5-Cre mouse line is 
activated after E8.5 and initial specification of cardiac progenitors.21 To confirm a 
knockdown in Rac1 mRNA expression, E12.5 Rac1Nkx2.5 ventricles were isolated for 
RNA and real-time PCR was performed. Rac1 mRNA expression was significantly 
decreased by approximately 35% in E12.5 Rac1Nkx2.5 ventricular myocardium compared 
to littermate Rac1f/f controls (Fig. 4.1A). Protein from E12.5 Rac1Nkx2.5 ventricular 
myocardium was also isolated for western blot analysis. The ratio of Rac1 protein 
expression to α-actinin was reduced by 42% in E12.5 Rac1Nkx2.5 ventricular myocardium 
compared to littermate Rac1f/f controls (Fig. 4.1B). These results confirm that Nkx2.5-Cre 
mediated recombination sufficiently downregulates Rac1 expression in the ventricular 
myocardium of the developing embryonic heart.     
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Figure 4.1.  Generation of mouse line with a ventricular myocardium specific 
deletion of Rac1 (Rac1Nkx2.5). 
Nkx2.5-Cre transgenic mice were crossed to Rac1f/f to generate Rac1Nkx2.5 mice. Rac1 
mRNA expression was significantly reduced in E12.5 Rac1Nkx2.5 ventricular myocardium 
compared to Rac1f/f littermates (A). Western blot analysis of E12.5 ventricular 
myocardium showed a significant decrease in Rac1 protein in Rac1Nkx2.5 hearts compared 
to controls (B). *P<0.05 by Student’s t-test.             
4.4.2 Lineage tracing of Nkx2.5-Cre transgenic mouse  
To trace where the Cre recombinase is active in Nkx2.5-Cre transgenic hearts, 
Nkx2.5-Cre mice were crossed to mT/mG reporter mice, which marks all tissues 
possessing Cre recombinase activity with GFP. McFadden et al, the group who first 
created the Nkx2.5-Cre transgenic mouse, used a lacZ reporter to show that the Cre 
recombinase is active throughout the ventricular myocardium with minimal 
recombination in the OFT and atria.21 At E12.5, we showed with the Nkx2.5-Cre;mT/mG 
mouse that the Cre recombinase is active throughout the ventricular myocardium and a 
large portion of the atria (Fig. 4.2A). In addition, a majority of the pulmonary artery 
myocardium and only some cells in the aorta, were GFP+ in E12.5 Nkx2.5-Cre;mT/mG 
hearts (Fig. 4.2B). Closer analysis of the aortic valves showed that some of the cells in 
the early aortic valves were also GFP+ in the Nkx2.5-Cre;mT/mG hearts (Fig. 4.2C). 
Furthermore, closer analysis of the epicardium and endocardial cells at E18.5 showed that 
these cells remained RFP+, indicating no Cre recombinase activity in these cell types 
(Fig. 4.2D-F).  Thus, the Nkx2.5-Cre mouse is an effective transgenic mouse to use to 
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study development of the ventricular myocardium, as the majority of these cells are 
GFP+. 
 
 
 
 
 
 
 
Figure 4.2.  Lineage tracing with Nkx2.5-Cre;mT/mG mice. 
GFP immunostaining of E12.5 Nkx2.5-Cre;mT/mG paraffin heart sections showing Cre 
recombinase activity in the ventricular myocardium (A), OFT (B) and aortic valve 
leaflets (C). Cryosections of E18.5 Nkx2.5-Cre;mT/mG hearts showed that the 
epicardium (arrows) and endothelial cells (arrowhead) remain RFP+ in Nkx2.5-
Cre;mT/mG hearts (D-F). RV, right ventricle; LV, left ventricle; PA, pulmonary artery; 
Ao, aorta; epi, epicardium. Scale bars: 250 µm (A-C), 10 µm (D-F).  
4.4.3 Congenital heart defects in Rac1Nkx2.5 hearts  
All P0 Rac1Nkx2.5 offspring were found dead at birth (n=5) from two litters. Gross 
morphological analysis of these P0 Rac1Nkx2.5 hearts revealed a bifid cardiac apex, similar 
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to what was observed and reported in our previous study with a Mef2c-Cre anterior 
second heart field-specific deletion of Rac1.19 Examination of all Rac1Nkx2.5 hearts at 
earlier embryonic time points showed evidence of a bifid cardiac apex as well, along with 
enlarged atria (Fig. 4.3A). In addition, Rac1Nkx2.5 hearts had incomplete development of 
the interventricular septum, resulting in a ventricular septal defect (VSD) (Fig. 4.3B-C, 
Table 4.3). Alignment of the outflow tract (OFT) to the ventricles was also defective in 
Rac1Nkx2.5 hearts compared to littermate Rac1f/f controls. A double outlet right ventricle 
(DORV) was observed in 11 of the 17 Rac1Nkx2.5 hearts (Fig. 4.3D-G, Table 4.3) and 6 of 
the 17 Rac1Nkx2.5 hearts exhibited an overriding aorta (Table 4.3). In addition, both the 
left ventricle (LV) and right ventricle (RV) of Rac1Nkx2.5 hearts had defective 
trabeculation (Fig. 4.4A-D). The compact myocardium of both Rac1Nkx2.5 ventricles at 
E15.5 was poorly formed and significantly thinner compared to littermate Rac1f/f controls 
(Fig. 4.4E). These findings suggest a critical role for Rac1 in interventricular septum 
formation, OFT alignment and development of the trabecular and compact ventricular 
myocardium.    
Table 4.3. Congenital heart defects in Rac1Nkx2.5 hearts (E14.5 – P0). 
 
 
 Bifid  
apex 
VSD DORV Overriding 
aorta 
Thin 
myocardium 
 
N=17 
 
 
17 
 
 
17 
 
11 
 
 
6 
 
 
17 
 
 
% 
 
100 
 
 
100 
 
64.7 
 
35.3 
 
100 
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VSD, ventricular septal defect; DORV, double outlet right ventricle. All 17 Rac1SHF 
hearts had more than one type of CHD. No CHDs defects were found in littermate E14.5-
P0 Rac1f/f hearts (n=11). 
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Figure 4.3.  Congenital heart defects in Rac1Nkx2.5. 
Bifid cardiac apex in an E16.5 Rac1Nkx2.5 heart. Arrow indicates bifurcation between the 
RV and LV (A). Ventricular septal defect (arrowhead) was found in E15.5 Rac1Nkx2.5 
hearts. Arrow indicates bifid cardiac apex (B, C). Double outlet right ventricle (DORV) 
was found in E15.5 Rac1Nkx2.5 hearts. The pulmonary artery connects to the RV in both 
Rac1f/f controls and Rac1Nkx2.5 hearts (D, E). The Rac1Nkx2.5 aorta (G) incorrectly connects 
to the RV compared to Rac1f/f controls, where the aorta connects to the LV (F). RA, right 
atrium; LA, left atrium. Scale bars: 500 µm. 
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Figure 4.4.  Ventricular myocardium defects in Rac1Nkx2.5 hearts. 
The RV and LV myocardium and trabeculation of E15.5 Rac1Nkx2.5 hearts (B, D) were 
severely defective compared to Rac1f/f controls (A, C). The thickness of the compact 
myocardial wall in E15.5 Rac1Nkx2.5 RV and LV was significantly decreased compared to 
littermate controls (E). Double-headed arrows in A-D indicate measurements of wall 
thickness. ***P<0.001 by Student’s t-test. Scale bars: 100 µm.   
4.4.4 Loss of cell polarity and organization in Rac1Nkx2.5 hearts 
To analyze the organization of the cardiomyocytes in the ventricular myocardium, 
E18.5 Rac1Nkx2.5 heart sections were stained with wheat germ agglutinin (WGA), which 
marks cell borders, and phalloidin to mark F-actin filaments. WGA staining revealed 
rounded, spherically shaped cardiomyocytes in Rac1Nkx2.5 hearts, in both the RV and LV 
(Fig. 4.5B). In comparison, littermate ventricular myocardium had cardiomyocytes that 
had undergone polarization and were an elongated shape in both the RV and LV (Fig. 
4.5A). In addition, Rac1Nkx2.5 hearts had severely disrupted F-actin filament organization 
(Fig. 4.5D) compared to controls, which had long, parallel running F-actin filaments 
throughout the myocardium (Fig. 4.5C). These findings are similar to the observations 
from our first study, where Rac1 was deleted in the SHF and all SHF-progenitors in 
Rac1SHF hearts.19 The RV in the SHF-Rac1 deficient hearts showed similar myocardial 
disorganization as the ventricular myocardium of Rac1Nkx2.5 hearts in this study. This data 
suggests a crucial role for Rac1 in the organization, polarization and elongation of 
cardiomyocytes during embryonic heart development.      
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Figure 4.5.  Disruption of cardiomyocyte polarity and organization in Rac1Nkx2.5 
hearts. 
WGA staining in E18.5 cryosections show rounded cardiomyocytes in Rac1Nkx2.5 
ventricular myocardium (B) compared to the elongated cardiomyocytes in controls (A). 
F-actin filament organization is disrupted in Rac1Nkx2.5 myocardium (D) compared to 
controls (C). Scale bars: 10 µm.   
4.4.5 Decreased Scrib protein in Rac1Nkx2.5 hearts 
Scrib genetically interacts with Rac1 and Scrib protein forms a complex with the 
Rac1-GEF, β-PIX, and Rac1 in the developing myocardium. Loss of either Scrib or Rac1 
leads to a reduction in membrane association of the other.20 To analyze the expression of 
Scrib, immunostaining was performed on E15.5 Rac1Nkx2.5 hearts. Scrib is highly 
expressed in the myocardium surrounding the opening of the aorta in control E15.5 hearts 
(Fig. 4.6A). In comparison, the expression of Scrib in this area is reduced in E15.5 
Rac1Nkx2.5 heart sections (Fig. 4.6B). In addition, expression of Scrib was also reduced in 
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E15.5 Rac1Nkx2.5 RV and LV myocardium compared to littermate controls (Fig. 4.6C-F). 
Similar to what was described in our first study,19 Scrib protein expression is abundant in 
the interventricular junction in control hearts at E15.5. Overall, Scrib protein expression 
was significantly decreased in E15.5 Rac1Nkx2.5 hearts compared to littermate controls 
(Fig. 4.6G). The loss of Scrib expression in Rac1Nkx2.5 hearts suggests a disruption in 
polarity and the PCP pathway, further supporting a failure of cardiomyocytes to undergo 
polarization.  
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Figure 4.6.  Loss of Scrib expression in Rac1Nkx2.5 hearts. 
Scrib immunostaining was performed on E15.5 Rac1Nkx2.5 and Rac1f/f heart sections. The 
areas analyzed included the myocardium surrounding the aorta (A, B), RV (C, D) and the 
LV (E, F). The number of Scrib-expressing positive cells was significantly decreased in 
the myocardium surrounding the aorta (OFT), RV and LV of Rac1Nkx2.5 hearts (G). 
*P<0.05, **P<0.01 by Student’s t-test. Scale bars: 50 µm.     
4.4.6 Decreased proliferation rate in Rac1Nkx2.5 hearts 
The observed defects in Rac1Nkx2.5 ventricular myocardium development could 
also be attributed to a decrease in cell proliferation and/or aberrant apoptosis. 
Proliferation of the heart chambers has been shown to be highest at E9.5 in the 
developing mouse heart.25 Thus, proliferation of E9.5 Rac1Nkx2.5 hearts was analyzed by 
immunostaining for phospho-histone H3 (pHH3), which is a marker of the mitotic phase 
of cell division. The proliferation rate of the ventricular chambers was found to be 
significantly reduced in E9.5 Rac1Nkx2.5 hearts compared to littermate Rac1f/f controls 
(Fig. 4.7A-C). Along with this, cyclin D1, a marker of cell cycle progression through the 
G1/S phase, was significantly decreased in E9.5 Rac1Nkx2.5 myocardium compared to 
Rac1f/f controls (Fig. 4.7D-F). Immunostaining for cleaved caspase-3 (CC3), a marker of 
activated apoptosis, showed little to no apoptosis in both control E9.5 Rac1f/f and 
Rac1Nkx2.5 ventricular myocardium (Fig. 4.7G, H), while apoptotic cells were found in 
tissue outside of the myocardium (Fig. 4.7I, J). However, this data does not preclude 
apoptosis from potentially playing a role in later developmental time points in Rac1Nkx2.5 
hearts. Thus, the decreased proliferation rate and expression of cyclin D1 in Rac1Nkx2.5 
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hearts suggests a critical role for Rac1 in regulation of cardiomyocyte proliferation and 
cell cycle progression in the ventricular myocardium, after initial specification of cardiac 
progenitors. 
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Figure 4.7.  Decreased proliferation rate in Rac1Nkx2.5 hearts. 
Phospho-histone H3 (pHH3) immunostaining to mark proliferating cells undergoing 
mitosis in ventricular myocardium of E9.5 Rac1Nkx2.5 and Rac1f/f hearts (A, B). 
Proliferation rate was significantly decreased in E9.5 Rac1Nkx2.5 ventricular myocardium 
compared to littermate controls (C). *P<0.05 by Student’s t-test. Cyclin D1 
immunostaining to mark cell cycle progression in ventricular myocardium of E9.5 
Rac1Nkx2.5 and Rac1f/f hearts (D, E). Cyclin D1 was significantly decreased in E9.5 
Rac1Nkx2.5 ventricular myocardium compared to littermate controls (F). **P<0.01 by 
Student’s t-test. Cleaved caspase-3 (CC3) immunostaining to mark apoptotic cells in 
ventricular myocardium of E9.5 Rac1Nkx2.5 and Rac1f/f hearts. No apoptosis was detected 
in E9.5 Rac1Nkx2.5 and Rac1f/f ventricular myocardium (G, H). Apoptotic cells were 
detected elsewhere in the embryo in cells outside of the ventricular myocardium (I, J). 
Scale bars: 10 µm (A, B, H, I), 50 µm (D-G).    
4.5 Discussion 
Recent studies have implicated PCP signaling and cell polarity as a critical 
regulator of compact myocardium development. Vangl2, Scrib and Dishevelled mouse 
mutants have cardiomyocytes that are not polarized and the ventricular myocardium is 
thinned, resembling LVNC.26-29 Rac1 is a known downstream effector of PCP signaling; 
however the role of Rac1 in ventricular myocardium development is unclear.30 In the 
present study, we demonstrated that downregulation of Rac1 signaling in the ventricular 
myocardium disrupted formation of a trabecular network and development of the 
compact myocardium. In addition, Rac1Nkx2.5 mice had a bifid cardiac apex, defects in 
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ventricular septum formation and OFT alignment. The organization and polarization of 
cardiomyocytes in the Rac1deficient ventricular myocardium was also abnormal. Overall, 
proliferation was decreased in Rac1Nkx2.5 hearts, along with expression of the PCP 
protein, Scrib. Our study demonstrates a critical role for Rac1 signaling during 
ventricular trabeculation and compact myocardium development (Fig. 4.8).   
Proliferation of the heart is a regulated spatially and temporally during 
development. Proliferation rate of the ventricular chambers peak at E9.5 and will 
gradually decrease during development.25 Studies have shown that cardiomyocyte 
proliferation during development is the major determinant of overall cardiac size. The 
mass of the heart must increase to match the increasing circulatory demands of the 
growing embryo.31 Rac1 has been shown to regulate proliferation through various 
pathways. Our data showed that a Rac1 deficiency in the ventricular myocardium led to a 
reduced proliferation rate. However, the mechanism through which Rac1 regulates 
cardiomyocyte proliferation is unclear. Rac1 has been shown to regulate cyclin D1, a cell 
cycle regulator, through NF-κB.32, 33 Whether Rac1 signaling acts through the NF-κB 
pathway in the developing ventricular myocardium to regulate cell cycle progression and 
proliferation should be determined in future studies (Fig. 4.8). 
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Figure 4.8.  Rac1 regulation of ventricular myocardium development. 
Rac1 signaling regulates actin polymerization, leading to cardiomyocyte polarization. In 
addition, Rac1 regulates cardiomyocyte proliferation through cyclin D1. Overall, Rac1 
signaling regulates proliferation and polarity of cardiomyocytes, leading to development 
of the compact myocardium and trabeculation formation.    
An earlier report by Boczonadi et al also used a Nkx2.5-Cre;Rac1f/f mouse line in 
their studies.20 However, the Nkx2.5-Cre mouse used by Boczonadi et al was an Nkx2.5 
heterozygous mouse since the Cre recombinase gene was knocked into the Nkx2.5 
genetic locus.34 In contrast, the Nkx2.5-Cre mouse used in this study is a transgenic 
mouse and retains homozygous expression of Nkx2.5.21 The Nkx2.5-Cre;Rac1f/f mice used 
in Boczonadi et al were embryonic lethal by E13.5, which precluded analysis of 
ventricular septation and OFT alignment with the developing ventricles.20 The earlier 
lethality of the Nkx2.5-Cre;Rac1f/f mouse line compared to the Rac1Nkx2.5 used in this 
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study is likely due to the heterozygous expression of Nkx2.5 compounded with decreased 
Rac1 signaling in the ventricular myocardium. Furthermore, whether the CHDs reported 
in the study by Boczonadi et al are exclusively due to deficient Rac1 signaling or also due 
to downregulation of Nkx2.5 is unclear. Our data only implicates Rac1 signaling and we 
were able to demonstrate that Rac1Nkx2.5 hearts also exhibit VSDs and OFT alignment 
defects.   
Our previous work also reported a bifid cardiac apex when Rac1 was specifically 
deleted in the anterior SHF and all anterior SHF-derived cells.19 We had postulated that 
loss of Rac1 signaling in the RV led to an inability of the nonpolarized and disorganized 
cardiomyocytes to bridge the interventricular junction to unify the two developing 
ventricles and form a distinct cardiac apex. However, from this work using the Rac1Nkx2.5 
hearts, we show that development of the cardiac apex is also dependent on polarization 
and organization of the cardiomyocytes in the LV myocardium. Interestingly, other 
reports where PCP signaling was disrupted did not report observations of a bifid cardiac 
apex, despite similar reports of cardiomyocyte disorganization.27, 28 Rac1 is a known 
downstream effector of PCP signaling, regulating actin cytoskeleton dynamics and cell 
polarity.35, 36 Our findings suggests that development of a bifid cardiac apex involves a 
pathway specific to Rac1 signaling. In addition, since Rac1 is a pleiotropic effector of 
numerous cellular events, the concomitant disruption of several cellular mechanisms are 
likely responsible for bifid cardiac apex, along with the other observed CHDs in 
Rac1Nkx2.5 hearts.        
Our lineage tracing analysis with the mT/mG global double florescence mouse 
showed similar GFP+ expression in domains of the heart that were reported by McFadden 
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et al, who used a lacZ reporter. However, we also showed Cre recombinase activity in the 
OFT and atria, which were reported to be minimal by McFadden et al.21 This discrepancy 
in Cre recombinase activity may be due to the additional β-galactosidase enzymatic 
reaction step that is required to visualize the blue colour of lacZ staining, making it a less 
efficient reporter compared to a GFP reporter. These results suggest that future lineage 
tracing analysis should use a florescence reporter as a more reliable readout of expression 
compared to a lacZ reporter.    
Rac1 is involved in reactive oxygen species (ROS) generation through activation 
of NADPH oxidase.37, 38 ROS mediates numerous cellular functions including 
proliferation, cell survival, differentiation and migration.39 The levels of ROS are finely 
tuned in a cell to regulate these diverse functions. For example, excess ROS induces 
apoptosis while basal levels of ROS regulate gene expression and proliferation.40-42 Work 
in our lab has shown that ROS levels must be tightly regulated to facilitate normal 
cardiac development. Excess ROS induced by pregestational maternal diabetes and 
decreased levels of ROS in the NADPH oxidase Nox2 knockout mouse have a 
detrimental effect on heart development, leading to a spectrum of CHDs.43, 44 Whether the 
CHDs observed in the Rac1Nkx2.5 hearts can also be attributed to decreased ROS levels 
should be determined in future studies.     
In summary, our study suggests a critical role for Rac1 regulation of 
cardiomyocyte organization and polarization in development of the ventricular 
myocardium. A Rac1 deficiency in the myocardium disrupts cardiomyocyte organization 
and proliferation, leading to bifid cardiac apex, VSDs and OFT alignment and ventricular 
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myocardium defects. Whether perturbed Rac1 signaling in the ventricular myocardium 
underlies human cases of LVNC should be further studied.  
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5 Chapter 5 Discussion  
5.1 Summary of Major Findings  
The overall objective of this thesis was to investigate the role of Rac1 during 
embryonic heart development in mice. Specifically, I studied the role of Rac1 in 
cardiomyocyte polarity and development of OFT, cardiac septum and the ventricular 
myocardium. To carry out these experiments, the Cre/LoxP system was used throughout 
the studies to generate a mouse model of Rac1 deficiency. More specifically, the Rac1f/f 
transgenic mouse was used, combined with the anterior SHF-specific Mef2c-Cre or the 
ventricular myocardium specific Nkx2.5-Cre transgenic mouse. The major aim of this 
thesis was to unravel the mechanisms of Rac1 regulation of cell polarity during 
embryonic heart development. Experimental approaches included in vivo lineage tracing, 
histological analysis of heart sections, immunostaining, in vitro cell cultures, ex vivo 
heart explants, and biochemical and molecular assays.  
In Chapter 2, I investigated the role of Rac1 in cardiomyocyte polarity and 
development of cardiac septium and right ventricular myocardium. To carry out this aim, 
the anterior SHF-specific Mef2c-Cre mouse was bred to the Rac1f/f mouse to generate a 
SHF-specific deletion of Rac1, Rac1SHF. One of the distinct CHDs first noticed was a 
bifid cardiac apex in Rac1SHF hearts, where the RV bifurcates from the LV instead of 
forming a distinct left-pointing apex. Cases of bifid cardiac apex are extremely rare in 
humans and are often associated with other CHDs.1, 2 Whether cases of bifid cardiac apex 
in humans are also associated with abberant Rac1 signaling during embryonic 
development remains unknown. The Rac1SHF hearts also had other CHDs including 
VSDs, ASDs and defective myocardium and trabeculation formation in the RV. Further 
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analysis of heart cryosections showed that cardiomyocyte organization, polarity and 
alignment was severly disrupted in P0 Rac1SHF hearts. The Rac1SHF cardiomyocytes were 
rounded and spherical shaped compared to controls, which were elongated and aligned 
with each other. The actin cytoskeleton organization, expression of β-catenin cell-cell 
junctions and expression of the PCP protein, Scrib, were also disrupted in Rac1SHF hearts. 
In addition, explant cultures of E12.5 Rac1SHF;mT/mG RV showed defects in migratory 
ability of GFP+ SHF-derived cells. In vitro primary cardiomyocyte cultures from Rac1SHF 
hearts displayed defects in lamellipodia formation and cardiomyocyte polarization along 
with a decreased cardiomyocyte axis length. Furthermore, in vivo lineage tracing showed 
a deficient SHF progenitor contribution to Rac1SHF hearts, likely due to defects in 
migratory ability of SHF progenitors. Molecular analysis demonstrated decreased 
expression levels of key cardiac transcription factors in E12.5 Rac1SHF RV compared to 
littermate controls including Nkx2.5, Gata4, Tbx5 and Hand2. In addition, apoptosis was 
significantly upregulated in the RV and interventricular septum of E11.5 Rac1SHF hearts 
with no significant difference in proliferation rate compared to littermate controls. 
Overall, this study showed that Rac1 is critical to embryonic heart development by 
regulating the actin cytoskeleton to direct cardiomyocyte polarity and migration of SHF 
progenitors into the developing heart.  
Building upon the findings that Rac1 is crucial for cardiomyocyte polarity from 
the first study in Chapter 2, the experiments in Chapter 3 analyzed the role of Rac1 in 
OFT development, which is known to be a process regulated by cell polarity.3, 4 This 
study demonstrated for the first time that Rac1 is critical for overall organization of the 
anterior SHF progenitors and OFT development. Analysis of Rac1SHF embryos at E9.5 
showed less SHF cells in the splanchnic mesoderm and the proliferation rate of SHF cells 
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was significantly reduced compared to controls. The Rac1SHF SHF progenitors in the 
dorsal pericardial wall had defects in overall cell shape and cell organization compared to 
littermate controls. As a result of these early defects at E9.5, the Rac1SHF OFT was 
shortened and organization of the myocardial cells was disrupted by E10.5. Furthermore, 
Rac1SHF hearts displayed a spectrum of OFT defects including double outlet right 
ventricle (DORV), overriding aorta, persistent truncus arteriosus (PTA), transposition of 
the great arteries (TGA), aortic atresia, pulmonary stenosis, vascular rings and aortic 
valve defects. At E12.5, Rac1SHF myocardial cells lacked a polarized morphology and 
displayed abnormalities in myocardialization and migration of cardiomyocytes into the 
flanking OFT cushion. Subsequently, the P0 Rac1SHF proximal OFT remained 
mesenchymal instead of muscularized. Interactions between SHF progenitors and cardiac 
neural crest cells have been shown to be critical for remodeling and development of the 
aortic arches.5 Sema3c expression, which acts as a chemoattractant for neural crest cells,6 
was reduced in E10.5 Rac1SHF OFT myocardium. Consequently, the number of migrating 
cardiac neural crest cells into Rac1SHF hearts was reduced. Moreover, in vivo lineage 
tracing with the mT/mG reporter mouse showed a decreased contribution of SHF cells to 
the Rac1SHF OFT myocardium and aortic valves at E12.5 and E14.5. Lastly, intrauterine 
echocardiography performed at E18.5 demonstrated evidence of aortic valve 
regurgitation along with reduced ejection fraction and fractional shortening in Rac1SHF 
embryos.  Taken together, this data suggests that Rac1 regulates SHF progenitor cell 
shape and organization in the splanchnic mesoderm, which is critical for overall cardiac 
OFT development.  
In Chapter 4, the Nkx2.5-Cre transgenic mouse was used to study the role of 
Rac1 in development of the ventricular myocardium. Thus far, in Chapter 2 and Chapter 
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3 of this thesis, the Mef2-Cre mouse was used, which directs Cre recombinase activity 
starting at E7.5 to the anterior SHF and all anterior SHF-derived structures, including the 
RV, interventricular septum and OFT.7 The Cre recombinase in the Nkx2.5-Cre 
transgenic mouse is activated after initial specification of cardiac progenitors at E8.5 but 
not in earlier cardiac progenitors and is also active in the developing LV, along with the 
RV myocardium.8 Mice with a Rac1 deficiency in the ventricular myocardium, 
Rac1Nkx2.5, also had bifid cardiac apex, similar to what was observed in Chapter 2 with the 
Rac1SHF hearts. Other CHDs found in Rac1Nkx2.5 hearts included VSDs, defects in 
trabeculation formation and a significantly thinner compact myocardium. Rac1Nkx2.5 
hearts also had misalignments of the OFT with the ventricles, leading to DORV and 
overriding aorta. Actin filament formation was severly disrupted and cardiomyocytes 
failed to undergo polarization in Rac1Nkx2.5 hearts. Proliferation of the myocardium in 
E9.5 Rac1Nkx2.5 hearts was significantly reduced compared to littermate controls, while no 
significant apoptosis was observed at this time point. In addition, expression of the PCP 
protein, Scrib, was reduced in E15.5 Rac1Nkx2.5 hearts compared to littermate controls. 
Overall, our study suggests a critical role for Rac1 regulation of myocardial organization 
and polarization. Whether perturbed Rac1 signaling in the ventricular myocardium is 
related to cases of left ventricular noncompaction (LVNC) defects reported in human 
patients remains to be determined.  
In summary, I have demonstrated a crucial role for Rac1 in embryonic heart 
development. More specifically, I showed that Rac1 is critical for development of 
cardiomyocyte polarity and a deficiency in Rac1 leads to defects in cardiomyocyte 
polarization. Next, I showed that Rac1 is crucial for organization of the anterior SHF 
progenitors in the dorsal pericardial wall and overall OFT development. Lastly, I showed 
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that Rac1 is essential for ventricular myocardium development and a Rac1 deficiency 
leads to trabecular defects and noncompaction of the myocardium. My studies provide 
novel insights into the developmental mechanisms that may be disturbed in some cases of 
human CHDs and may provide information for improved diagostics and therapies. A 
summary of the findings from these studies is shown in Figure 5.1.   
 
 
 
Figure 5.1.  Summary of the cellular mechanisms by which Rac1 regulates 
embryonic heart development.   
Rac1 signaling regulates various mechanisms of heart development including 
proliferation, actin polymerization, gene expression and cell survival, leading to 
cardiomyocyte polarity, development of the OFT, cardiac septum and the ventricular 
myocardium.   
 
 
189 
 
5.2 Study Limitations 
5.2.1 Mouse models of CHDs  
Mouse models have been used extensively to understand physiology and 
pathophysiology, including the mechanisms of normal heart development and how CHDs 
arise in humans. The cardiac developmental events and anatomy of the heart are very 
similar in mouse and humans.9 Since the mouse genome was first sequenced in 2002, it 
has been shown that approximately 99% of mouse genes are homologous to human 
genes.10 This makes the mouse an excellent mammalian model for comparative genomics 
and a powerful tool to help us further understand cardiogenesis. In addition, 
manipulations to the mouse genome are relatively straightforward and specific, making it 
an invaluable model to study the mechanisms of CHDs.11 However, despite great 
advancements to research that the genetically modified mouse has provided, use of the 
mouse model in some cases does not always completely recapitulate the CHDs observed 
in humans due to distinct physiological differences and mouse genetic backgrounds.12 For 
example, in mutant mice with one copy of Tbx5, the CHDs that arise accurately reflect 
those found in Holt-Oram Syndrome (HOS) patients with a heterozygous mutation of 
Tbx5.13 On the other hand, deletion of one copy of Nkx2.5 in mice only recapitulates 
some aspects of the CHDs found in humans with an Nkx2.5 deficiency. This indicates 
that specific genes may have differing dosage sensitivities between mouse and humans.14 
In addition, polymorphisms or mutations of a gene in humans often present as a reduction 
in the protein level and/or activity. The associated phenotypes with these human 
mutations may not always be accurately reflected in a genetic knockout mouse.11 
Furthermore, different genetic modifiers such as epigenetics can influence phenotypical 
expression of genetic mutations in differerent mouse strains. For example, mutations in 
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Gata4 in the C57BL6/J strain have an increased frequency of CHDs compared to the 
FVB/NCrl strain.12 In addition to potential genetic variabilities in mouse models, 
differences in physiology such as a shorter gestation time in mouse and a faster heart rate 
compared to humans could also influence the phenotypes that arise in mouse mutants.9 
Overall, the use of mouse models will continue to be a vital tool in medical research but 
their inherent limitations must be considered when they are employed to study CHDs.  
Conventional gene targeting, where a specific gene is completely ablated in all 
cells of a mouse, has been a critical genetic tool to elucidate gene function. However, 
approximately 30% of these knockout mice are embryonic lethal or have early postnatal 
lethality, which precludes analysis at later time points.15 To avoid this issue, the Cre/loxP 
system has been used extensively to allow spatial control of genetic deletions. Lox/P 
sequences flank a critical gene region and act as recognition sites for Cre recombinase, 
which is under regulatory control of a tissue specific promoter. The Rac1 knockout 
mouse is embryonic lethal,16 therefore the Cre/loxP system was used extensively 
throughout this thesis to specifically delete Rac1 in the anterior SHF and the ventricular 
myocardium. The heart is comprised of different progenitors that give rise to numerous 
cell types including cardiomyocytes, fibroblasts, epicardial cells and endothelial cells. 
The use of the Cre/loxP system allows tracking, isolation and characterization of specific 
cardiac progenitors and their derivatives, thus facilitating our understanding of heart 
development.11 However, the Cre/loxP system does present with potential limitations that 
must be considered. Some studies have reported Cre recombinase toxicity in transgenic 
mice. There have also been reports of phenotypical abnormalities and altered gene 
expression at the sites surrounding Cre insertion. To reduce the potential of Cre toxicity, 
the transgene should stay as a single copy as it is passed onto future generations.17-19 
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Another issue with the Cre/loxP system is expression of Cre in other unintended tissues. 
With Cre driven lineage tracing, a reporter gene (ex. GFP, lacZ) is expressed once the 
gene controlling Cre expression is turned on. All daughter cells derived from the first cell 
expressing the Cre will also be labeled. However, this may not be a true lineage tracing 
of a progenitor cell since any cell type with that particular Cre-controlling gene expressed 
will also be labeled.  For example, the Isl1-Cre mouse has been used to study the SHF. 
However, the Isl1-Cre transgene is also expressed in tissues outside of the cardiac 
progenitor population, including motor neuron cells and the dorsal root ganglia.20 
Recently, a study showed that Isl1-Cre also marks a subset of cardiac neural crest cells, 
revealing a need for more specific cardiac progenitor markers or the use of multiple or 
alternative tissue-specific Cre drivers within a study. The anterior SHF Mef2c-Cre 
transgene was found to not overlap with cardiac neural crest cells.21  
Another issue with some Cre/loxP mouse models is whether the Cre is transmitted 
from the male or female parent. In this study with the Mef2c-Cre transgenic mouse, the 
Cre was always inherited from the male parent. The Mef2c-Cre is also active in the 
female germline and female inheritance would have led to full body expression of Cre 
recombinase in the offspring. Moreover, another potential limitation to the Cre/loxP 
system is that some floxed sequences may be more easily recombined than others based 
on the distance between loxP sites and chromatin state of the loxP sites.22 In this study, 
the same line of Rac1f/f  and mT/mG transgenic mice were used for all experiments, 
therefore the efficiency of recombination should be similar for all samples. Another 
limitation to the Cre/loxP system is the inability to control the level or efficiency of Cre 
activity. For example, the Mef2c-Cre transgenic mouse was able to sufficiently 
downregulate Rac1 expression by 51% while the Nkx2.5-Cre mouse was only able to do 
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so by 35%. This inability to control the level of Cre activity can be a limitation when 
trying to recapitulate CHDs based on human genetic mutations that present with dosage 
sensitivities. Nevertheless, despite the inability to regulate Cre efficiency, the phenotypes 
shown using the Cre/loxP system with the Mef2c-Cre and Nkx2.5-Cre transgenic mouse 
in this thesis allowed us to elucidate the role of Rac1 in embryonic heart development, 
furthering our basic understanding of the mechanisms that could underly CHDs that arise 
in humans. Whether human patients have deficiencies in Rac1 expression and/or activity 
that lead to development of CHDs remains to be determined.   
5.2.2 Use of in vitro cell culture systems  
In Chapter 2 of this thesis, in vitro cell cultures and explants were used to 
understand the role of Rac1 in cardiomyocyte polarity. Specifically, E12.5 RV from 
Rac1SHF;mT/mG and littermate controls were explant cultured onto collagen to study 
migration of GFP+ SHF-derived cells. This allowed us to visualize and monitor the 
migratory ability of SHF-derived cells in a live manner. In addition, primary 
cardiomyocytes from WT hearts were isolated and treated with Ad-Rac1N17 to study 
lamellipodia formation after a scratch injury. Primary cardiomyocytes from P0 Rac1SHF 
RV were also cultured to analyze cellular characteristics such as length and shape. All of 
these in vitro techniques allowed us to examine the role of Rac1 in cardiomoycte polarity 
and embryonic heart development, which would have been difficult to do in the in vivo 
model. A limitation to the use of in vitro cell cultures is that it does not fully simulate the 
in vivo environment that the cells would normally reside in. Cells in an in vivo model are 
under constant nourishment from the surrounding blood vessels, have interactions with 
other cardiac cell types in a 3D environment and undergo biomechanical forces due to the 
beating movements of the heart, which cannot be fully replicated in the in vitro setting. 
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Furthermore, use of the adenovirus, Ad-Rac1N17, to knock down Rac1 expression in WT 
primary cardiomyocyte cultures likely does not replicate the deficiency in Rac1 
expression found in Rac1SHF hearts. However, culture of WT cardiomyocytes was 
necessary since primary culture of cardiomyocytes from Rac1SHF RV did not form a 
confluent cell layer to facilitate a scratch assay due to the inability of many of the 
Rac1SHF cardiomyocytes to adhere to the culture plate. Despite the limitations that in vitro 
cultures present, use of these techniques in this thesis were crucial to help further 
delineate the specific role of Rac1 in cardiac progenitor migration and cardiomyocyte 
polarity during cardiac development. Overall, these in vitro experiments act as supporting 
data for the in vivo findings in Chapter 2.  
5.3 Suggestions for Future Research  
This thesis demonstrated a critical role for Rac1 in embryonic heart development, 
specificially in cardiomyocyte polarity, SHF progenitor cellular organization and 
development of the OFT and ventricular myocardium. However, some aspects of Rac1 
signaling should be investigated in future studies to gain a further understanding of the 
role of Rac1 in cardiogenesis. 
In Chapter 2 and Chapter 4 of this thesis, I showed that a deficiency in Rac1 
leads to defects in ventricular myocardium development. The trabeculation of Rac1SHF 
RV and Rac1Nkx2.5 RV and LV are poorly formed and the compact myocardium is thinner 
compared to littermate controls. It would be of interest to study cardiac conduction 
system development in these hearts as well. Parts of the conduction system are derived 
from the embryonic myocardium that retain a primitive phenotype while the surrounding 
myocardial cells developing into ventricular myocardium.23 Therefore, I would predict 
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that defects in ventricular myocardium development would likely lead to defects in 
cardiac conduction system development as well. Cardiac neural crest cells have been 
shown to have a role in the development and maturation of the conduction system. 
Ablation of cardiac neural crest cells in chick embryos result in noncompaction of the 
conduction system bundles.24 In mouse lineage tracing studies, cardiac neural crest cells 
have been shown to contribute to formation of the cardiac conduction system.25 In 
addition, SHF progenitors have also been demonstrated to contribute to development of 
the cardiac conduction system. The sinal atrial node and conduction system of the RV are 
derived from the SHF, along with a small subset of cells in the atrial-ventricular node, 
His Bundle and left bundle branches.26 Whether Rac1 plays a role in development of the 
cardiac conduction system remains to be determined. Future studies using the Rac1SHF 
mouse to study the conduction system would be particularly interesting since I would 
predict the conduction system to be malformed in the RV. Furthermore, since cardiac 
neural crest cells also contribute to the conduction system, the LV conduction system 
may also be defective in Rac1SHF hearts. However, whether SHF cells signal to cardiac 
neural crest cells through semaphorin-plexin signaling during conduction system 
development is currently unknown.   
In addition to the cardiac conduction system, development of the coronary arteries 
could also be analyzed in future studies. The defects observed in myocardium 
development in Chapter 2 and Chapter 4 likely lead to defects in coronary artery 
formation as well. Coronary artery development depends on complex crosstalk signaling 
between the epicardium and the myocardium, mediated in part by growth factors 
including fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and 
angiopoietin signaling.27 Whether this crosstalk signaling and coronary artery formation 
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is also disrupted in Rac1Nkx2.5 and Rac1SHF hearts remains unknown. Interestingly, 
disruption of the PCP pathway in homozygous Looptail (Lp) mutant mice displayed 
defects in coronary artery development, despite the lack of expression of Vangl2 in the 
epicardium and epicardial-derived cells. Thus, the coronary artery defects were attributed 
to abnormal development of the adjacent myocardial cells.28    
In Chapter 3, I showed that loss of Rac1 in SHF progenitors in Rac1SHF hearts 
also lead to defects in aortic valve maturation and remodeling. P0 Rac1SHF aortic valves 
are thickened with a reduced cell density compared to littermate controls, which have thin 
elongated aortic valve leaflets. Aortic valve development involves ECM remodeling and 
Rac1 has been shown to regulate the ECM remodeling process in the eye and the knee.29-
31 Whether Rac1 plays a similar role during the process of aortic valve development and 
remodeling in cardiogenesis is unknown. Future studies could use specific Cre 
recombinase transgenic mice that target specific cells in the valves to study the role of 
Rac1, such as the endothelial Tie2-Cre mouse.32  
In Chapter 2, I showed that expression of some key cardiac transcription factors 
were downregulated in the E12.5 Rac1SHF RV. Rac1 has been shown to promote gene 
expression through NF-κB and/or JNK signaling.33, 34 Another study has shown that Rac1 
promotes nuclear accumulation of β-catenin in the canonical Wnt pathway.35 Whether 
Rac1 acts through these above mentioned pathways or others to regulate gene expression 
should be determined in future studies. Furthermore, it would be of interest to determine 
whether the same cardiac transcription factors that are downregulated in Rac1SHF hearts 
are also downregulated in Rac1Nkx2.5 hearts from Chapter 4. The developing RV and LV 
have distinct gene regulatory programs. For example, the transcription factor Hand1 is 
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mostly expressed in the in the LV and loss of Hand1 results in LV defects and 
dysregulation of downstream gene expression. The transcription factor Hand2 is mostly 
expressed in the SHF and loss of Hand2 results in RV defects, along with defects in the 
OFT.36 Although Hand1 and Hand2 have partially overlapping roles in ventricular 
development, their individual expression patterns in the developing heart suggests 
existence of a distinct gene regulatory program between the RV and LV.8 Therefore, 
whether loss of Rac1 in the LV of Rac1Nkx2.5 hearts lead to dysregulation of the same 
genes in the Rac1Nkx2.5 RV should be further studied.            
Rac1, along with other Rho GTPases, have a tight spatio-temporal level of 
regulation. For example, loss of Rac1 in embryonic hematopoietic stem cells does not 
affect proliferation rate, in contrast to adult hematopoietic stem cells, where the 
proliferation rate is decreased.37, 38 In Chapter 2 of this thesis, which used the Rac1SHF 
mouse, Rac1 was found to regulate cell survival in the ventricular myocardium at E11.5 
and no differences were observed in proliferation rate of the myocardium. However, at an 
earlier developmental time point in Chapter 4, which used the Rac1Nkx2.5 mouse, Rac1 
was found to regulate proliferation of the E9.5 ventricular myocardium with no effect on 
cell apoptosis. Proliferation of the mouse heart is highest at E9.5 and will gradually 
decrease as development proceeds.39 Our results suggest a temporal regulation of Rac1 
control of proliferation in the ventricular myocardium, where Rac1 plays a critical role 
during the highest growth rate at E9.5. Although proliferation of the ventricular 
myocardium continues, Rac1 does not seem to play a critical role by E11.5. Similarly, 
Rac1 control of cell survival also seems to be regulated in a temporal manner in the 
ventricular myocardium. However, whether the temporal differences observed in this 
thesis were due to differences in the level of Rac1 downregulation remain to be 
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determined. Specifically, in Chapter 2, the Mef2c-Cre transgenic mouse was used while 
in Chapter 4, the Nkx2.5-Cre mouse was used, and differences in Cre recombinase 
activity likely exist between these two transgenic mouse lines. To definitively determine 
the temporal pattern of Rac1 activity, the same Cre recombinase transgenic mouse should 
be used for analysis. In addition, a tamoxifen inducible Cre transgenic mouse could be 
used to delete Rac1 at specific developmental time points. Lastly, further studies will be 
necessary to determine the upstream signals, such as growth factors, hormones, cytokines 
and/or adhesion molecules that temporally regulate Rac1 in development of the heart.   
Finally, in Chapter 4, proliferation was significantly decreased in the Rac1Nkx2.5 
ventricular myocardium. However, the specific mechanisms that Rac1 act through to 
regulate proliferation during cardiac development is unclear. Rac1 signals through NF-κB 
to regulate cyclin D1, the cell cycle regulator.40 Furthermore, the D-type cyclins have 
been shown to be critical regulators of cardiomyocyte proliferation during normal heart 
development.41 Future studies will be performed to determine whether this is the pathway 
that Rac1 acts through to regulate cardiomyocyte proliferation.     
5.4 Conclusion 
This thesis is the first to provide evidence of a critical role for Rac1 signaling in 
embryonic heart development. Here I demonstrated the importance of Rac1 signaling in 
cardiomyocyte polarity, development of OFT and cardiac septum, and formation of the 
ventricular myocardium. Deficient Rac1 signaling disrupts several developmental 
pathways including proliferation, cell survival, gene expression and actin dynamics, 
leading to a spectrum of CHDs including a bifid apex, ASDs, VSDs, OFT defects and 
ventricular myocardium defects. While further research is required to determine whether 
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Rac1 mutations are involved in human patients with CHDs, this thesis provides evidence 
that abberrant Rac1 signaling may underly some cases of this disease. In addition to 
potential mutations in the Rac1 gene in humans, abberant signaling of this pathway may 
also be due to mutations in the GEFs and GAPs that regulate Rac1. For example, 
mutations in the GEF, Son of sevenless homolog 1 (Sos1) is found in 10-15% of Noonan 
syndrome patients, who present with a range of developmental defects including 
CHDs.42-44 Sos1 acts as a bifunctional GEF for Ras and Rac and a missense mutation in 
E846K leads to constitutive activation.45 A study using a mutant mouse model of Noonan 
syndrome showed CHDs along with other birth defects, which could be ameliorated with 
prenatal administration of a MEK inhibitor.46 Whether this type of treatment can be 
applied to human patients should be further studied. Overall, the work in this thesis has 
provided valuable insight into the mechanisms by which Rac1 regulates cardiomyocyte 
polarity and embryonic heart development. My research has broadened our understanding 
of the developmental mechanisms regulated by Rac1 and may have implications in future 
diagnosis or treatment of CHDs.  
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